Diacylglycerol acyltransferase genes, proteins, and uses thereof

ABSTRACT

The present invention relates to diacylglycerol acyltransferase genes and proteins, and methods of their use. In particular, the invention describes genes and proteins that exhibit both long-chain acyltransferase and acetyltransferase activity. The present invention encompasses both native and recombinant wild-type forms of the transferase, as well as mutants and variant forms, some of which possess altered characteristics relative to the wild-type transferase. The present invention also relates to methods of using diacylglycerol acyltransferase genes and proteins, including in their expression in transgenic organisms and in the production of acetyl-glycerides in plant oils, and in particular seed oils.

This application claims priority to provisional patent application Ser.No. 60/475,371, filed Jun. 3, 2003, which is herein incorporated byreference in its entirety.

The present application was funded in part with government support undergrant number 98-35503-6362 from the USDA-CSREES. The government may havecertain rights in this invention.

FIELD OF THE INVENTION

The present invention relates to isolated diacylglycerolacetyltransferase (AcDAGAT) genes and polypeptides, and in particularEuonymus and Euonymus-like AcDAGAT genes and polypeptides where theenzyme exhibits an increased specificity for acetyl-CoA. The presentinvention also provides compositions comprising unique triacylglycerolssynthesized by an AcDAGAT enzyme. The present invention also providesmethods for using diacylglycerol acetyltransferase genes andpolypeptides.

BACKGROUND OF THE INVENTION

Vegetable oils are utilized not only in the food industry, but alsoincreasingly in the chemical industry. The utility of any particular oildepends upon chemical and physico-chemical properties of the oil, whichare determined by the composition of the constituent fatty acids. Plantoils are often modified to meet industry specifications. Suchmodification of vegetable oil has typically been achieved by chemicalmeans (fractionation, interesterification, hydrogenation, or otherchemical derivatization), but genetic means (plant breeding, mutagenesisand genetic engineering) are increasingly being used to provide noveloil feedstocks.

One class of particular interest is the class of triacylglycerolscontaining sn-3-acetyl glycerides (1,2-diacyl-3-acetins). These unusualtriacylglycerols have an acetyl group at their sn-3 position. Theoccurrence and structural characterization of sn-3-acetyl glycerides inseed oils was first reported by Kleiman et al. (1967) (Lipids2:473-478). Unlike most triacylglycerols, sn-3-acetyl glycerides exhibitstrong optical activity. They are found at high levels in Euonymusspecies, representing up to 98% of the total triacylglycerols in theseed oil, and are also found in varying amounts in some other plantspecies. In the Euonymus sn-3-acetyl glycerides, the sn-1 and sn-2positions are esterified with common long-chain fatty acids,predominantly palmitate, oleate and linoleate.

Currently, there are no commercial sources of oils rich in sn-3-acetylglycerides. Moreover, plants with high levels of sn-3-acetyl glyceridesare not grown commercially. In fact, the biosynthesis of these novelglycerides has only recently been investigated.

There are several triacylglycerol producing reactions that undergo sn-3acylation or transacylation reactions, including two classes of DAGATgenes, and a phospholipid:diacylglycerol acyltransferase. One class ofDAGAT genes has been isolated and expressed from Arabidopsis based upontheir homology to the mammalian DAGAT gene, and more broadly toacyl-CoA:cholesterol acyltransferase (ACAT)-like genes, and by mappingof the gene corresponding to a mutation. A second class of DAGAT genescan be identified based upon homology to a DAGAT first purified from afungus, Mortierella ramanniana. However, a gene has not been identified,much less isolated and expressed, from an organism that exhibits aunique triacylglycerol such as is found in seed oils of the genusEuonymus.

Moreover, the availability of a DAGAT withacetyl-CoA:sn-1,2-diacylglycerol acyltransferase activity would allownovel triacylglycerol structures to be produced; such noveltriacylglycerol molecules could by synthesized in vitro or in vivo. Thepresence of an acetyl group rather than a long-chain fatty acidesterified at one or more, but not all, of the positions on the glycerolbackbone will reduce the calorific value of the oil while notinterfering with its functionality in foods. Also, an oil such as oliveoil or high oleic oils, or castor oil, which all contain a large amountof trifunctional triacylglycerols, such as triolein or triricinolein,would easily be converted to bifunctional oils if an acetyl groupreplaced the fatty acid at the sn-3 position. Such oils would havedifferent industrial applications than their trifunctional counterparts.For example, a bifunctional triacylglycerol would produce linear(thermoplastic) polymers whereas a trifunctional triacylglycerol wouldproduce cross-linked (thermosetting) polymers.

Therefore, it would be desirable to be able to generate vegetable oilswith high amounts of acetyl glycerides, and in particular sn-3-acetylglycerides. One route is by identifying and isolating a plant gene thatis capable of synthesizing acetyl glycerides. Such a gene could then beused to transform oil crop plants. Identification of such a gene couldalso be used to synthesize novel acetyl glycerides that do not existnaturally.

SUMMARY OF THE INVENTION

Thus, in some embodiments, the present invention provides an isolatednucleic acid sequence encoding a diacylglycerol acetyltransferase. Insome further embodiments, the diacylglycerol acetyltransferase is from aplant of the genus Euonymus. In yet further embodiments, the plant is aEuonymus alata plant. In yet further embodiments, the nucleic acidsequence encodes SEQ ID NO:2. And in yet further embodiments, thenucleic acid sequence comprises SEQ ID NO: 1.

In other embodiments, the present invention provides an isolated nucleicacid sequence encoding a polypeptide comprising SEQ ID NO:2. In yetother embodiments, the present invention provides an isolated nucleicacid sequence that hybridizes under conditions of high stringency to anucleic sequence comprising SEQ ID NO: 1, wherein the sequence encodes adiacylglycerol acetyltransferase.

In other embodiments, the present invention provides an isolatedantisense sequence corresponding to any of the nucleic acid sequencesdescribed above. In some embodiments, the present invention provides aninterfering RNA targeted to a sequence in an mRNA transcribed from anyof the nucleic acid sequences described above. In some furtherembodiments, the present invention provides a nucleic acid sequenceencoding any of the interfering RNAs described above.

In other embodiments, the present invention provides any of the nucleicacid sequences described above operably linked to a heterologouspromoter. In yet further embodiments, the nucleic acid sequencesdescribed above operably linked to a heterologous promoter are in avector. In other embodiments, the present invention provides a vectorcomprising any of the nucleic acid sequences described above.

In some embodiments, the present invention provides a purifiedpolypeptide encoded by any of the nucleic acid sequences describedabove, where the nucleic acid sequences encode a diacylglycerolacetyltransferase. In other embodiments, the present invention providesa purified diacylglycerol acetyltransferase. In some furtherembodiments, the diacylglycerol acetyltransferase is from a plant of thegenus Euonymus. In yet further embodiments, the plant is a Euonymusalata. In yet further embodiments, the purified diacylglycerolacetyltransferase comprises SEQ ID NO:2. In other embodiments, thepresent invention provides a purified polypeptide comprising SEQ IDNO:2.

In other embodiments, the present invention provides a host celltransformed with any of the nucleic acid sequences described above; inparticular embodiments, the nucleic acid sequence comprises aheterologous gene encoding a plant diacylglycerol acetyltransferase. Insome further embodiments, the host cell is a plant cell or amicroorganism. In some further embodiments, the host cell is amicroorganism selected from the group consisting of bacteria and yeast.In other embodiments, the present invention provides oil from atransgenic microorganism as described above.

In yet other embodiments, the present embodiment provides a plant orplant part transformed with any of the nucleic acid sequences describedabove, wherein the plant or plant part is selected from the groupconsisting of a plant, a plant organ, a plant tissue, and a plant cell;in particular embodiments, the nucleic acid sequence comprises aheterologous gene encoding a plant diacylglycerol acetyltransferase. Insome embodiments, the present invention provides a plant seedtransformed with any of the nucleic acid sequences described above; inparticular embodiments, the nucleic acid sequence comprises aheterologous gene encoding a plant diacylglycerol acetyltransferase. Inother embodiments, the present invention provides oil from a transgenicplant as described above.

In some embodiments, the present invention provides a method to identifydiacylglycerol acetyltransferase coding sequences, comprising: obtaininga non-cDNA library for DAGAT by using RT-PCR with degenerated primers togive a partial length clone; using 3′ and 5′ RACE to define the 3′ and5′ cDNA ends; obtaining a full length cDNA clone via RT-PCR usingprimers based on the sequence of the 3′ and 5′ RACE products; and usingthe full length cDNA clone to confirm the identity of the encodedpolypeptide as a diacylglycerol acetyltransferase (AcDAGAT). In somefurther embodiments, confirmation of the identity of the encodedpolypeptide as an AcDAGAT comprises: expressing the encoded polypeptideof the full length cDNA: and characterizing the expressed polypeptide.In yet further embodiments, characterizing the expressed polypeptide isby detecting the presence of the expressed polypeptide byantibody-binding; in some further embodiments, the antibody is specificfor AcDAGAT. In yet other further embodiments, characterizing theexpressed polypeptide is by detecting reaction products of the expressedpolypeptide in an AcDAGAT activity assay. In some other furtherembodiments, acetyl glycerides (AcTAGs) are present in the tissue fromwhich the non-cDNA library is prepared.

In some embodiments, the present invention provides a method ofproducing acetyl glycerides comprising one acetyl group and twolong-chain acyl groups, comprising: providing a host cell transformedwith a heterologous gene encoding a diacylglycerol acetyltransferase(AcDAGAT); and growing the host cell under conditions sufficient toeffect production of acetyl glycerides.

In some embodiments, the present invention provides a method ofproducing acetyl glycerides comprising one acetyl group and twolong-chain acyl groups, comprising: incubating an isolated nucleic acidsequence encoding a diacylglycerol acetyltransferase (AcDAGAT) in an invitro expression system under conditions sufficient to effect productionof acetyl glycerides. In other embodiments, the present inventionprovides a method of producing acetyl glycerides comprising one acetylgroup and two long-chain acyl groups, comprising: incubating andiacylglycerol acetyltransferase (AcDAGAT) in an in vitro reactionmixture under conditions sufficient to effect production of acetylglycerides. In further embodiments, the expression system or thereaction mixture of the in vitro methods described above furthercomprises a substrate of AcDAGAT. In other further embodiments, theexpression system or reaction mixture of the in vitro methods furthercomprises means for generating at least one substrate of the AcDAGAT. Inother further embodiments, the method of producing acetyl glyceridescomprising one acetyl group and two long-chain acyl groups as describedabove further comprises collecting the acetyl glycerides produced.

In other embodiments, the present invention provides a method forproducing novel triglycerides (TAGs), comprising: providing adiacylglycerol substrate to a diacylglycerol acetyltransferase (AcDAGAT)under conditions sufficient to produce a triglyceride produced from theprovided substrate, wherein at least one of the fatty acyl chains of thediacylglycerol substrate is selected from the group consistingpalmitoleic acid, a ricinoleic acid, divemolic acid, and capric acid.

In yet other embodiments, the present invention provides a method forproducing novel triglycerides (TAGs), comprising: providing at least oneof acetyl-CoA, propionyl-CoA, butyryl-CoA, benzoyl-CoA, or cinnamoyl-CoAsubstrate to a diacylglycerol acetyltransferase (AcDAGAT) underconditions sufficient to produce a triglyceride comprising the providedacetyl, propionyl, butyryl, benzoyl, or cinnamoyl group.

In yet other embodiments, the present invention provides a noveltriglyceride produced by any of the methods described above. In yetother embodiments, the present invention provides a novel triglyceride,wherein the triglyceride is an acetyldipalmitolein,propionyldipalmitolein, butyryldipalmitolein, benzoyldipalmitolein,cinnamoyldipalmitolein, acetyldiricinolein, acetyldivernolin, oracetyldicaprin.

DESCRIPTION OF THE FIGURES

FIG. 1 shows the accumulation of fresh weight, dry weight, and totallipids in developing Euonymus alata seeds.

FIG. 2 shows the accumulation of 1,2-diacyl-3-acetins (AcTAG), normaltriacylglycerols (TAG), diacylglycerols (DAG) and polar lipids (PL) indeveloping Euonymus seed (embryo and endosperm). To keep the AcTAG onthe same scale as the other lipid classes its value has been compressed10-fold.

FIG. 3 shows the accumulation of total lipids, 1,2-diacyl-3-acetins(AcTAG) and normal triacylglycerols (TAG) in developing Euonymus seed(embryo and endosperm) and other tissues.

FIG. 4 shows [¹⁴C] acetate incorporation into the major acyl lipidclasses by halved Euonymus seeds as a function of seed development. Themajor lipid classes are long-chain triacylglycerol (TAG),1,2-diacyl-3-acetin (AcTAG), 1,2-diacylglycerol (DAG) andphosphatidyl-choline (PC). For 1,2-diacyl-3-acetin, the incorporation oflabel in sn-3 acetyl group and the sn-1 and sn-2 labeled fatty acids isshown separately, as each can be determined independently.

FIG. 5 shows the nucleotide sequence of Euonymus alata seeddiacylglycerol acetyltransferase (EaDAGAT) cDNA (SEQ ID NO:1).

FIG. 6 shows the deduced amino acid sequence (SEQ ID NO:2) encoded bythe nucleotide sequence of the Euonymus alata seed diacylglycerolacyltransferase (EaDAGAT) cDNA shown in FIG. 5.

FIG. 7 shows an alignment of the deduced amino acid sequences of theDAGAT genes of Euonymus alata (E.a.), Arabidopsis thaliana (A.t.),Nicotiana tabaccum (N.t.), and Perilla frutescens (P.f.). Thehighlighting indicates identical amino acids for at least two genes inthe four gene alignment.

GENERAL DESCRIPTION OF THE INVENTION

The present invention relates to compositions comprising diacylglycerolacyltransferase (DAGAT) genes and polypeptides, and in particularEuonymus and Euonymus-like DAGAT genes and polypeptides, where theenzyme exhibits an increased specificity for acetyl-CoA or the CoAesters of groups related to acetate (described further below). Thesepolypeptides are referred to as diacylglycerol acetyltransferase,designated “AcDAGAT,” indicating an activity of increased specificityfor transfer of acetyl or related groups, and/or “EaDAGAT,” indicatingan enzyme obtained from Euonymus alata. The present inventionencompasses compositions comprising both native and recombinant forms ofthe enzyme, as well as mutant and variant forms, some of which possessaltered characteristics relative to the wild-type. The present inventionalso comprises novel triacylglycerols synthesized by AcDAGAT. Thepresent invention also provides methods for using AcDAGAT genes andpolypeptides.

In some embodiments, the present invention provides novel isolatednucleic acid sequences encoding an AcDAGAT. In other embodiments, theinvention provides isolated nucleic acid sequences encoding mutants,variants, homologs, chimeras, and fusions of an AcDAGAT. In otherembodiments, the present invention provides methods of generating suchsequences. In other embodiments, the present invention provides methodsof cloning and expressing such sequences, as well as methods ofpurifying and assaying the expression product of such sequences.

In additional embodiments, the present invention provides purifiedAcDAGAT polypeptides. In other embodiments, the present inventionprovides mutants, variants, homologs, chimeras, and fusion proteins ofAcDAGAT. In some embodiments, the present invention provides methods ofpurifying, and assaying the biochemical activity of wild type as well asmutants, variants, homologs, chimeras, and fusions of AcDAGAT, as wellas methods of generating antibodies to such proteins.

In other embodiments, the present invention provides compositionscomprising novel triacylglycerols synthesized by an AcDAGAT of thepresent invention. Such syntheses may be accomplished by any of themethods described below.

In some embodiments, the present invention provides methods of usingnovel isolated nucleic acid sequences encoding an AcDAGAT to produceproducts of the acetyltransferase activity. In some embodiments, themethods involve adding the sequences to in vitro transcription andtranslations systems that include the substrates of the AcDAGAT, suchthat the products of the acetyltransferase may be recovered. In otherembodiments, the methods involve transforming organisms with thesequences such that the sequences are expressed and products of theAcDAGAT are produced. In particular embodiments, the products arerecovered. In other embodiments, the products remain in situ.

In some embodiments, the present invention provides methods of usingrecombinant AcDAGAT polypeptides to produce products of theacetyltransferase activity. In some embodiments, the methods involveadding the polypeptides to in vitro systems which include the substratesof the AcDAGAT, such that the products of the AcDAGAT may be recovered.

In other embodiments, the methods involve transforming a plant with anovel isolated nucleic acid sequence encoding an AcDAGAT such thatproducts of the AcDAGAT are produced.

In some embodiments, the present invention provides an organismtransformed with heterologous gene encoding an AcDAGAT. In someembodiments, the organism is a microorganism. In other embodiments, theorganism is a plant.

In some embodiments, the present invention also provides a celltransformed with a heterologous gene encoding an AcDAGAT. In someembodiments, the cell is a microorganism. In other embodiments, the cellis a plant cell.

In other embodiments, the present invention provides a plant seedtransformed with a nucleic acid sequence encoding an AcDAGAT.

In yet other embodiments, the present invention provides an oil from aplant, a plant seed, or a microorganism transformed with a heterologousgene encoding an AcDAGAT.

Definitions

To facilitate an understanding of the present invention, a number ofterms and phrases as used herein are defined below:

The term “plant” is used in it broadest sense. It includes, but is notlimited to, any species of woody, ornamental or decorative, crop orcereal, fruit or vegetable plant, and photosynthetic green algae (forexample, Chlamydomonas reinhardtii). It also refers to a plurality ofplant cells which are largely differentiated into a structure that ispresent at any stage of a plant's development. Such structures include,but are not limited to, a fruit, shoot, stem, leaf, flower petal, etc.The term “plant tissue” includes differentiated and undifferentiatedtissues of plants including those present in roots, shoots, leaves,pollen, seeds and tumors, as well as cells in culture (for example,single cells, protoplasts, embryos, callus, etc.). Plant tissue may bein planta, in organ culture, tissue culture, or cell culture. The term“plant part” as used herein refers to a plant structure or a planttissue.

The term “crop” or “crop plant” is used in its broadest sense. The termincludes, but is not limited to, any species of plant or algae edible byhumans or used as a feed for animals or used, or consumed by humans, orany plant or algae used in industry or commerce.

The term “oil-producing species” refers to plant species that produceand store triacylglycerol in specific organs, primarily in seeds. Suchspecies include but are not limited to soybean (Glycine max), rapeseedand canola (including Brassica napus and B. campestris), sunflower(Helianthus annus), cotton (Gossypium hirsutum), corn (Zea mays), cocoa(Theobroma cacao), safflower (Carthamus tinctorius), oil palm (Elaeisguineensis), coconut palm (Cocos nucifera), flax (Linum usitatissimum),castor (Ricinus communis) and peanut (Arachis hypogaea). The group alsoincludes non-agronomic species which are useful in developingappropriate expression vectors such as tobacco, rapid cycling Brassicaspecies, and Arabidopsis thaliana, and wild species which may be asource of unique fatty acids.

The term “Euonymus” refers to a plant or plants from the genus Euonymus.Non-limiting examples of Euonymus include plants from the species E.alata. The term also refers to E. alata plants from which nucleic acidsequence SEQ ID NO:1 was isolated.

The term plant cell “compartments or organelles” is used in its broadestsense. The term includes but is not limited to, the endoplasmicreticulum, Golgi apparatus, trans Golgi network, plastids, sarcoplasmicreticulum, glyoxysomes, mitochondrial, chloroplast, and nuclearmembranes, and the like.

The term “host cell” refers to any cell capable of replicating and/ortranscribing and/or translating a heterologous gene.

The terms “diacylglycerol” and “diglyceride” refer to a moleculecomprising a glycerol backbone to which two acyl groups are esterified.Typically, the acyl groups are esterified to the sn-1 and sn-2positions, although the acyl groups may also be esterified to the sn-1and sn-3 positions, or to the sn-2 and sn-3 positions; the remainingposition is unesterified and contains a hydroxyl group. This term may berepresented by the abbreviation DAG.

The terms “triacylglycerol” and “triglyceride” refer to a moleculecomprising a glycerol backbone to which three acyl groups areesterified. This term may be represented by the abbreviation TAG.

The term “long chain triacylglycerol” refers to a triacylglycerol inwhich all three acyl groups are long chain, or in other words each chainis a linear aliphatic chain of 6 carbons or greater in length (an acylgroup may be referred to by the letter C followed by the number ofcarbons in the linear aliphatic chain, as, for example, C6 refers to anacyl group of 6 carbons in length). This term may be represented by theabbreviation LcTAG.

The terms “acetyl glyceride” and “acetyl triacylglycerol” and the likerefer to a triglyceride to which at least one acetyl or related group isesterified to the glycerol backbone. A particular acetyl glyceride isdenoted by the position(s) to which an acetyl or related group isesterified; thus, “sn-3-acetyl glyceride” or “1,2-diacyl-3-acetin”refers to triacylglycerol with an acetyl group at the sn-3 position.These terms may be represented by the abbreviation AcTAG.

An “acetyl” or “related group”, when used in reference to AcTAG, refersto an acyl moiety other than a long-chain acyl group esterified to TAG.The acyl moiety is any linear aliphatic chain of less than 6 carbons inlength; it may or may not have side group chains or substituents. Theacyl moiety may also be aromatic. Related group members include but arenot limited to propionyl and butyryl groups, and aromatic groups such asbenzoyl and cinnamoyl.

The term “diacylglycerol acyltransferase” refers to a polypeptide withthe capacity to transfer an acyl group to a diacylglycerol substrate.Typically, a diacylglycerol acyltransferase transfers an acyl group tothe sn-3 position of the diacylglycerol, though transfer to the sn-1 andsn-2 positions are also possible. The acyl substrate for the transferaseis typically esterified to CoA; thus, the acyl substrate is typicallyacyl-CoA. The enzyme is therefore also referred to as an“diacylglycerol:acyl-CoA acyltransferase,” and in some particularembodiments, as an “acyl-CoA:sn-1,2-diacylglycerol acyltransferase,” andthe like. The term may be referred to by the abbreviation DAGAT.

The term “diacylglycerol acetyltransferase” refers to a diacylglycerolacyltransferase polypeptide with a unique acyl group transferspecificity, such that the polypeptide is able to transfer an acetyl orrelated group to a diacylglycerol substrate, and such that thediacylglycerol acetyltransferase exhibits increased specificity for anacetyl or related group compared to a diacylglycerol acyltransferaseobtained from a plant in which acetyl TAGs are not present, or arepresent in only trace amounts (in other words, less than about 1% of thetotal TAGs). The specificity may be determined by either in vivo or invitro assays. From an in vivo assay, the specificity is the proportionof total TAGs that are AcTAGs, where the AcTAGs are synthesized by thepresence of a heterologous diacylglycerol acetyltransferase. From an invitro assay, the specificity is the activity of transfer of an acetyl orrelated group to a diacylglycerol, when the substrate is an acetyl-CoAor related group esterified to CoA. The increase in specificity oftransferring an acetyl or related group for an AcDAGAT is at least about1.5 times, or about 2 times, or about 5 times, or about 10 times, orabout 20 times, or about 50 times, or about 100 times, or up to about2000 times, the specificity of a DAGAT obtained from a plant in whichacetyl TAGs are not present, or are present in only trace amounts. Onestandard DAGAT to which an AcDAGAT is compared, in order to determinespecificity of transfer of an acetyl or related group, is a DAGATobtained from Arabidopsis (AtDAGAT), as described in Example 4.

The acetyl or related group substrate of the transferase is typicallyesterified to CoA; thus, typical acetyl substrate include but are notlimited to acetyl-CoA, propionyl-CoA, butyryl-CoA, benzoyl-CoA, orcinnamoyl-CoA, as described above. These CoA substrates are typicallynon-micellar acyl-CoAs, or possess high critical micelle concentrations(CMCs), in that they form micelles at relatively high concentrationswhen compared to the CMCs of long chain acyl-CoAs.

The diacylglycerol substrate of AcDAGAT is typically a long chaindiacylglycerol, although other groups are also contemplated. The acyl(or other) groups are esterified to the sn-1 and sn-2 positions,although the acyl groups may also be esterified to the sn-1 and sn-3positions, or to the sn-2 and sn-3 positions.

Thus, the enzyme is also referred to as an “diacylglycerol:acetyl-CoAacetyltransferase,” or in particular embodiments, as an“acetyl-CoA:sn-1,2-diacylglycerol acetyltransferase” and the like. Thisterm may be referred to by the abbreviation AcDAGAT, indicating anactivity of increased specificity for transfer of acetyl or relatedgroups.

The terms “Euonymus” and “Euonymus-like” when used in reference to aDAGAT refer to a DAGAT obtained from Euonymus alata or with a substratespecificity that is similar to a DAGAT obtained from Euonymus alata. Theterm may be referred to by the abbreviation, “EaDAGAT,” indicating anenzyme obtained from Euonymus alata, or from the genus Euonymus, or fromthe closely related plant family Celestraceae, or an enzyme which has anamino acid sequence with a high degree of similarity to or identity witha DAGAT obtained from Euonymus alata. By “high degree of similarity” itis meant that it is more closely related to EaDAGAT than to AtDAGAT byBLAST scores or other amino acid sequence comparison/alignment softwareprograms.

The term “substrate specificity” refers to the range of substrates thatan enzyme will act upon to produce a product.

The term “competes for binding” is used in reference to a firstpolypeptide with enzymatic activity which binds to the same substrate asdoes a second polypeptide with enzymatic activity, where the secondpolypeptide is variant of the first polypeptide or a related ordissimilar polypeptide. The efficiency (for example, kinetics orthermodynamics) of binding by the first polypeptide may be the same asor greater than or less than the efficiency substrate binding by thesecond polypeptide. For example, the equilibrium binding constants(K_(D)) for binding to the substrate may be different for the twopolypeptides.

The terms “protein” and “polypeptide” refer to compounds comprisingamino acids joined via peptide bonds and are used interchangeably.

As used herein, “amino acid sequence” refers to an amino acid sequenceof a protein molecule. “Amino acid sequence” and like terms, such as“polypeptide” or “protein,” are not meant to limit the amino acidsequence to the complete, native amino acid sequence associated with therecited protein molecule. Furthermore, an “amino acid sequence” can bededuced from the nucleic acid sequence encoding the protein.

The term “portion” when used in reference to a protein (as in “a portionof a given protein”) refers to fragments of that protein. The fragmentsmay range in size from four amino acid residues to the entire aminosequence minus one amino acid.

The term “homology” when used in relation to amino acids refers to adegree of similarity or identity. There may be partial homology orcomplete homology (in other words, identity). “Sequence identity” refersto a measure of relatedness between two or more proteins, and is givenas a percentage with reference to the total comparison length. Theidentity calculation takes into account those amino acid residues thatare identical and in the same relative positions in their respectivelarger sequences. Calculations of identity may be performed byalgorithms contained within computer programs.

The term “chimera” when used in reference to a polypeptide refers to theexpression product of two or more coding sequences obtained fromdifferent genes, that have been cloned together and that, aftertranslation, act as a single polypeptide sequence. Chimeric polypeptidesare also referred to as “hybrid” polypeptides. The coding sequencesinclude those obtained from the same or from different species oforganisms.

The term “fusion” when used in reference to a polypeptide refers to achimeric protein containing a protein of interest joined to an exogenousprotein fragment (the fusion partner). The fusion partner may servevarious functions, including enhancement of solubility of thepolypeptide of interest, as well as providing an “affinity tag” to allowpurification of the recombinant fusion polypeptide from a host cell orfrom a supernatant or from both. If desired, the fusion partner may beremoved from the protein of interest after or during purification.

The term “homolog” or “homologous” when used in reference to apolypeptide refers to a high degree of sequence identity between twopolypeptides, or to a high degree of similarity between thethree-dimensional structure or to a high degree of similarity betweenthe active site and the mechanism of action. In a preferred embodiment,a homolog has a greater than 60% sequence identity, and more preferablegreater than 75% sequence identity, and still more preferably greaterthan 90% sequence identity, with a reference sequence.

The terms “variant” and “mutant” when used in reference to a polypeptiderefer to an amino acid sequence that differs by one or more amino acidsfrom another, usually related polypeptide. The variant may have“conservative” changes, wherein a substituted amino acid has similarstructural or chemical properties (for example, replacement of leucinewith isoleucine). More rarely, a variant may have “non-conservative”changes (for example, replacement of a glycine with a tryptophan).Similar minor variations may also include amino acid deletions orinsertions (in other words, additions), or both. Guidance in determiningwhich and how many amino acid residues may be substituted, inserted ordeleted without abolishing biological activity may be found usingcomputer programs well known in the art, for example, DNAStar software.Variants can be tested in functional assays. Preferred variants haveless than 10%, and preferably less than 5%, and still more preferablyless than 2% changes (whether substitutions, deletions, and so on).

The term “gene” refers to a nucleic acid (for example, DNA or RNA)sequence that comprises coding sequences necessary for the production ofRNA, or a polypeptide or its precursor (for example, proinsulin). Afunctional polypeptide can be encoded by a full length coding sequenceor by any portion of the coding sequence as long as the desired activityor functional properties (for example, enzymatic activity, ligandbinding, signal transduction, etc.) of the polypeptide are retained. Theterm “portion” when used in reference to a gene refers to fragments ofthat gene. The fragments may range in size from a few nucleotides to theentire gene sequence minus one nucleotide. Thus, “a nucleotidecomprising at least a portion of a gene” may comprise fragments of thegene or the entire gene.

The term “gene” also encompasses the coding regions of a structural geneand includes sequences located adjacent to the coding region on both the5′ and 3′ ends for a distance of about 1 kb on either end such that thegene corresponds to the length of the full-length mRNA. The sequenceswhich are located 5′ of the coding region and which are present on themRNA are referred to as 5′ non-translated sequences. The sequences whichare located 3′ or downstream of the coding region and which are presenton the mRNA are referred to as 3′ non-translated sequences. The term“gene” encompasses both cDNA and genomic forms of a gene. A genomic formor clone of a gene contains the coding region interrupted withnon-coding sequences termed “introns” or “intervening regions” or“intervening sequences.” Introns are segments of a gene that aretranscribed into nuclear RNA (hnRNA); introns may contain regulatoryelements such as enhancers. Introns are removed or “spliced out” fromthe nuclear or primary transcript; introns therefore are absent in themessenger RNA (mRNA) transcript. The mRNA functions during translationto specify the sequence or order of amino acids in a nascentpolypeptide.

In addition to containing introns, genomic forms of a gene may alsoinclude sequences located on both the 5′ and 3′ end of the sequencesthat are present on the RNA transcript. These sequences are referred toas “flanking” sequences or regions (these flanking sequences are located5′ or 3′ to the non-translated sequences present on the mRNAtranscript). The 5′ flanking region may contain regulatory sequencessuch as promoters and enhancers that control or influence thetranscription of the gene. The 3′ flanking region may contain sequencesthat direct the termination of transcription, posttranscriptionalcleavage and polyadenylation.

The term “heterologous gene” refers to a gene encoding a factor that isnot in its natural environment (in other words, has been altered by thehand of man). For example, a heterologous gene includes a gene from onespecies introduced into another species. A heterologous gene alsoincludes a gene native to an organism that has been altered in some way(for example, mutated, added in multiple copies, linked to a non-nativepromoter or enhancer sequence, etc.). Heterologous genes may compriseplant gene sequences that comprise cDNA forms of a plant gene; the cDNAsequences may be expressed in either a sense (to produce mRNA) oranti-sense orientation (to produce an anti-sense RNA transcript that iscomplementary to the mRNA transcript). Heterologous genes aredistinguished from endogenous plant genes in that the heterologous genesequences are typically joined to nucleotide sequences comprisingregulatory elements such as promoters that are not found naturallyassociated with the gene for the protein encoded by the heterologousgene or with plant gene sequences in the chromosome, or are associatedwith portions of the chromosome not found in nature (for example, genesexpressed in loci where the gene is not normally expressed).

The term “oligonucleotide” refers to a molecule comprised of two or moredeoxyribonucleotides or ribonucleotides, preferably more than three, andusually more than ten. The exact size will depend on many factors, whichin turn depends on the ultimate function or use of the oligonucleotide.The oligonucleotide may be generated in any manner, including chemicalsynthesis, DNA replication, reverse transcription, or a combinationthereof.

The term “an oligonucleotide having a nucleotide sequence encoding agene” or “a nucleic acid sequence encoding” a specified polypeptiderefers to a nucleic acid sequence comprising the coding region of a geneor in other words the nucleic acid sequence which encodes a geneproduct. The coding region may be present in either a cDNA, genomic DNAor RNA form. When present in a DNA form, the oligonucleotide may besingle-stranded (in other words, the sense strand) or double-stranded.Suitable control elements such as enhancers/promoters, splice junctions,polyadenylation signals, etc. may be placed in close proximity to thecoding region of the gene if needed to permit proper initiation oftranscription and/or correct processing of the primary RNA transcript.Alternatively, the coding region utilized in the expression vectors ofthe present invention may contain endogenous enhancers/promoters, splicejunctions, intervening sequences, polyadenylation signals, etc. or acombination of both endogenous and exogenous control elements.

The terms “complementary” and “complementarity” refer to polynucleotides(in other words, a sequence of nucleotides) related by the base-pairingrules. For example, for the sequence “A-G-T,” is complementary to thesequence “T-C-A.” Complementarity may be “partial,” in which only someof the nucleic acids' bases are matched according to the base pairingrules. Or, there may be “complete” or “total” complementarity betweenthe nucleic acids. The degree of complementarity between nucleic acidstrands has significant effects on the efficiency and strength ofhybridization between nucleic acid strands. This is of particularimportance in amplification reactions, as well as detection methods thatdepend upon binding between nucleic acids.

The term “homology” when used in relation to nucleic acids refers to adegree of complementarity. There may be partial homology or completehomology (in other words, identity). “Sequence identity” refers to ameasure of relatedness between two or more nucleic acids, and is givenas a percentage with reference to the total comparison length. Theidentity calculation takes into account those nucleotide residues thatare identical and in the same relative positions in their respectivelarger sequences. Calculations of identity may be performed byalgorithms contained within computer programs such as “GAP” (GeneticsComputer Group, Madison, Wis.) and “ALIGN” (DNAStar, Madison, Wis.). Apartially complementary sequence is one that at least partially inhibits(or competes with) a completely complementary sequence from hybridizingto a target nucleic acid is referred to using the functional term“substantially homologous.” The inhibition of hybridization of thecompletely complementary sequence to the target sequence may be examinedusing a hybridization assay (Southern or Northern blot, solutionhybridization and the like) under conditions of low stringency. Asubstantially homologous sequence or probe will compete for and inhibitthe binding (in other words, the hybridization) of a sequence that iscompletely homologous to a target under conditions of low stringency.This is not to say that conditions of low stringency are such thatnon-specific binding is permitted; low stringency conditions requirethat the binding of two sequences to one another be a specific (in otherwords, selective) interaction. The absence of non-specific binding maybe tested by the use of a second target which lacks even a partialdegree of complementarity (for example, less than about 30% identity);in the absence of non-specific binding the probe will not hybridize tothe second non-complementary target.

When used in reference to a double-stranded nucleic acid sequence suchas a cDNA or genomic clone, the term “substantially homologous” refersto any probe which can hybridize to either or both strands of thedouble-stranded nucleic acid sequence under conditions of low stringencyas described infra.

Low stringency conditions when used in reference to nucleic acidhybridization comprise conditions equivalent to binding or hybridizationat 42° C. in a solution consisting of 5×SSPE (43.8 g/l NaCl, 6.9 g/lNaH₂PO₄.H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS,5× Denhardt's reagent [50× Denhardt's contains per 500 ml: 5 g Ficoll(Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 μg/mldenatured salmon sperm DNA followed by washing in a solution comprising5×SSPE, 0.1% SDS at 42° C. when a probe of about 500 nucleotides inlength is employed.

High stringency conditions when used in reference to nucleic acidhybridization comprise conditions equivalent to binding or hybridizationat 42° C. in a solution consisting of 5×SSPE (43.8 g/l NaCl, 6.9 g/lNaH₂PO₄.H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS,5× Denhardt's reagent and 100 μg/ml denatured salmon sperm DNA followedby washing in a solution comprising 0.1×SSPE, 1.0% SDS at 42° C. when aprobe of about 500 nucleotides in length is employed.

It is well known that numerous equivalent conditions may be employed tocomprise low stringency conditions; factors such as the length andnature (DNA, RNA, base composition) of the probe and nature of thetarget (DNA, RNA, base composition, present in solution or immobilized,etc.) and the concentration of the salts and other components (forexample, the presence or absence of formamide, dextran sulfate,polyethylene glycol) are considered and the hybridization solution maybe varied to generate conditions of low stringency hybridizationdifferent from, but equivalent to, the above listed conditions. Inaddition, the art knows conditions that promote hybridization underconditions of high stringency (for example, increasing the temperatureof the hybridization and/or wash steps, the use of formamide in thehybridization solution, etc.).

When used in reference to a double-stranded nucleic acid sequence suchas a cDNA or genomic clone, the term “substantially homologous” refersto any probe that can hybridize to either or both strands of thedouble-stranded nucleic acid sequence under conditions of low to highstringency as described above.

When used in reference to a single-stranded nucleic acid sequence, theterm “substantially homologous” refers to any probe that can hybridize(in other words, it is the complement of) the single-stranded nucleicacid sequence under conditions of low to high stringency as describedabove.

The term “hybridization” refers to the pairing of complementary nucleicacids. Hybridization and the strength of hybridization (in other words,the strength of the association between the nucleic acids) is impactedby such factors as the degree of complementary between the nucleicacids, stringency of the conditions involved, the T_(m) of the formedhybrid, and the G:C ratio within the nucleic acids. A single moleculethat contains pairing of complementary nucleic acids within itsstructure is said to be “self-hybridized.”

The term “T_(m)” refers to the “melting temperature” of a nucleic acid.The melting temperature is the temperature at which a population ofdouble-stranded nucleic acid molecules becomes half dissociated intosingle strands. The equation for calculating the T_(m) of nucleic acidsis well known in the art. As indicated by standard references, a simpleestimate of the T_(m) value may be calculated by the equation:T_(m)=81.5+0.41(% G+C), when a nucleic acid is in aqueous solution at 1M NaCl (See for example, Anderson and Young, Quantitative FilterHybridization (1985) in Nucleic Acid Hybridization). Other referencesinclude more sophisticated computations that take structural as well assequence characteristics into account for the calculation of T_(m).

As used herein the term “stringency” refers to the conditions oftemperature, ionic strength, and the presence of other compounds such asorganic solvents, under which nucleic acid hybridizations are conducted.With “high stringency” conditions, nucleic acid base pairing will occuronly between nucleic acid fragments that have a high frequency ofcomplementary base sequences. Thus, conditions of “low” stringency areoften required with nucleic acids that are derived from organisms thatare genetically diverse, as the frequency of complementary sequences isusually less.

“Amplification” is a special case of nucleic acid replication involvingtemplate specificity. It is to be contrasted with non-specific templatereplication (in other words, replication that is template-dependent butnot dependent on a specific template). Template specificity is heredistinguished from fidelity of replication (in other words, synthesis ofthe proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-)specificity. Template specificity is frequently described in terms of“target” specificity. Target sequences are “targets” in the sense thatthey are sought to be sorted out from other nucleic acid. Amplificationtechniques have been designed primarily for this sorting out.

Template specificity is achieved in most amplification techniques by thechoice of enzyme. Amplification enzymes are enzymes that, underconditions they are used, will process only specific sequences ofnucleic acid in a heterogeneous mixture of nucleic acid. For example, inthe case of Q βreplicase, MDV-1 RNA is the specific template for thereplicase (Kacian et al. (1972) Proc. Natl. Acad. Sci. USA, 69:3038).Other nucleic acid will not be replicated by this amplification enzyme.Similarly, in the case of T7 RNA polymerase, this amplification enzymehas a stringent specificity for its own promoters (Chamberlin et al.(1970) Nature, 228:227). In the case of T4 DNA ligase, the enzyme willnot ligate the two oligonucleotides or polynucleotides, where there is amismatch between the oligonucleotide or polynucleotide substrate and thetemplate at the ligation junction (Wu and Wallace (1989) Genomics,4:560). Finally, Taq and Pfu polymerases, by virtue of their ability tofunction at high temperature, are found to display high specificity forthe sequences bounded and thus defined by the primers; the hightemperature results in thermodynamic conditions that favor primerhybridization with the target sequences and not hybridization withnon-target sequences (H. A. Erlich (ed.) (1989) PCR Technology, StocktonPress).

The term “amplifiable nucleic acid” refers to nucleic acids that may beamplified by any amplification method. It is contemplated that“amplifiable nucleic acid” will usually comprise “sample template.”

The term “sample template” refers to nucleic acid originating from asample that is analyzed for the presence of “target” (defined below). Incontrast, “background template” is used in reference to nucleic acidother than sample template that may or may not be present in a sample.Background template is most often inadvertent. It may be the result ofcarryover, or it may be due to the presence of nucleic acid contaminantssought to be purified away from the sample. For example, nucleic acidsfrom organisms other than those to be detected may be present asbackground in a test sample.

The term “primer” refers to an oligonucleotide, whether occurringnaturally as in a purified restriction digest or produced synthetically,which is capable of acting as a point of initiation of synthesis whenplaced under conditions in which synthesis of a primer extension productwhich is complementary to a nucleic acid strand is induced, (in otherwords, in the presence of nucleotides and an inducing agent such as DNApolymerase and at a suitable temperature and pH). The primer ispreferably single stranded for maximum efficiency in amplification, butmay alternatively be double stranded. If double stranded, the primer isfirst treated to separate its strands before being used to prepareextension products. Preferably, the primer is anoligodeoxyribonucleotide. The primer must be sufficiently long to primethe synthesis of extension products in the presence of the inducingagent. The exact lengths of the primers will depend on many factors,including temperature, source of primer and the use of the method.

The term “polymerase chain reaction” (“PCR”) refers to the method of K.B. Mullis U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188, thatdescribe a method for increasing the concentration of a segment of atarget sequence in a mixture of genomic DNA without cloning orpurification. This process for amplifying the target sequence consistsof introducing a large excess of two oligonucleotide primers to the DNAmixture containing the desired target sequence, followed by a precisesequence of thermal cycling in the presence of a DNA polymerase. The twoprimers are complementary to their respective strands of the doublestranded target sequence. To effect amplification, the mixture isdenatured and the primers then annealed to their complementary sequenceswithin the target molecule. Following annealing, the primers areextended with a polymerase so as to form a new pair of complementarystrands. The steps of denaturation, primer annealing, and polymeraseextension can be repeated many times (in other words, denaturation,annealing and extension constitute one “cycle”; there can be numerous“cycles”) to obtain a high concentration of an amplified segment of thedesired target sequence. The length of the amplified segment of thedesired target sequence is determined by the relative positions of theprimers with respect to each other, and therefore, this length is acontrollable parameter. By virtue of the repeating aspect of theprocess, the method is referred to as the “polymerase chain reaction”(hereinafter “PCR”). Because the desired amplified segments of thetarget sequence become the predominant sequences (in terms ofconcentration) in the mixture, they are said to be “PCR amplified.”

With PCR, it is possible to amplify a single copy of a specific targetsequence in genomic DNA to a level detectable by several differentmethodologies (for example, hybridization with a labeled probe;incorporation of biotinylated primers followed by avidin-enzymeconjugate detection; incorporation of ³²P-labeled deoxynucleotidetriphosphates, such as dCTP or dATP, into the amplified segment). Inaddition to genomic DNA, any oligonucleotide or polynucleotide sequencecan be amplified with the appropriate set of primer molecules. Inparticular, the amplified segments created by the PCR process itselfare, themselves, efficient templates for subsequent PCR amplifications.

The terms “PCR product,” “PCR fragment,” and “amplification product”refer to the resultant mixture of compounds after two or more cycles ofthe PCR steps of denaturation, annealing and extension are complete.These terms encompass the case where there has been amplification of oneor more segments of one or more target sequences.

The term “amplification reagents” refers to those reagents(deoxyribonucleotide triphosphates, buffer, etc.), needed foramplification except for primers, nucleic acid template, and theamplification enzyme. Typically, amplification reagents along with otherreaction components are placed and contained in a reaction vessel (testtube, microwell, etc.).

The term “reverse-transcriptase” or “RT-PCR” refers to a type of PCRwhere the starting material is mRNA. The starting mRNA is enzymaticallyconverted to complementary DNA or “cDNA” using a reverse transcriptaseenzyme. The cDNA is then used as a “template” for a “PCR” reaction.

The term “RACE” refers to Rapid Amplification of cDNA Ends.

The term “gene expression” refers to the process of converting geneticinformation encoded in a gene into RNA (for example, mRNA, rRNA, tRNA,or snRNA) through “transcription” of the gene (in other words, via theenzymatic action of an RNA polymerase), and into protein, through“translation” of mRNA. Gene expression can be regulated at many stagesin the process. “Up-regulation” or “activation” refers to regulationthat increases the production of gene expression products (in otherwords, RNA or protein), while “down-regulation” or “repression” refersto regulation that decrease production. Molecules (for example,transcription factors) that are involved in up-regulation ordown-regulation are often called “activators” and “repressors,”respectively.

The terms “in operable combination”, “in operable order” and “operablylinked” refer to the linkage of nucleic acid sequences in such a mannerthat a nucleic acid molecule capable of directing the transcription of agiven gene and/or the synthesis of a desired protein molecule isproduced. The term also refers to the linkage of amino acid sequences insuch a manner so that a functional protein is produced.

The term “regulatory element” refers to a genetic element that controlssome aspect of the expression of nucleic acid sequences. For example, apromoter is a regulatory element that facilitates the initiation oftranscription of an operably linked coding region. Other regulatoryelements are splicing signals, polyadenylation signals, terminationsignals, etc.

Transcriptional control signals in eukaryotes comprise “promoter” and“enhancer” elements. Promoters and enhancers consist of short arrays ofDNA sequences that interact specifically with cellular proteins involvedin transcription (Maniatis, et al., Science 236:1237, 1987). Promoterand enhancer elements have been isolated from a variety of eukaryoticsources including genes in yeast, insect, mammalian and plant cells.Promoter and enhancer elements have also been isolated from viruses andanalogous control elements, such as promoters, are also found inprokaryotes. The selection of a particular promoter and enhancer dependson the cell type used to express the protein of interest. Someeukaryotic promoters and enhancers have a broad host range while othersare functional in a limited subset of cell types (for review, see Voss,et al., Trends Biochem. Sci., 11:287, 1986; and Maniatis, et al., supra1987).

The terms “promoter element,” “promoter,” or “promoter sequence” as usedherein, refer to a DNA sequence that is located at the 5′ end (in otherwords precedes) the protein coding region of a DNA polymer. The locationof most promoters known in nature precedes the transcribed region. Thepromoter functions as a switch, activating the expression of a gene. Ifthe gene is activated, it is said to be transcribed, or participating intranscription. Transcription involves the synthesis of mRNA from thegene. The promoter, therefore, serves as a transcriptional regulatoryelement and also provides a site for initiation of transcription of thegene into mRNA.

Promoters may be tissue specific or cell specific. The term “tissuespecific” as it applies to a promoter refers to a promoter that iscapable of directing selective expression of a nucleotide sequence ofinterest to a specific type of tissue (for example, seeds) in therelative absence of expression of the same nucleotide sequence ofinterest in a different type of tissue (for example, leaves). Tissuespecificity of a promoter may be evaluated by, for example, operablylinking a reporter gene to the promoter sequence to generate a reporterconstruct, introducing the reporter construct into the genome of a plantsuch that the reporter construct is integrated into every tissue of theresulting transgenic plant, and detecting the expression of the reportergene (for example, detecting mRNA, protein, or the activity of a proteinencoded by the reporter gene) in different tissues of the transgenicplant. The detection of a greater level of expression of the reportergene in one or more tissues relative to the level of expression of thereporter gene in other tissues shows that the promoter is specific forthe tissues in which greater levels of expression are detected. The term“cell type specific” as applied to a promoter refers to a promoter thatis capable of directing selective expression of a nucleotide sequence ofinterest in a specific type of cell in the relative absence ofexpression of the same nucleotide sequence of interest in a differenttype of cell within the same tissue. The term “cell type specific” whenapplied to a promoter also means a promoter capable of promotingselective expression of a nucleotide sequence of interest in a regionwithin a single tissue. Cell type specificity of a promoter may beassessed using methods well known in the art, for example,immunohistochemical staining. Briefly, tissue sections are embedded inparaffin, and paraffin sections are reacted with a primary antibody thatis specific for the polypeptide product encoded by the nucleotidesequence of interest whose expression is controlled by the promoter. Alabeled (for example, peroxidase conjugated) secondary antibody that isspecific for the primary antibody is allowed to bind to the sectionedtissue and specific binding detected (for example, with avidin/biotin)by microscopy.

Promoters may be constitutive or regulatable. The term “constitutive”when made in reference to a promoter means that the promoter is capableof directing transcription of an operably linked nucleic acid sequencein the absence of a stimulus (for example, heat shock, chemicals, light,etc.). Typically, constitutive promoters are capable of directingexpression of a transgene in substantially any cell and any tissue.Exemplary constitutive plant promoters include, but are not limited toSD Cauliflower Mosaic Virus (CaMV SD; see for example, U.S. Pat. No.5,352,605, incorporated herein by reference), mannopine synthase,octopine synthase (ocs), superpromoter (see for example, WO 95/14098),and ubi3 (see for example, Garbarino and Belknap (1994) Plant Mol. Biol.24:119-127) promoters. Such promoters have been used successfully todirect the expression of heterologous nucleic acid sequences intransformed plant tissue.

In contrast, a “regulatable” promoter is one that is capable ofdirecting a level of transcription of an operably linked nuclei acidsequence in the presence of a stimulus (for example, heat shock,chemicals, light, etc.) which is different from the level oftranscription of the operably linked nucleic acid sequence in theabsence of the stimulus.

The enhancer and/or promoter may be “endogenous” or “exogenous” or“heterologous.” An “endogenous” enhancer or promoter is one that isnaturally linked with a given gene in the genome. An “exogenous” or“heterologous” enhancer or promoter is one that is placed injuxtaposition to a gene by means of genetic manipulation (in otherwords, molecular biological techniques) such that transcription of thegene is directed by the linked enhancer or promoter. For example, anendogenous promoter in operable combination with a first gene can beisolated, removed, and placed in operable combination with a secondgene, thereby making it a “heterologous promoter” in operablecombination with the second gene. A variety of such combinations arecontemplated (for example, the first and second genes can be from thesame species, or from different species.

The presence of “splicing signals” on an expression vector often resultsin higher levels of expression of the recombinant transcript ineukaryotic host cells. Splicing signals mediate the removal of intronsfrom the primary RNA transcript and consist of a splice donor andacceptor site (Sambrook, et al. (1989) Molecular Cloning: A LaboratoryManual, 2nd ed., Cold Spring Harbor Laboratory Press, New York, pp.16.7-16.8). A commonly used splice donor and acceptor site is the splicejunction from the 16S RNA of SV40.

Efficient expression of recombinant DNA sequences in eukaryotic cellsrequires expression of signals directing the efficient termination andpolyadenylation of the resulting transcript. Transcription terminationsignals are generally found downstream of the polyadenylation signal andare a few hundred nucleotides in length. The term “poly(A) site” or“poly(A) sequence” as used herein denotes a DNA sequence which directsboth the termination and polyadenylation of the nascent RNA transcript.Efficient polyadenylation of the recombinant transcript is desirable, astranscripts lacking a poly(A) tail are unstable and are rapidlydegraded. The poly(A) signal utilized in an expression vector may be“heterologous” or “endogenous.” An endogenous poly(A) signal is one thatis found naturally at the 3′ end of the coding region of a given gene inthe genome. A heterologous poly(A) signal is one which has been isolatedfrom one gene and positioned 3′ to another gene. A commonly usedheterologous poly(A) signal is the SV40 poly(A) signal. The SV40 poly(A)signal is contained on a 237 bp BamHI/BclI restriction fragment anddirects both termination and polyadenylation (Sambrook, supra, at16.6-16.7).

The term “selectable marker” refers to a gene which encodes an enzymehaving an activity that confers resistance to an antibiotic or drug uponthe cell in which the selectable marker is expressed, or which confersexpression of a trait which can be detected (for example., luminescenceor fluorescence). Selectable markers may be “positive” or “negative.”Examples of positive selectable markers include the neomycinphosphotransferase (NPTII) gene that confers resistance to G418 and tokanamycin, and the bacterial hygromycin phosphotransferase gene (hyg),which confers resistance to the antibiotic hygromycin. Negativeselectable markers encode an enzymatic activity whose expression iscytotoxic to the cell when grown in an appropriate selective medium. Forexample, the HSV-tk gene is commonly used as a negative selectablemarker. Expression of the HSV-tk gene in cells grown in the presence ofgancyclovir or acyclovir is cytotoxic; thus, growth of cells inselective medium containing gancyclovir or acyclovir selects againstcells capable of expressing a functional HSV TK enzyme.

The term “vector refers to nucleic acid molecules that transfer DNAsegment(s) from one cell to another. The term “vehicle” is sometimesused interchangeably with “vector.”

The terms “expression vector” or “expression cassette” refer to arecombinant DNA molecule containing a desired coding sequence andappropriate nucleic acid sequences necessary for the expression of theoperably linked coding sequence in a particular host organism. Nucleicacid sequences necessary for expression in prokaryotes usually include apromoter, an operator (optional), and a ribosome binding site, oftenalong with other sequences. Eukaryotic cells are known to utilizepromoters, enhancers, and termination and polyadenylation signals.

The term “transfection” refers to the introduction of foreign DNA intocells. Transfection may be accomplished by a variety of means known tothe art including calcium phosphate-DNA co-precipitation,DEAE-dextran-mediated transfection, polybrene-mediated transfection,glass beads, electroporation, microinjection, liposome fusion,lipofection, protoplast fusion, viral infection, biolistics (in otherwords, particle bombardment) and the like.

The terms “infecting” and “infection” when used with a bacterium referto co-incubation of a target biological sample, (for example, cell,tissue, etc.) with the bacterium under conditions such that nucleic acidsequences contained within the bacterium are introduced into one or morecells of the target biological sample.

The term “Agrobacterium” refers to a soil-borne, Gram-negative,rod-shaped phytopathogenic bacterium that causes crown gall. The term“Agrobacterium” includes, but is not limited to, the strainsAgrobacterium tumefaciens, (which typically causes crown gall ininfected plants), and Agrobacterium rhizogens (which causes hairy rootdisease in infected host plants). Infection of a plant cell withAgrobacterium generally results in the production of opines (forexample, nopaline, agropine, octopine etc.) by the infected cell. Thus,Agrobacterium strains which cause production of nopaline (for example,strain LBA4301, C58, A208, GV3101) are referred to as “nopaline-type”Agrobacteria; Agrobacterium strains which cause production of octopine(for example, strain LBA4404, Ach5, B6) are referred to as“octopine-type” Agrobacteria; and Agrobacterium strains which causeproduction of agropine (for example, strain EHA105, EHA101, A281) arereferred to as “agropine-type” Agrobacteria.

The terms “bombarding, “bombardment,” and “biolistic bombardment” referto the process of accelerating particles towards a target biologicalsample (for example, cell, tissue, etc.) to effect wounding of the cellmembrane of a cell in the target biological sample and/or entry of theparticles into the target biological sample. Methods for biolisticbombardment are known in the art (for example, U.S. Pat. No. 5,584,807,the contents of which are incorporated herein by reference), and arecommercially available (for example, the helium gas-drivenmicroprojectile accelerator (PDS-1000/He, BioRad).

The term “microwounding” when made in reference to plant tissue refersto the introduction of microscopic wounds in that tissue. Microwoundingmay be achieved by, for example, particle bombardment as describedherein.

The term “transgenic” when used in reference to a plant or fruit or seed(in other words, a “transgenic plant” or “transgenic fruit” or a“transgenic seed”) refers to a plant or fruit or seed that contains atleast one heterologous gene in one or more of its cells. The term“transgenic plant material” refers broadly to a plant, a plantstructure, a plant tissue, a plant seed or a plant cell that contains atleast one heterologous gene in one or more of its cells.

The terms “transformants” or “transformed cells” include the primarytransformed cell and cultures derived from that cell without regard tothe number of transfers. All progeny may not be precisely identical inDNA content, due to deliberate or inadvertent mutations. Mutant progenythat have the same functionality as screened for in the originallytransformed cell are included in the definition of transformants.

The term “wild-type” when made in reference to a gene refers to a genethat has the characteristics of a gene isolated from a naturallyoccurring source. The term “wild-type” when made in reference to a geneproduct refers to a gene product that has the characteristics of a geneproduct isolated from a naturally occurring source. A wild-type gene isthat which is most frequently observed in a population and is thusarbitrarily designated the “normal” or “wild-type” form of the gene. Incontrast, the term “modified” or “mutant” when made in reference to agene or to a gene product refers, respectively, to a gene or to a geneproduct which displays modifications in sequence and/or functionalproperties (in other words, altered characteristics) when compared tothe wild-type gene or gene product. It is noted that naturally-occurringmutants can be isolated; these are identified by the fact that they havealtered characteristics when compared to the wild-type gene or geneproduct.

The term “antisense” refers to a deoxyribonucleotide sequence whosesequence of deoxyribonucleotide residues is in reverse 5′ to 3′orientation in relation to the sequence of deoxyribonucleotide residuesin a sense strand of a DNA duplex. A “sense strand” of a DNA duplexrefers to a strand in a DNA duplex that is transcribed by a cell in itsnatural state into a “sense mRNA.” Thus an “antisense” sequence is asequence having the same sequence as the non-coding strand in a DNAduplex. The term “antisense RNA” refers to a RNA transcript that iscomplementary to all or part of a target primary transcript or mRNA andthat blocks the expression of a target gene by interfering with theprocessing, transport and/or translation of its primary transcript ormRNA. The complementarity of an antisense RNA may be with any part ofthe specific gene transcript, in other words, at the 5′ non-codingsequence, 3′ non-coding sequence, introns, or the coding sequence. Inaddition, as used herein, antisense RNA may contain regions of ribozymesequences that increase the efficacy of antisense RNA to block geneexpression. “Ribozyme” refers to a catalytic RNA and includessequence-specific endoribonucleases. “Antisense inhibition” refers tothe production of antisense RNA transcripts capable of preventing theexpression of the target protein.

The term “siRNAs” refers to short interfering RNAs. In some embodiments,siRNAs comprise a duplex, or double-stranded region, of about 18-25nucleotides long; often siRNAs contain from about two to four unpairednucleotides at the 3′ end of each strand. At least one strand of theduplex or double-stranded region of a siRNA is substantially homologousto or substantially complementary to a target RNA molecule. The strandcomplementary to a target RNA molecule is the “antisense strand;” thestrand homologous to the target RNA molecule is the “sense strand,” andis also complementary to the siRNA antisense strand. siRNAs may alsocontain additional sequences; non-limiting examples of such sequencesinclude linking sequences, or loops, as well as stem and other foldedstructures. siRNAs appear to function as key intermediaries intriggering RNA interference in invertebrates and in vertebrates, and intriggering sequence-specific RNA degradation during posttranscriptionalgene silencing in plants.

The term “target RNA molecule” refers to an RNA molecule to which atleast one strand of the short double-stranded region of an siRNA ishomologous or complementary. Typically, when such homology orcomplementary is about 100%, the siRNA is able to silence or inhibitexpression of the target RNA molecule. Although it is believed thatprocessed mRNA is a target of siRNA, the present invention is notlimited to any particular hypothesis, and such hypotheses are notnecessary to practice the present invention. Thus, it is contemplatedthat other RNA molecules may also be targets of siRNA. Such targetsinclude unprocessed mRNA, ribosomal RNA, and viral RNA genomes.

The term “RNA interference” or “RNAi” refers to the silencing ordecreasing of gene expression by siRNAs. It is the process ofsequence-specific, post-transcriptional gene silencing in animals andplants, initiated by siRNA that is homologous in its duplex region tothe sequence of the silenced gene. The gene may be endogenous orexogenous to the organism, present integrated into a chromosome orpresent in a transfection vector that is not integrated into the genome.The expression of the gene is either completely or partially inhibited.RNAi may also be considered to inhibit the function of a target RNA; thefunction of the target RNA may be complete or partial.

The term “posttranscriptional gene silencing” or “PTGS” refers tosilencing of gene expression in plants after transcription, and appearsto involve the specific degradation of mRNAs synthesized from generepeats.

The term “overexpression” refers to the production of a gene product intransgenic organisms that exceeds levels of production in normal ornon-transformed organisms. The term “cosuppression” refers to theexpression of a foreign gene that has substantial homology to anendogenous gene resulting in the suppression of expression of both theforeign and the endogenous gene. The term “altered levels” refers to theproduction of gene product(s) in transgenic organisms in amounts orproportions that differ from that of normal or non-transformedorganisms.

The term “recombinant” when made in reference to a nucleic acid moleculerefers to a nucleic acid molecule that is comprised of segments ofnucleic acid joined together by means of molecular biologicaltechniques. The term “recombinant” when made in reference to a proteinor a polypeptide refers to a protein molecule that is expressed using arecombinant nucleic acid molecule.

The terms “Southern blot analysis” and “Southern blot” and “Southern”refer to the analysis of DNA on agarose or acrylamide gels in which DNAis separated or fragmented according to size followed by transfer of theDNA from the gel to a solid support, such as nitrocellulose or a nylonmembrane. The immobilized DNA is then exposed to a labeled probe todetect DNA species complementary to the probe used. The DNA may becleaved with restriction enzymes prior to electrophoresis. Followingelectrophoresis, the DNA may be partially depurinated and denaturedprior to or during transfer to the solid support. Southern blots are astandard tool of molecular biologists (J. Sambrook et al. (1989)Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp9.31-9.58).

The term “Northern blot analysis” and “Northern blot” and “Northern” asused herein refer to the analysis of RNA by electrophoresis of RNA onagarose gels to fractionate the RNA according to size followed bytransfer of the RNA from the gel to a solid support, such asnitrocellulose or a nylon membrane. The immobilized RNA is then probedwith a labeled probe to detect RNA species complementary to the probeused. Northern blots are a standard tool of molecular biologists (J.Sambrook, et al. (1989) supra, pp 7.39-7.52).

The terms “Western blot analysis” and “Western blot” and “Western”refers to the analysis of protein(s) (or polypeptides) immobilized ontoa support such as nitrocellulose or a membrane. A mixture comprising atleast one protein is first separated on an acrylamide gel, and theseparated proteins are then transferred from the gel to a solid support,such as nitrocellulose or a nylon membrane. The immobilized proteins areexposed to at least one antibody with reactivity against at least oneantigen of interest. The bound antibodies may be detected by variousmethods, including the use of radiolabeled antibodies.

The term “isolated” when used in relation to a nucleic acid, as in “anisolated oligonucleotide” refers to a nucleic acid sequence that isidentified and separated from at least one contaminant nucleic acid withwhich it is ordinarily associated in its natural source. Isolatednucleic acid is present in a form or setting that is different from thatin which it is found in nature. In contrast, non-isolated nucleic acids,such as DNA and RNA, are found in the state they exist in nature. Forexample, a given DNA sequence (for example, a gene) is found on the hostcell chromosome in proximity to neighboring genes; RNA sequences, suchas a specific mRNA sequence encoding a specific protein, are found inthe cell as a mixture with numerous other mRNAs that encode a multitudeof proteins. However, isolated nucleic acid encoding a plant DAGATincludes, by way of example, such nucleic acid in cells ordinarilyexpressing a DAGAT, where the nucleic acid is in a chromosomal locationdifferent from that of natural cells, or is otherwise flanked by adifferent nucleic acid sequence than that found in nature. The isolatednucleic acid or oligonucleotide may be present in single-stranded ordouble-stranded form. When an isolated nucleic acid or oligonucleotideis to be utilized to express a protein, the oligonucleotide will containat a minimum the sense or coding strand (in other words, theoligonucleotide may single-stranded), but may contain both the sense andanti-sense strands (in other words, the oligonucleotide may bedouble-stranded).

The term “purified” refers to molecules, either nucleic or amino acidsequences that are removed from their natural environment, isolated orseparated. An “isolated nucleic acid sequence” is therefore a purifiednucleic acid sequence. “Substantially purified” molecules are at least60% free, preferably at least 75% free, and more preferably at least 90%free from other components with which they are naturally associated. Theterm “purified” or “to purify” also refer to the removal of contaminantsfrom a sample. The removal of contaminating proteins results in anincrease in the percent of polypeptide of interest in the sample. Inanother example, recombinant polypeptides are expressed in plant,bacterial, yeast, or mammalian host cells and the polypeptides arepurified by the removal of host cell proteins; the percent ofrecombinant polypeptides is thereby increased in the sample.

The term “sample” is used in its broadest sense. In one sense it canrefer to a plant cell or tissue. In another sense, it is meant toinclude a specimen or culture obtained from any source, as well asbiological and environmental samples. Biological samples may be obtainedfrom plants or animals (including humans) and encompass fluids, solids,tissues, and gases. Environmental samples include environmental materialsuch as surface matter, soil, water, and industrial samples. Theseexamples are not to be construed as limiting the sample types applicableto the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compositions comprising isolateddiacylglycerol acyltransferase (DAGAT) genes and polypeptides, and inparticular to compositions comprising isolated Euonymus andEuonymus-like DAGAT genes and polypeptides, where the enzyme exhibits anincreased specificity for acetyl-CoA. These polypeptides are referred toas diacylglycerol acetyltransferase, designated “AcDAGAT,” indicating anactivity of increased specificity for transfer of acetyl or relatedgroups, and/or “EaDAGAT,” indicating an enzyme obtained from Euonymusalata. The present invention also provides compositions comprising bothnative and recombinant forms of the enzyme, as well as mutant andvariant forms, some of which possess altered characteristics relative tothe wild-type. The present invention also provides compositionscomprising novel triacylglycerols, which can be synthesized by anAcDAGAT, such as acetyldipalmitolein, acetyldiolein, acetyldiricinolein,and acetyldivernolin. The present invention also provides methods forusing AcDAGAT genes and polypeptides.

The description below provides specific, but not limiting, illustrativeexamples of embodiments of the present invention. This descriptionincludes a discovery of an AcDAGAT from Euonymus, AcDAGAT polypeptidesof the present invention, AcDAGAT coding sequences of the presentinvention, methods of identifying AcDAGATs proteins and codingsequences, methods of expressing AcDAGAT coding sequences, methods ofproducing acetyl glycerides, and methods of manipulating diacylglycerolacetyltransferase activity in plants.

I. Discovery of Diacylglycerol Acetyltransferase Gene and Polypeptide inEuonymus

Although the occurrence and structural characterization of the unusualsn-3-acetyl triacylglycerols in seed oils has been known for over thirtyyears (Kleiman et al. (1967) Lipids 2:473-478), the biosynthesis ofthese novel glycerides has only recently been investigated. Theseunusual triacylglycerols are found in varying amounts in a few plantspecies, but in Euonymus species they represent up to 98% of the totaltriacylglycerols in the seed oil. Thus, Euonymus was selected as apotential source from which an acyl-CoA:sn-1,2-diacylglycerolacyltransferase gene could be identified and isolated.

In the Euonymus sn-3-acetyl glycerides, the sn-1 and sn-2 positions areesterified with common long-chain fatty acids, predominantly palmitate,oleate and linoleate. Investigations of the biosynthesis of sn-3-acetylglycerides in Euonymus revealed that sn-3-acetyl glycerides aresynthesized by a DAGAT activity. These investigations included studiesof the tissue distribution of the acetyl glycerides, of in vivo labelingof developing seeds with [¹⁴C]acetate, and of an assay ofacetyltransferase in cell free extracts in Euonymus alata, an ornamentalshrub common to the Mid-West. The common name for this plant is BurningBush, from its distinctive red autumn foliage.

Tissue distribution of 1,2-diacyl-3-acetins and long chaintriacylglycerols. The accumulation of seed oil was examined over seeddevelopment; the results are shown in FIGS. 1 and 2. The resultsindicated an endogenous rate of accumulation of 1,2-diacyl-3-acetins(AcTAG) of about 0.5 mmoles/hour/gram fresh weight seed atmid-maturation. In addition, various tissues were analyzed for thepresence and amounts of total lipids, 1,2-diacyl-3-acetins (AcTAG), andnormal triacylglycerols (TAG); the results are shown in FIG. 3. Theglycerides were analyzed using high temperature gas chromatography (GC)with odd-chain internal standards. As expected, the largest amounts oflipids were found in embryo and endosperm tissue. TAGs were found in alltissues except root. AcTAG was found to be specific for embryo tissue,and was most predominant in endosperm tissue. Thus, AcTAG was notobserved in leaves, stems, roots, or developing floral buds.

In vivo labeling of developing Euonymus alata seeds with [¹⁴C]acetate.The incorporation of [¹⁴C]acetate into the major acyl lipid classes,namely long-chain triacylglycerol (TAG), 1,2-diacyl-3-acetin (Ac-TAG),1,2-diacylglycerol (DAG) and phosphatidyl-choline (PC), was examined inhalved seeds as a function of seed development; the results are shown inFIG. 4. The major period of endogenous lipid deposition is from day 20to day 60, which coincides with the maximum labeling of AcTAG. AcTAG islabeled both in the acetyl group and in the fatty acids, withapproximately equal labeling of fatty acids at sn-1 and sn-2 positions.Specific activity per C2 unit is much higher for sn-3 acetyl labeling (1unit/molecule) when compared to fatty acid labeling (17 or 18 C2units/molecule).

Time course for Euonymus alata seed labeling with [¹⁴C]acetate. Theincorporation of [¹⁴C]acetate into the major acyl lipid classes byhalved seeds was examined as a function of incubation time.Incorporations of acetate into total lipids and into total fatty acidsare linear with time. More significantly, incorporation into the sn-3acetyl group of 1,2-diacyl-3-acetins is also linear. There is noapparent lag phase that would indicate that there is an intermediateacetyl pool which then provides acetyl groups to the sn-3 position ofglycerides by a transacylase mechanism. This is consistent with directutilization of acetyl-CoA for the acylation of diacylglycerol (DAG).

Neither phosphatidylcholine (PC) nor diacylglycerol (DAG) containing a[¹⁴C]acetyl group was present amongst the reaction products. Moreover,acetate is used preferentially for the sn-3 acetylation of DAG whencompared to de novo fatty acid synthesis. This is consistent with acytosolic acetyl-transferase reaction.

Characterization of acyltransferase activity by in vitro assays.Acyltransferase activity was assayed by incubating [¹⁴C]acetyl-CoA withcell free extracts from developing Euonymus alata seeds and exogenous1,2-diacylglycerol (DAG). Total lipids were extracted, radioactivityassayed, then the amount of label in the 1,2-diacyl-3-acetin fractiondetermined by TLC. There was a very high (greater than about 20-fold),largely soluble acetyl-CoA hydrolase activity that competed with thetransferase for substrate. Cofactor additions that would generate otheractivated acetyl donors, namely UDP-glucose to give 1-O-acetyl-glucoseor carnitine plus carnitine acetyltransferase to give acetyl carnitine,did not enhance activity.

It was determined that the acetyltransferase can use either endogenousor exogenous 1,2-diacylglycerols as acetyl acceptors. Endogenous DAG areC18C18 or C16C18 species (C18/C16). For an exogenous DAG, both1,2-diolein (C18/C18) and 1,2-dihexanoin (C6/C6) were used. Dihexanoinwas observed to compete with endogenous DAG as the acetyl acceptor. Froman acetyl-CoA concentration curve, an estimate Of Vmax of 120nmoles/hour/gram fresh weight seed tissue was calculated. This may becompared to the endogenous rate of about 500 nmoles/hour/gram freshweight seed tissue.

Normal-phase silica TLC was routinely used for product analysis. The[¹⁴C]acetyl glyceride bands were recovered and further analyzed byreversed-phase TLC. The results indicated that the labeled AcTAGproducts co-chromatographed with mass standards (endogenous Ac-TAG forC18/C16 and a synthetic 3-acetyl-1,2-dihexanoin standard for C6/C6).

The incorporation of [¹⁴C]acetyl groups into [¹⁴C]acetyl-glycerideshowed a linear initial rate with no lag phase, which indicates nodetectable [¹⁴C]acetyl biosynthetic intermediate. This is alsoconsistent with direct utilization of acetyl-CoA for the acetylation ofDAG.

Strategy for identifying an AcDAT coding sequence. Based upon theevidence obtained from the investigations of the biosynthesis ofsn-3-acetyl glycerides in Euonymus described above, a strategy foridentifying an AcDAGAT coding sequence was developed. This strategybegins with the observation of the presence of sn-3-acetyl glycerides ina plant tissue. The next step is labeling studies of intact tissues andtissue homogenates, to confirm that the ability to synthesizesn-3-acetyl glycerides is in fact present in the tissue and to determinethe exact structure of the reaction substrates and particularly theacetyl donor. The next step is obtaining the correct cDNA from total RNAprepared from tissue (which for Euonymus is the developing seeds), whichsynthesizes sn-3-acetyl glycerides, preferably to a relatively highlevel. For Euonymus, the lipid profiles of developing seeds wereanalyzed, to determine the developmental stage when sn-3-acetylglycerides accumulated at the highest rate; seeds obtained at thisdevelopmental stage are then used to prepare a cDNA library. A cDNA forAcDAGAT is obtained via RT-PCR using degenerated primers for highlyconserved sequences identified from DAGAT gene sequences found in thedatabases, and subsequently using 3′ and 5′ RACE to define the 3′ and 5′cDNA ends (Described in more detail in Example 3). A full length cDNAclone is obtained via RT-PCR using primers based on the sequence of the3′ and 5′ RACE products; this clone is used to confirm the identity ofthe encoded sequence as an AcDAGAT.

Confirmation that the cloned sequence encodes an AcDAGAT is obtained byexpression of the clone in either an in vitro or in vivo system, suchthat either sn-3-acetyl glycerides are produced only upon expression ofthe clone, or increased amounts of sn-3-acetyl glycerides are producedonly upon expression of the clone. The 3-acetyl glycerides may beproduced in cells of an organism, or in an enzyme assay conducted withextracts obtained from an organism. Preferably, the system is in vivo,and the clone transfected into and expressed in a host organism. Morepreferably, the system in one in which sn-3-acetyl glycerides are notnormally produced; a non-limiting example is a system in which the hostorganism is a yeast strain. Even more preferably, the system possessesor is able to synthesize a suitable substrate, such as dioleoylglycerol(di-18:1-DAG), and is able to tolerate the presence of novel acyl groupsin triglycerides; a non-limiting example is a system in the hostorganism is cultured tobacco cells.

Identification of AcDAGAT coding sequence. This strategy was utilizedfor developing Euonymus alata seeds, as described above and in theExamples, and resulted in the identification and isolation of a fulllength cDNA coding sequence for a DAGAT, as shown in FIG. 5; the deducedamino acid sequence is shown in FIG. 6. The Euonymus AcDAGAT deducedamino acid sequence shares high similarity to DAGATs from other plantsources, as shown in FIG. 7. The deduced amino acid sequence is highlysimilar to all DAGAT proteins described so far for plants (50.7%identity; 91% similarity). The region of the Euonymus AcDAGAT proteinthat is most different from the other DAGAT proteins is the N-terminalend (amino acids 1-93). Other regions with differences include aminoacids 158-200 and 243-268. Ten predicted hydrophobic regions aredescribed for plant DAGATs by Kyte-Doolittle hydropathy plots, asdescribed by Hobbs et al. (1999) FEBS Lett. 452: 145-149, Bouvier-Naveet al. (2000) Eur. J. Biochem. 267: 85-96, Routaboul et al. (1999) Plantphysiol. Biochem. 37: 831-840, and Zou et al. (1999) Plant J. 19:645-653. These regions are present in the EaDAGAT. Seven transmembranespanning domains have been identified in another member of the DAGATgene family, namely the human acyl-CoA:cholesterol acyltransferase-1protein (Lin et al. (1999) J. Biol. Chem. 274: 23276-23285) using anepitope tagging approach. It is possible that a pair of transmembranedomains were missed by this approach. Given the similarity with DAGATs,it is likely that DAGATs have seven or nine actual transmembranedomains. Putative acyl-binding and active sites are described by Jako etal. (2001), Plant Phys 126, 861-874, and by others mentioned above.Putative acyl-binding and putative active sites are shown by underliningin FIG. 7.

Confirmation of the identity of the Euonymus alata AcDAGAT (EaDAGAT),and the ability of EaDAGAT to synthesize sn-3-acetyl glycerides(AcTAGs), was obtained by expression of EADAGAT in yeast cells, andobserving TAGs synthesized both in vivo in intact yeast cells, and invitro with transgenic yeast membrane fractions. Expression of EuonymusDAGAT (EaDAGAT) in yeast cells resulted in the increased synthesis oflong chain triacylglycerols (LcTAG) of about 5 fold (as described inExample 4) when compared to the control (yeast transformed with an emptyvector). Moreover, expression of EaDAGAT in yeast cells also resulted inthe synthesis of sn-3-acetyl glycerides (AcTAG) to about 0.26% of theamount of LcTAG synthesized. Three molecular species of AcTAG wereidentified by GC analysis of the hydrogenated AcTAG enriched fractionisolated by TLC; these three species are C16C16, C16C18, and C18C18(where the molecular species is identified by the length of the twofatty acyl residues at the sn1 and sn-2 positions). The C16C18 AcTAGspecies was identified by mass spectroscopy asacetyl-palmitoylsteroylglycerol, which corresponds toacetyl-palmitoleoyloleoylglycerol before hydrogenation.

Expression of Arabidopsis DAGAT (AtDAGAT) in yeast cells also resultedin increased synthesis of LcTAG (about 20 fold over control levels), aswell as in synthesis of AcTAG (about 0.09% of the amount of LcTAG).Thus, EaDAGAT exhibits an increased propensity to synthesize AcTAG whencompared to AtDAGAT in vivo in yeast cells (about 3 fold, whendetermined as the proportion of total TAGs synthesized). This enhancedpropensity to synthesize AcTAG in vivo demonstrates an increasedsubstrate specificity of the EaDAGAT for acetyl-CoA in vivo.

From in vitro assays, when assayed in the presence of an acyl donor,such as oleoyl-CoA, AtDAGAT and EaDAGAT appeared about equally active.However, when assayed in the presence of acetyl-CoA, the AtDAGAT wasmuch less active than the EaDAGAT and resulted in the synthesis of onlytrace amounts of AcTAG, whereas the EaDAGAT resulted in the synthesis oflarge amounts of AcTAG. Thus, the EaDAGAT exhibited at least about a 20fold or greater acetyltransferase activity than did the AtDAGAT. Fromthese results, the EaDAGAT demonstrates a much greater capacity tosynthesize AcTAG when provided with an acetyl donor. In summary, thesedata clearly confirm that the identified Euonymus gene encodes a proteinwhich functions as a diacylglycerol acyltransferase (DAGAT) withenhanced ability to synthesize sn-3-acetyl glycerides.

Sequence similarity alone is not sufficient to demonstrate proteinfunction and identity, as demonstrated by the similarities of thedifferent DAGAT amino acid sequences, and their different activities invivo and in vitro. Confirmation of the identity and activity of EaDAGATis obtained by expression of the isolated coding sequence anddetermination of the activity of the encoded protein. However, theEaDAGAT amino acid sequence can be used to discover other AcDAGATs, asis described further below.

II. Diacylglycerol Acetyltransferase Polypeptides

The present invention provides compositions comprising purifieddiacylglycerol acetyltransferase (AcDAGAT) polypeptides as well ascompositions comprising variants of AcDAGAT, including homologs,mutants, fragments, and fusion proteins thereof (as described furtherbelow).

In some embodiments of the present invention, the polypeptide is apurified product, obtained from expression of a native gene in a cell,while in other embodiments it may be a product of chemical syntheticprocedures, and in still other embodiments it may be produced byrecombinant techniques using a prokaryotic or eukaryotic host (forexample, by bacterial, yeast, higher plant, insect and mammalian cellsin culture). In some embodiments, depending upon the host employed in arecombinant production procedure, the polypeptide of the presentinvention may be glycosylated or may be non-glycosylated. In otherembodiments, the polypeptides of the invention may also include aninitial methionine amino acid residue.

A. Reaction Catalyzed

An AcDAGAT is a diacylglycerol acyltransferase polypeptide with a uniqueacyl group transfer specificity, such that the polypeptide is able totransfer an acetyl or related group to a diacylglycerol substrate, andsuch that the diacylglycerol acetyltransferase exhibits increasedspecificity for an acetyl or related group compared to a diacylglycerolacyltransferase obtained from a plant in which acetyl TAGs are notpresent, or are present in only trace amounts (in other words, less thanabout 1% of the total TAGs).

Thus, an AcDAGAT polypeptide catalyzes the transfer of an acetyl orrelated group to diacylglycerol (DAG), as exemplified by the followingreaction:DAG+acetyl group-->AcTAG,where the acetyl group is acetyl or a related group, and where theacetyl is transferred to diacylglycerol (DAG) to form acetyl triglycerol(AcTAG). Typically, the acetyl or related group is transferred to thesn-3 position of DAG, although other positions are also contemplated,such as the sn-1 and sn-2 positions of DAG. The enzyme in situ mostlikely acts on an acetyl group of acetyl-CoA, and most likely transfersthe acetyl group to the sn-3 position of DAG. However, the enzyme mayutilize different substrates under different conditions to differingdegrees of activity, and may produce other products as well. Thus, othersubstrates may include DAG where the sn-1 or the sn-2 position isavailable to accept the acetyl group. Other groups transferred includegroups related to acetyl, such as propionyl, butyryl, benzoyl, andcinnamoyl; typically, these groups are esterified to Co-A, such that thesubstrate of the transferase are propionyl-CoA, butyryl-CoA,benzoyl-CoA, or cinnamoyl-CoA.

The specificity of AcDAGAT may be determined by either in vivo or invitro assays. From an in vivo assay, the specificity is the proportionof total TAGs that are AcTAGs, where the AcTAGs are synthesized by thepresence of a heterologous diacylglycerol acetyltransferase. From an invitro assay, the specificity is the activity of transfer of an acetyl orrelated group to a diacylglycerol, when the substrate is an acetyl-CoAor related group esterified to CoA. The increase in specificity oftransferring an acetyl or related group for an AcDAGAT is at least about1.5 times, or about 2 times, or about 5 times, or about 10 times, orabout 20 times, or about 50 times, or about 100 times, or up to about2000 times, the specificity of a DAGAT obtained from a plant in whichacetyl TAGs are not present, or are present in only trace amounts. Onestandard DAGAT to which an AcDAGAT is compared, in order to determinespecificity of transfer of an acetyl or related group, is a DAGATobtained from Arabidopsis (AtDAGAT), as described in Example 4.

B. Euonymus Diacylglycerol Acetyltransferase Polypeptide

In some embodiments, the polypeptide comprises a Euonymus DAGAT; inother embodiments, the polypeptide comprises a Euonymus alata DAGAT. Inone embodiment, the polypeptide is encoded by the sequence shown in FIG.5 (SEQ ID NO:1); in other embodiments, the polypeptide comprises theamino acid sequence shown in FIG. 6 (SEQ ID NO:2).

As described above under the reaction catalyzed by an AcDAGAT, aparticular feature of an AcDAGAT from Euonymus is its ability to useacetyl-CoA (or a related group-CoA) instead of long-chain acyl-CoAs.These latter substrates presumably bind to acyl-CoA binding proteins andto membranes, and form micelles by themselves, whereas acetyl-CoA istruly water soluble. Thus the ability of an AcDAGAT to utilize awater-soluble acyl-CoA (or related group-CoA) substrate is an importantfeature.

C. Variant Diacylglycerol Acetyltransferase Polypeptides

In other embodiments, the present invention provides isolated variantsof the disclosed AcDAGAT polypeptides; these variants include mutants,fragments, fusion proteins or functional equivalents of AcDAGAT.Exemplary variants are described further below.

D. Assay of Diacylglycerol Acetyltransferase Polypeptides

The activity of diacylglycerol acetyltransferase (AcDAGAT) may beassayed in a number of ways. These include, but are not limited to, invivo assays and in vitro assays, as described further below.

In some embodiments, enzyme activity is determined in vivo by expressinga nucleic acid sequence encoding the acetyltransferase in a transgenicorganism and then analyzing the content and composition of the TAGfraction present in the transgenic organism. Thus, the activity ismeasured as the presence of or increase in the amount of endogenous TAGand acetylated TAG (AcTAG) in a transgenic organism which comprises anexogenous nucleic acid sequence having a coding sequence of the presentinvention (for example, encoding an AcDAGAT, as, for example, SEQ IDNO:2, or comprising an AcDAGAT coding sequence, as, for example, SEQ IDNO: 1); such transgenic organisms are obtained as described below. Theamount of TAG and AcTAG in a transgenic organism is compared to thatpresent in a non-transgenic organism. The TAGs are typically analyzedfrom lipids extracted from samples of a transgenic organism; the samplesare homogenized in methanol/chloroform (2:1, v/v) and the lipidsextracted as described by Bligh and Dyer (1959) Can. J. Biochem.Physiol. 37: 911-917, or in hexane:isopropanol as described by Hara andRadin (1978) Anal. Biochem. 90: 420-426.

In other embodiments, enzyme activity is determined in vivo by addingexogenous substrates to tissue samples obtained from an organism thatmay or may not be transgenic (transgenic organisms are described below).For example, in plants, tissue samples include but are not limited toleaf samples (such as discs), stem and root samples, and developing andmature seed embryonic or endosperm tissue. Typically, tissue samples areincubated with [¹⁴C]acetate substrate, which can be taken up andincorporated into tissue lipids. Incubations generally proceed at roomtemperature in a buffered solution, such as 0.1M potassium MES at pH5.5-6.5, for a suitable period of time. The samples are then washed inbuffer, and the tissue samples homogenized in methanol/chloroform (2:1,v/v) and the lipids extracted as described by Bligh and Dyer (1959), orin hexane:isopropanol as described by Hara and Radin (1978).

In yet other embodiments, enzyme activity is determined in vitro in acell-free homogenate or subcellular fraction obtained from an organismwhich may or may not be transgenic (transgenic organisms are describedbelow), where the tissue is disrupted and filtered or centrifuged toresult in cell-free fractions. For example, in plants, subcellularfractions may be obtained from any of the types of tissues describedabove, and include whole cell and microsomal membranes, plastids andplastid membrane fractions, or other isolated and purified organellesand membranes such as mitochondria and peroxisomes and plasmalemma. Thepreparation of such fractions is well-known in the art. The subcellularfraction is then incubated with an acetyl- or related group-CoAsubstrate, such as ¹⁴C-acetyl-CoA, which can be taken up andincorporated into tissue lipids. Additional co-factors for lipidsynthesis, as required, may be present during the incubation; suchco-factors include but are not limited to DAG. Other reagents which mayenhance lipid synthesis may also be added; such reagents includephospholipid liposomes (for example, containing DAG) and lipid transferproteins. The samples are incubated and the lipids extracted asdescribed above.

In yet other embodiments, enzyme activity is determined from an in-vitronucleic acid expression system, to which a nucleic acid sequence havinga coding sequence of the present invention (for example, encoding anAcDAGAT, as, for example, SEQ ID NO:2, or comprising an AcDAGAT codingsequence, as, for example, SEQ ID NO: 1) is added and the encoded enzymeexpressed, and the activity of the expressed enzyme determined. Suchexpression systems are well-known in the art, and include, for examplereticulocyte lysate or wheat germ. The enzyme may be stabilized by thepresence of TAGs and/or other glycerolipids, by phosphoglycerolipidsthat produce membrane structures, or by mixtures of lipids anddetergents that produce micellar structures; these structures may beincluded in the mixture and may include the substrate upon which theenzyme might act, and might include the product produced by the enzyme.It is preferable that such micellar structures are obtained from sourcessuch as from plant tissues where the plant does not contain endogenousdiacylglycerol acetyltransferase activity, but which does possess DAG,or other lipids which can be used to produce DAG (such as aglycerolipid), or which can incorporate DAG. Direct and quantitativemeasurements require the incorporation of labeled lipids into themicellar or membrane structures and the assurance that the utilizationof a DAG substrate is not limiting. The activity of newly-expressedenzyme is then analyzed as described above for subcellular fractions.

The extracted lipid products of AcDAGAT are analyzed by methodswell-known in the art. For example, the extracted TAG products can beanalyzed by normal-phase silica TLC, reversed-phase or silver nitrateTLC (used, for example, for analysis of products first separated bynormal-phase silica TLC), high temperature GC (in some cases withodd-chain internal standards), by GC/MS, and by HPLC.

E. Purification of Diacylglycerol Acetyltransferase Polypeptides

In some embodiments of the present invention, a diacylglycerolacetyltransferase (AcDAGAT) polypeptide purified from organisms isprovided; such organisms include transgenic organisms, comprising aheterologous AcDAGAT gene, as well as organisms in which AcDAGAT occursnaturally. In other embodiments, an AcDAGAT polypeptide is purified froman in vitro nucleic acid expression system, which comprises a nucleicacid sequence having a coding sequence of the present invention (forexample, encoding an AcDAGAT, as, for example, SEQ ID NO:2, orcomprising an AcDAGAT coding sequence, as, for example, SEQ ID NO: 1)and from which the expressed AcDAGAT can be purified. The presentinvention provides a purified AcDAGAT polypeptide as well as variants,including homologs, mutants, fragments, and fusion proteins thereof (asdescribed further below).

The present invention also provides methods for recovering and purifyingplant AcDAGAT from an organism or from an in vitro nucleic acidexpression system; exemplary organisms include single and multi-cellularorganisms. When isolated from an organism, the cells are typically firstdisrupted and then fractionated before subsequent enzyme purification;disruption and fractionation methods are well-known.

Purification methods are also well-known, and include, but are notlimited to, ammonium sulfate or ethanol precipitation, acid extraction,anion or cation exchange chromatography, phosphocellulosechromatography, hydrophobic interaction chromatography, affinitychromatography, hydroxylapatite chromatography and lectinchromatography, and ioselectric focusing. It is contemplated thatAcDAGAT purified in an active or inactive form will require the presenceof detergents to maintain its solubility in aqueous media duringfractionation. It is further contemplated that assay of the enzymeactivity will require removal of the detergent and reconstitution inliposomes to recover full activity. Such methods are well known, forexample see Hjelmeland and Chrambach, Furth et al., and van Renswoudeand Kempf (1984) Methods in Enzymology 104, p305, 318 and 329respectively.

The present invention further provides nucleic acid sequences having acoding sequence of the present invention (for example, SEQ ID NO: 1)fused in frame to a marker sequence that allows for expression alone orboth expression and purification of the polypeptide of the presentinvention. A non-limiting example of a marker sequence is ahexahistidine tag that may be supplied by a vector, for example, apQE-30 vector which adds a hexahistidine tag to the N terminal of anAcDAGAT and which results in expression of the polypeptide in the caseof a bacterial host, and in other embodiments by vector PT-23B, whichadds a hexahistidine tag to the C terminal of an AcDAGAT and whichresults in improved ease of purification of the polypeptide fused to themarker in the case of a bacterial host, or, for example, the markersequence may be a hemagglutinin (HA) tag when a mammalian host is used.The HA tag corresponds to an epitope derived from the influenzahemagglutinin protein (Wilson et al. (1984) Cell 37:767).

F. Chemical Synthesis of Diacylglycerol Acetyltransferase Polypeptides

In some embodiments of the present invention, an AcDAGAT protein isproduced using chemical methods to synthesize either an entire AcDAGATamino acid sequence or a portion thereof. For example, peptides aresynthesized by solid phase techniques, cleaved from the resin, andpurified by preparative high performance liquid chromatography (See forexample, Creighton (1983) Proteins Structures And Molecular Principles,W H Freeman and Co, New York N.Y.). In other embodiments of the presentinvention, the composition of the synthetic peptides is confirmed byamino acid analysis or sequencing (See for example, Creighton, supra).

Direct peptide synthesis can be performed using various solid-phasetechniques (Roberge et al. (1995) Science, 269:202-204) and automatedsynthesis may be achieved, for example, using ABI 431A PeptideSynthesizer (Perkin Elmer) in accordance with the instructions providedby the manufacturer. Additionally, an amino acid sequence of an AcDAGAT,or any part thereof, may be altered during direct synthesis and/orcombined using chemical methods with other sequences to produce avariant polypeptide.

G. Generation of Diacylglycerol Acetyltransferase Antibodies

In some embodiments of the present invention, antibodies are generatedto allow for the detection and characterization of an AcDAGAT protein.The antibodies may be prepared using various immunogens. In oneembodiment, the immunogen is a Euonymus AcDAGAT peptide (for example, anamino acid sequence as depicted in SEQ ID NO:2, or fragments thereof) togenerate antibodies that recognize Euonymus AcDAGAT. Such antibodiesinclude, but are not limited to polyclonal, monoclonal, chimeric, singlechain, Fab fragments, and Fab expression libraries.

Various procedures known in the art may be used for the production ofpolyclonal antibodies directed against an AcDAGAT. For the production ofantibody, various host animals can be immunized by injection with thepeptide corresponding to an AcDAGAT epitope including but not limited torabbits, mice, rats, sheep, goats, etc. In a preferred embodiment, thepeptide is conjugated to an immunogenic carrier (for example, diphtheriatoxoid, bovine serum albumin (BSA), or keyhole limpet hemocyanin (KLH)).Various adjuvants may be used to increase the immunological response,depending on the host species, including but not limited to Freund's(complete and incomplete), mineral gels (for example, aluminumhydroxide), surface active substances (for example, lysolecithin,pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpethemocyanins, dinitrophenol, and potentially useful human adjuvants suchas BCG (Bacille Calmette-Guerin) and Corynebacterium parvum).

For preparation of monoclonal antibodies directed toward an AcDAGAT, itis contemplated that any technique that provides for the production ofantibody molecules by continuous cell lines in culture finds use withthe present invention (See for example, Harlow and Lane, Antibodies: ALaboratory Manual, Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N.Y.). These include but are not limited to the hybridomatechnique originally developed by Köhler and Milstein (Köhler andMilstein (1975) Nature, 256:495-497), as well as the trioma technique,the human B-cell hybridoma technique (See for example, Kozbor et al.(1983) Immunol. Tod., 4:72), and the EBV-hybridoma technique to producehuman monoclonal antibodies (Cole et al. (1985) in Monoclonal Antibodiesand Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

In addition, it is contemplated that techniques described for theproduction of single chain antibodies (U.S. Pat. No. 4,946,778) find usein producing an AcDAGAT-specific single chain antibodies. An additionalembodiment of the invention utilizes the techniques described for theconstruction of Fab expression libraries (Huse et al. (1989) Science,246:1275-1281) to allow rapid and easy identification of monoclonal Fabfragments with the desired specificity for an AcDAGAT.

It is contemplated that any technique suitable for producing antibodyfragments finds use in generating antibody fragments that contain theidiotype (antigen binding region) of the antibody molecule. For example,such fragments include but are not limited to: F(ab′)₂ fragment that canbe produced by pepsin digestion of the antibody molecule; Fab′ fragmentsthat can be generated by reducing the disulfide bridges of the F(ab′)₂fragment, and Fab fragments that can be generated by treating theantibody molecule with papain and a reducing agent.

In the production of antibodies, it is contemplated that screening forthe desired antibody is accomplished by techniques known in the art (forexample, radioimmunoassay, ELISA (enzyme-linked immunosorbant assay),“sandwich” immunoassays, immunoradiometric assays, gel diffusionprecipitin reactions, immunodiffusion assays, in situ immunoassays (forexample, using colloidal gold, enzyme or radioisotope labels, forexample), Western blots, precipitation reactions, agglutination assays(for example, gel agglutination assays, hemagglutination assays, etc.),complement fixation assays, immunofluorescence assays, protein A assays,and immunoelectrophoresis assays, etc.

In one embodiment, antibody binding is detected by detecting a label onthe primary antibody. In another embodiment, the primary antibody isdetected by detecting binding of a secondary antibody or reagent to theprimary antibody. In a further embodiment, the secondary antibody islabeled. Many methods are known in the art for detecting binding in animmunoassay and are within the scope of the present invention. As iswell known in the art, the immunogenic peptide should be provided freeof the carrier molecule used in any immunization protocol. For example,if the peptide was conjugated to KLH, it may be conjugated to BSA, orused directly, in a screening assay.

In some embodiments of the present invention, the foregoing antibodiesare used in methods known in the art relating to the expression of anAcDAGAT (for example, for Western blotting), measuring levels thereof inappropriate biological samples, etc. The antibodies can be used todetect AcDAGAT in a biological sample from a plant. The biologicalsample can be an extract of a tissue, or a sample fixed for microscopicexamination.

The biological samples are then tested directly for the presence ofAcDAGAT using an appropriate strategy (for example, ELISA orradioimmunoassay) and format (for example, microwells, dipstick (forexample, as described in International Patent Publication WO 93/03367),etc. Alternatively, proteins in the sample can be size separated (forexample, by polyacrylamide gel electrophoresis (PAGE), in the presenceor not of sodium dodecyl sulfate (SDS), and the presence of AcDAGATdetected by immunoblotting (Western blotting). Immunoblotting techniquesare generally more effective with antibodies generated against a peptidecorresponding to an epitope of a protein, and hence, are particularlysuited to the present invention.

III. Diacylglycerol Acetyltransferase Coding Sequences

The present invention provides compositions comprising purified nucleicacid sequences encoding any of the diacylglycerol acetyltransferasesdescribed above or below. Coding sequences include but are not limitedto genes, cDNA, and RNA.

Thus, the present invention provides compositions comprising purifiednucleic acid sequences encoding an AcDAGAT, as well as nucleic acidsequences encoding variants of AcDAGAT, including homologs, mutants, orfragments, or fusion proteins thereof, as described above and below. Inyet other embodiments, the nucleic acid sequences encode a portion of anAcDAGAT that retains some functional characteristic of a DAGAT. Examplesof functional characteristics include the ability to act as an immunogento produce an antibody that recognizes a DAGAT.

Coding sequences for AcDAGAT include sequences isolated from anorganism, which either comprises the coding sequence naturally or istransgenic and comprises a heterologous AcDAGAT coding sequence,sequences which are chemically synthesized, as well as sequences whichrepresent a combination of isolated and synthesized (as, for example,where isolated sequences are mutagenized, or where a sequence comprisesparts of sequences isolated from different sources and/or synthesizedfrom different sources).

Thus, in some embodiments of the invention, the coding sequence of adiacylglycerol acetyltransferase (AcDAGAT) is synthesized, whole or inpart, using chemical methods well known in the art (See for example,Caruthers et al. (1980) Nucl. Acids Res. Symp. Ser. 7:215-233; Crea andHorn (1980) Nucl. Acids Res. 9:2331; Matteucci and Caruthers (1980)Tetrahedron Lett. 21:719; and Chow and Kempe (1981) Nucl. Acids Res.9:2807-2817.

A. Euonymus Diacylglycerol Acetyltransferase Coding Sequence

In some embodiments, the sequences encode a Euonymus diacylglycerolacetyltransferase (AcDAGAT); in other embodiments, the sequences encodea Euonymus alata AcDAGAT. In some embodiments, the sequences comprisethe sequence shown in FIG. 5 (SEQ ID NO:1); in other embodiments, thesequences encode the amino acid sequence shown in FIG. 6 (SEQ ID NO:2).

B. Variant Diacylglycerol Acetyltransferase Coding Sequences

In other embodiments, the sequences encode a variant of the discloseddiacylglycerol acetyltransferase (AcDAGAT) polypeptides; these variantsinclude mutants, fragments, fusion proteins or functional equivalents ofAcDAGAT. Exemplary sequences encoding variants are described furtherbelow.

C. Additional Diacylglycerol Acetyltransferase Coding Sequences andGenes

The present invention provides isolated nucleic acid sequences encodingAcDAGAT in addition to those described above. For example, someembodiments of the present invention provide isolated polynucleotidesequences that are capable of hybridizing to SEQ ID NO: 1 underconditions of low to high stringency as long as the polynucleotidesequence capable of hybridizing encodes a protein that retains a desiredbiological activity of AcDAGAT as described above. In preferredembodiments, hybridization conditions are based on the meltingtemperature (T_(m)) of the nucleic acid binding complex and confer adefined “stringency” as explained above (See for example, Wahl et al.(1987) Meth. Enzymol., 152:399-407, incorporated herein by reference).

In other embodiments, an isolated nucleic acid sequence encoding anAcDAGAT that is homologous to the Euonymus DAGAT is provided; in someembodiments, the sequence is obtained from a plant from familiesCelastraceae, Lardizabalaceae, Rosaceae and Ranunculaceae.

In other embodiments of the present invention, alleles of an AcDAGAT areprovided. In preferred embodiments, alleles result from a mutation, (inother words, a change in the nucleic acid sequence) and generallyproduce altered mRNAs or polypeptides whose structure or function may ormay not be altered. Any given gene may have none, one or many allelicforms. Common mutational changes that give rise to alleles are generallyascribed to deletions, additions or substitutions of nucleic acids. Eachof these types of changes may occur alone, or in combination with theothers, and at the rate of one or more times in a given sequence.

These additional AcDAGAT genes are discovered by the methods such as aredescribed below.

IV. Methods of Identifying Diacylglycerol Acetyltransferase CodingSequences and Genes

Other embodiments of the present invention provide methods to isolatenucleic acid sequences encoding AcDAGAT. In some embodiments, themethods include the step of providing plant tissue in which AcTAGs arepresent; this step is based upon the hypothesis that the presence ofAcTAGs in plant tissue, preferably seed tissue, is indicative of thepresence of DAGAT with diacylglycerol acetyltransferase activity, or anAcDAGAT. AcTAG is present in a tissue if it is present at greater thanabout 1% of the total TAGs in that tissue; in preferred embodiments,AcTAGs are present at greater than about 5% of the total TAGs in thattissue, or present at greater than about 10% of the total TAGs in thattissue.

In some embodiments, method involve obtaining a cDNA for DAGAT by usingRT-PCR with degenerated primers (exemplary primers are listed in theExamples; alternatively, methods for determining degenerated primers arealso provided in the Examples) to give a partial length clone, andsubsequently using 3′ and 5′ RACE to define the 3′ and 5′ cDNA ends. Afull length cDNA clone is then obtained via RT-PCR using primers basedon the sequence of the 3′ and 5′ RACE products; this clone is then usedto confirm the identity of the encoded polypeptide as an AcDAGAT.Confirmation of the identity of the encoded polypeptide includesexpressing the polypeptide of the sequence encoding a putative AcDAGAT(for example the full length cDNA clone), and characterizing thepolypeptide of the putative AcDAGAT coding sequence. Characterizationincludes but is not limited to detecting the presence of the expressedpolypeptide by antibody-binding (where, for example, the antibody isspecific for AcDAGAT, such as by binding to Euonymus AcDAGAT) or bydetecting the reaction products of the expressed polypeptide as in anyof the AcDAGAT assays described above. In further embodiments, AcTAGsare present in the tissue from which the cDNA is prepared. Employingthis RT-PCR method resulted in the discovery of a Euonymus AcDAGAT, asdescribed above and in illustrative Examples. The isolated novel codingsequence was demonstrated to encode a diacylglycerol acetyltransferase,as described in the illustrative Examples. Thus, the nucleotide sequenceencoding a Euonymus AcDAGAT, and the deduced amino acid sequence of theEuonymus, are shown in FIGS. 5 and 6 (SEQ ID NOs: 1 and 2,respectively).

In some other embodiments, methods involve the preparation of a cDNAlibrary from tissue; in further embodiments, AcTAGs are present in thetissue from which the cDNA library is prepared. In some preferredembodiments, AcTAGs are present in relatively high levels, at greaterthan about 25% of the total TAGs in the tissue, or at greater than about50% of the total TAGs in the tissue. The cDNA library may be screened byhybridization with a DAGAT probe, or with an AcDAGAT probe (obtained,for example, from SEQ ID NO:1). cDNA clones are identified which appearto encode a DAGAT or an AcDAGAT; in other embodiments, cDNA clones areidentified which appear to code for a portion of a DAGAT or AcDAGAT, andwhich can be assembled into or utilized to create a complete codingsequence. Further embodiments include confirmation of a coding sequenceas an AcDAGAT, as described above.

In yet other embodiments, methods involve first an examination of aplant expressed sequence tag (EST) database, in order to discover novelpotential DAGAT encoding sequences. Preferably, the plant source of theEST database comprises tissue in which AcTAGs are present, such as itsseed tissue. In some embodiments, examination of a plant EST databaseinvolves blasting the database with the amino acid sequence of theEuonymus AcDAGAT (for example, SEQ ID NO:2), in order to discover ESTsencoding amino acid sequences with homology to the Euonymus AcDAGATprotein. In some further embodiments, the methods involve nextassembling a clone encoding a complete putative AcDAGAT, andcharacterizing the expression products of such sequences so discoveredas described above. In other further embodiments, these methods nextinvolve sequencing likely candidate sequences, and characterizing theexpression products of such sequences so discovered as described above.In some embodiments, AcDAGAT coding sequences, discovered by the methodsof the present invention, can also be used to identify and isolate otherplant genes. To isolate a gene, a ³²P-radiolabeled AcDAGAT codingsequence (or cDNA) is used to screen, by DNA-DNA hybridization, agenomic library constructed from a plant genomic DNA. In furtherembodiments, AcTAGs are present in the tissue from which the cDNA isprepared. Single isolated clones that test positive for hybridizationare proposed to contain part or all of an AcDAGAT gene, and aresequenced. The sequence of the positive cloned plant genomic DNA is usedto confirm the identity of the gene as an AcDAGAT. If a particular cloneencodes only part of the gene, additional clones that test positive forhybridization to the AcDAGAT coding sequence (or cDNA) are isolated andsequenced. Comparison of the full-length sequence of a putative AcDAGATgene to a cDNA is used to determine the location of introns, if they arepresent.

In other embodiments of the present invention, upstream sequences suchas promoters and regulatory elements of a gene encoding an AcDAGAT aredetected by extending the gene by utilizing a nucleotide sequenceencoding AcDAGAT (for example, SEQ ID NO:1) in various methods known inthe art. In some embodiments, it is contemplated that polymerase chainreaction (PCR) finds use in the present invention. This is a directmethod that uses universal primers to retrieve unknown sequence adjacentto a known locus (Gobinda et al. (1993) PCR Methods Applic., 2:318-322).First, genomic DNA is amplified in the presence of primer to a linkersequence and a primer specific to the known region. The amplifiedsequences are then subjected to a second round of PCR with the samelinker primer and another specific primer internal to the first one.Products of each round of PCR are transcribed with an appropriate RNApolymerase and sequenced using reverse transcriptase.

In another embodiment, inverse PCR is used to amplify or extendsequences using divergent primers based on a known region (Triglia etal. (1988) Nucleic Acids Res., 16:8186). The primers may be designedusing Oligo 4.0 (National Biosciences Inc, Plymouth Minn.), or anotherappropriate program, to be, for example, 22-30 nucleotides in length, tohave a GC content of 50% or more, and to anneal to the target sequenceat temperatures about 68-72° C. The method uses several restrictionenzymes to generate a suitable fragment in the known region of a gene.The fragment is then circularized by intramolecular ligation and used asa PCR template. In yet other embodiments of the present invention,capture PCR (Lagerstrom et al. (1991) PCR Methods Applic., 1: 111-119)is used. This is a method for PCR amplification of DNA fragmentsadjacent to a known sequence in human and yeast artificial chromosome(YAC) DNA. Capture PCR also requires multiple restriction enzymedigestions and ligations to place an engineered double-stranded sequenceinto an unknown portion of the DNA molecule before PCR. In still otherembodiments, walking PCR is utilized. Walking PCR is a method fortargeted gene walking that permits retrieval of unknown sequence (Parkeret al. (1991) Nucleic Acids Res., 19:3055-60). The PROMOTERFINDER kit(Clontech) uses PCR, nested primers and special libraries to “walk in”genomic DNA. This process avoids the need to screen libraries and isuseful in finding intron/exon junctions. In yet other embodiments of thepresent invention, add TAIL PCR is used as a preferred method forobtaining flanking genomic regions, including regulatory regions (Luiand Whittier, (1995); Lui et al. (1995)).

Preferred libraries for screening for full-length cDNAs includelibraries that have been size-selected to include larger cDNAs. Also,random primed libraries are preferred, in that they contain moresequences that contain the 5′ and upstream gene regions. A randomlyprimed library may be particularly useful in cases where an oligo d(T)library does not yield full-length cDNA. Genomic libraries are usefulfor obtaining introns and extending 5′ sequence.

It is contemplated that the methods described above are used to discoverother AcDAGATs coding sequences and genes from plants that are known topossess AcTAGs. Exemplary plants include those from familiesCelastraceae, Lardizabalaceae, Rosaceae and Ranunculaceae.

V. Variants of Diacylglycerol Acetyltransferase

In some embodiments, the present invention provides isolated variants ofthe disclosed nucleic acid sequence encoding AcDAGAT, and thepolypeptides encoded thereby; these variants include mutants, fragments,fusion proteins, or functional equivalents of AcDAGAT. Thus, nucleotidesequences of the present invention are engineered in order to alter anAcDAGAT coding sequence for a variety of reasons, including but notlimited to alterations that modify the cloning, processing and/orexpression of the gene product (such alterations include inserting newrestriction sites, altering glycosylation patterns, and changing codonpreference) as well as varying the enzymatic activity (such changesinclude but are not limited to differing substrate affinities, differingsubstrate preferences and utilization, differing inhibitor affinities oreffectiveness, differing reaction kinetics, varying subcellularlocalization, and varying protein processing and/or stability). Forexample, mutations are introduced which alter the substrate specificity,such that the preferred substrate is changed.

In other embodiments, the present invention provides isolated nucleicacid sequences encoding an AcDAGAT, where the encoded acetyltransferasecompetes for binding to an unsaturated fatty acid substrate with aprotein comprising the amino acid sequence of SEQ ID NO:2.

A. Mutants and Homologs of a Plant Diacylglycerol Acetyltransferase

Some embodiments of the present invention provide mutant forms of anAcDAGAT (in other words, muteins). In preferred embodiments, variantsresult from mutation, (in other words, a change in the nucleic acidsequence) and generally produce altered mRNAs or polypeptides whosestructure or function may or may not be altered. Any given gene may havenone, one, or many mutant forms. Common mutational changes that giverise to variants are generally ascribed to deletions, additions orsubstitutions of nucleic acids. Each of these types of changes may occuralone, or in combination with the others, and at the rate of one or moretimes in a given sequence.

Still other embodiments of the present invention provide isolatednucleic acid sequence encoding AcDAGAT homologs, and the polypeptidesencoded thereby.

It is contemplated that is possible to modify the structure of a peptidehaving an activity (for example, a diacylglycerol acetyltransferaseactivity) for such purposes as increasing synthetic activity or alteringthe affinity of the AcDAGAT for a substrate, or for increasing stabilityor turnover or subcellular location of the polypeptide. Such modifiedpeptides are considered functional equivalents of peptides having anactivity of an AcDAGAT as defined herein. A modified peptide can beproduced in which the nucleotide sequence encoding the polypeptide hasbeen altered, such as by substitution, deletion, or addition.

In some preferred embodiments of the present invention, the alterationincreases synthetic activity or alters the affinity of the AcDAGAT for aparticular acetyl- or related group-CoA or acetyl or related groupacceptor substrate. In particularly preferred embodiments, thesemodifications do not significantly reduce the synthetic activity of themodified enzyme. In other words, construct “X” can be evaluated in orderto determine whether it is a member of the genus of modified or variantAcDAGAT of the present invention as defined functionally, rather thanstructurally. In preferred embodiments, the activity of variant AcDAGATis evaluated by the methods described in the Examples. Accordingly, insome embodiments the present invention provides nucleic acids encodingan AcDAGAT that complement the coding region of SEQ ID NO: 1. In otherembodiments, the present invention provides nucleic acids encoding anAcDAGAT that compete for the binding of diacylglycerol or acetylsubstrates with the protein encoded by SEQ ID NO: 1.

In other preferred embodiments of the alteration, the alteration resultsin intracellular half-lives dramatically different from that of thecorresponding wild-type protein. For example, an altered protein isrendered either more stable or less stable to proteolytic degradation orother cellular process that result in destruction of, or otherwiseinactivate AcDAGAT. Such homologs, and the genes that encode them, canbe utilized to alter the activity of AcDAGAT by modulating the half-lifeof the protein. For instance, a short half-life can give rise to moretransient AcDAGAT biological effects. Other variants havecharacteristics which are either similar to wild-type AcDAGAT, or whichdiffer in one or more respects from wild-type AcDAGAT.

As described above, mutant forms of an AcDAGAT are also contemplated asbeing equivalent to those peptides and DNA molecules that are set forthin more detail herein. For example, it is contemplated that isolatedreplacement of a leucine with an isoleucine or valine, an aspartate witha glutamate, a threonine with a serine, or a similar replacement of anamino acid with a structurally related amino acid (in other words,conservative mutations) will not have a major effect on the biologicalactivity of the resulting molecule. Accordingly, some embodiments of thepresent invention provide variants of an AcDAGAT disclosed hereincontaining conservative replacements. Conservative replacements arethose that take place within a family of amino acids that are related intheir side chains. Genetically encoded amino acids can be divided intofour families: (1) acidic (aspartate, glutamate); (2) basic (lysine,arginine, histidine); (3) nonpolar (alanine, valine, leucine,isoleucine, proline, phenylalanine, methionine, tryptophan); and (4)uncharged polar (glycine, asparagine, glutamine, cysteine, serine,threonine, tyrosine). Phenylalanine, tryptophan, and tyrosine aresometimes classified jointly as aromatic amino acids. In similarfashion, the amino acid repertoire can be grouped as (1) acidic(aspartate, glutamate); (2) basic (lysine, arginine, histidine), (3)aliphatic (glycine, alanine, valine, leucine, isoleucine, serine,threonine), with serine and threonine optionally be grouped separatelyas aliphatic-hydroxyl; (4) aromatic (phenylalanine, tyrosine,tryptophan); (5) amide (asparagine, glutamine); and (6)sulfur-containing (cysteine and methionine) (for example, Stryer ed.(1981) Biochemistry, pg. 17-21, 2nd ed, WH Freeman and Co.). Whether achange in the amino acid sequence of a peptide results in a functionalhomolog can be readily determined by assessing the ability of thevariant peptide to function in a fashion similar to the wild-typeprotein. Peptides having more than one replacement can readily be testedin the same manner.

More rarely, a variant includes “nonconservative” changes (for example,replacement of a glycine with a tryptophan). Analogous minor variationscan also include amino acid deletions or insertions, or both. Guidancein determining which amino acid residues can be substituted, inserted,or deleted without abolishing biological activity can be found usingcomputer programs (for example, LASERGENE software, DNASTAR Inc.,Madison, Wis.).

Mutants of an AcDAGAT can be generated by any suitable method well knownin the art, including but not limited to site-directed mutagenesis,randomized “point” mutagenesis, and domain-swap mutagenesis in whichportions of the Euonymus DAGAT cDNA are “swapped” with the analogousportion of other plant or bacterial DAGAT-encoding cDNAs (Back andChappell (1996) PNAS 93: 6841-6845).

Variants may be produced by methods such as directed evolution or othertechniques for producing combinatorial libraries of variants. Thus, thepresent invention further contemplates a method of generating sets ofcombinatorial mutants of the present AcDAGAT proteins, as well astruncation mutants, and is especially useful for identifying potentialvariant sequences (in other words, homologs) that possess the biologicalactivity of an AcDAGAT of the present invention (for example, transferof an acetyl or related group to diacylglycerol). In addition, screeningsuch combinatorial libraries is used to generate, for example, novelAcDAGAT homologs that possess novel substrate specificities or otherbiological activities all together; examples of substrate specificitiesare described above.

It is contemplated that the AcDAGAT nucleic acids (for example, SEQ IDNO: 1, and fragments and variants thereof) can be utilized as startingnucleic acids for directed evolution. These techniques can be utilizedto develop AcDAGAT variants having desirable properties such asincreased synthetic activity or altered affinity for a particularacyl-CoA or acyl acceptor substrate.

In some embodiments, artificial evolution is performed by randommutagenesis (for example, by utilizing error-prone PCR to introducerandom mutations into a given coding sequence). This method requiresthat the frequency of mutation be finely tuned. As a general rule,beneficial mutations are rare, while deleterious mutations are common.This is because the combination of a deleterious mutation and abeneficial mutation often results in an inactive enzyme. The idealnumber of base substitutions for targeted gene is usually between 1.5and 5 (Moore and Arnold (1996) Nat. Biotech., 14, 458-67; Leung et al.(1989) Technique, 1:11-15; Eckert and Kunkel (1991) PCR Methods Appl.,1:17-24; Caldwell and Joyce (1992) PCR Methods Appl., 2:28-33; and Zhaoand Arnold (1997) Nuc. Acids. Res., 25:1307-08). After mutagenesis, theresulting clones are selected for desirable activity (for example,screened for diacylglycerol acetyltransferase activity as describedsubsequently). Successive rounds of mutagenesis and selection are oftennecessary to develop enzymes with desirable properties. It should benoted that only the useful mutations are carried over to the next roundof mutagenesis.

In other embodiments of the present invention, the polynucleotides ofthe present invention are used in gene shuffling or sexual PCRprocedures (for example, Smith (1994) Nature, 370:324-25; U.S. Pat. Nos.5,837,458; 5,830,721; 5,811,238; 5,733,731). Gene shuffling involvesrandom fragmentation of several mutant DNAs followed by their reassemblyby PCR into full length molecules. Examples of various gene shufflingprocedures include, but are not limited to, assembly following DNasetreatment, the staggered extension process (STEP), and random priming invitro recombination. In the DNase mediated method, DNA segments isolatedfrom a pool of positive mutants are cleaved into random fragments withDNaseI and subjected to multiple rounds of PCR with no added primer. Thelengths of random fragments approach that of the uncleaved segment asthe PCR cycles proceed, resulting in mutations in present in differentclones becoming mixed and accumulating in some of the resultingsequences. Multiple cycles of selection and shuffling have led to thefunctional enhancement of several enzymes (Stemmer (1994) Nature,370:398-91; Stemmer (1994) Proc. Natl. Acad. Sci. USA, 91, 10747-10751;Crameri et al. (1996) Nat. Biotech., 14:315-319; Zhang et al. (1997)Proc. Natl. Acad. Sci. USA, 94:4504-09; and Crameri et al. (1997) Nat.Biotech., 15:436-38). Variants produced by directed evolution can bescreened for DAGAT activity by the methods described subsequently (seefor example Example 2).

In some embodiments of a combinatorial mutagenesis approach of thepresent invention, the amino acid sequences of a population of AcDAGATcoding sequences are aligned, preferably to promote the highest homologypossible. Such a population of variants can include, for example,AcDAGAT homologs from one or more species, or AcDAGAT homologs from thesame species but which differ due to mutation. Amino acids that appearat each position of the aligned sequences are selected to create adegenerate set of combinatorial sequences.

In preferred embodiments of the present invention, the combinatorialAcDAGAT library is produced by way of a degenerate library of genesencoding a library of polypeptides that each include at least a portionof candidate AcDAGAT-protein sequences. For example, a mixture ofsynthetic oligonucleotides is enzymatically ligated into gene sequencessuch that the degenerate set of candidate AcDAGAT sequences areexpressible as individual polypeptides, or alternatively, as a set oflarger fusion proteins (for example, for phage display) containing theset of AcDAGAT sequences therein.

There are many ways by which the library of potential AcDAGAT homologscan be generated from a degenerate oligonucleotide sequence. In someembodiments, chemical synthesis of a degenerate gene sequence is carriedout in an automatic DNA synthesizer, and the synthetic genes are ligatedinto an appropriate gene for expression. The purpose of a degenerate setof genes is to provide, in one mixture, all of the sequences encodingthe desired set of potential AcDAGAT sequences. The synthesis ofdegenerate oligonucleotides is well known in the art (See for example,Narang (1983) Tetrahedron Lett., 39:3-9; Itakura et al. (1981)Recombinant DNA, in Walton (ed.), Proceedings of the 3rd ClevelandSymposium on Macromolecules, Elsevier, Amsterdam, pp 273-289; Itakura etal. (1984) Annu. Rev. Biochem., 53:323; Itakura et al. (1984) Science198:1056; Ike et al. (1983) Nucl. Acid Res., 11:477). Such techniqueshave been employed in the directed evolution of other proteins (See forexample, Scott et al. (1980) Science, 249:386-390; Roberts et al. (1992)Proc. Natl. Acad. Sci. USA, 89:2429-2433; Devlin et al. (1990) Science,249: 404-406; Cwirla et al. (1990) Proc. Natl. Acad. Sci. USA, 87:6378-6382; as well as U.S. Pat. Nos. 5,223,409, 5,198,346, and5,096,815).

B. Truncation Mutants of Plant Diacylglycerol Acetyltransferase

In addition, the present invention provides isolated nucleic acidsequences encoding fragments of AcDAGAT (in other words, truncationmutants), and the polypeptides encoded by such nucleic acid sequences.In preferred embodiments, the AcDAGAT fragment is biologically active.

In some embodiments of the present invention, when expression of aportion of an AcDAGAT protein is desired, it may be necessary to add astart codon (ATG) to the oligonucleotide fragment containing the desiredsequence to be expressed. It is well known in the art that a methionineat the N-terminal position can be enzymatically cleaved by the use ofthe enzyme methionine aminopeptidase (MAP). MAP has been cloned from E.coli (Ben-Bassat et al. (1987) J. Bacteriol., 169:751-757) andSalmonella typhimurium and its in vitro activity has been demonstratedon recombinant proteins (Miller et al. (1990) Proc. Natl. Acad. Sci.USA, 84:2718-1722). Therefore, removal of an N-terminal methionine, ifdesired, can be achieved either in vivo by expressing such recombinantpolypeptides in a host that produces MAP (for example, E. coli or CM89or S. cerevisiae), or in vitro by use of purified MAP.

C. Fusion Proteins Containing Plant Diacylglycerol Acetyltransferase

The present invention also provides nucleic acid sequences encodingfusion proteins incorporating all or part of AcDAGAT, and thepolypeptides encoded by such nucleic acid sequences. In someembodiments, the fusion proteins have an AcDAGAT functional domain witha fusion partner. Accordingly, in some embodiments of the presentinvention, the coding sequences for the polypeptide (for example, anAcDAGAT functional domain) is incorporated as a part of a fusion geneincluding a nucleotide sequence encoding a different polypeptide. In oneembodiment, a single fusion product polypeptide transfers an acetylgroup to diacylglycerol (one fusion partner possesses the ability tosynthesize AcTAG).

In some embodiments of the present invention, chimeric constructs codefor fusion proteins containing a portion of an AcDAGAT and a portion ofanother gene. In some embodiments, the fusion proteins have biologicalactivity similar to the wild type AcDAGAT (for example, have at leastone desired biological activity of AcDAGAT). In other embodiments, thefusion proteins have altered biological activity.

In other embodiments of the present invention, chimeric constructs codefor fusion proteins containing an AcDAGAT gene or portion thereof and aleader or other signal sequences which direct the protein to targetedsubcellular locations. Such sequences are well known in the art, anddirect proteins to locations such as the chloroplast, the mitochondria,the endoplasmic reticulum, the tonoplast, the golgi network, and theplasmalemma.

In addition to utilizing fusion proteins to alter biological activity,it is widely appreciated that fusion proteins can also facilitate theexpression and/or purification of proteins, such as an AcDAGAT proteinof the present invention. Accordingly, in some embodiments of thepresent invention, an AcDAGAT is generated as aglutathione-S-transferase (in other words, GST fusion protein). It iscontemplated that such GST fusion proteins enables easy purification ofan AcDAGAT, such as by the use of glutathione-derivatized matrices (Seefor example, Ausabel et al. (eds.) (1991) Current Protocols in MolecularBiology, John Wiley & Sons, NY).

In another embodiment of the present invention, a fusion gene coding fora purification leader sequence, such as a poly-(His)/enterokinasecleavage site sequence at the N-terminus of the desired portion of anAcDAGAT allows purification of the expressed AcDAGAT fusion protein byaffinity chromatography using a Ni²⁺ metal resin. In still anotherembodiment of the present invention, the purification leader sequence isthen subsequently removed by treatment with enterokinase (See forexample, Hochuli et al. (1987) J. Chromatogr., 411:177; and Janknecht etal. Proc. Natl. Acad. Sci. USA, 88:8972). In yet other embodiments ofthe present invention, a fusion gene coding for a purification sequenceappended to either the N (amino) or the C (carboxy) terminus allows foraffinity purification; one example is addition of a hexahistidine tag tothe carboxy terminus of an AcDAGAT, which is contemplated to be usefulfor affinity purification.

Techniques for making fusion genes are well known. Essentially, thejoining of various nucleic acid fragments coding for differentpolypeptide sequences is performed in accordance with conventionaltechniques, employing blunt-ended or stagger-ended termini for ligation,restriction enzyme digestion to provide for appropriate termini,filling-in of cohesive ends as appropriate, alkaline phosphatasetreatment to avoid undesirable joining, and enzymatic ligation. Inanother embodiment of the present invention, the fusion gene can besynthesized by conventional techniques including automated DNAsynthesizers. Alternatively, in other embodiments of the presentinvention, PCR amplification of gene fragments is carried out usinganchor primers that give rise to complementary overhangs between twoconsecutive gene fragments that can subsequently be annealed to generatea chimeric gene sequence (See for example, Current Protocols inMolecular Biology, supra). In yet other embodiments of the presentinvention, epitope tags of AcDAGAT are prepared. Epitope tags areprepared as described by Lin et al., who epitope tagged a human ACAT,which is in the same gene family as DAGAT. The epitope tags were singleHA tags internally, at 12 well distributed sites along the polypeptide,and a C-terminal his tag, and the protein retained full or partialactivity with these tags.

D. Screening Gene Products

A wide range of techniques are known in the art for screening geneproducts of combinatorial libraries made by point mutations, and forscreening cDNA libraries for gene products having a certain property.Such techniques are generally adaptable for rapid screening of the genelibraries generated by the combinatorial mutagenesis of AcDAGAThomologs. The most widely used techniques for screening large genelibraries typically comprise cloning the gene library into replicableexpression vectors, transforming appropriate cells with the resultinglibrary of vectors, and expressing the combinatorial genes underconditions in which detection of a desired activity facilitatesrelatively easy isolation of the vector encoding the gene whose productwas detected. Each of the illustrative assays described below areamenable to high through-put analysis as necessary to screen largenumbers of degenerate sequences created by combinatorial mutagenesistechniques.

Accordingly, in one embodiment of the present invention, the candidateAcDAGAT gene products are displayed on the surface of a cell or viralparticle, and the ability of particular cells or viral particles tosynthesize AcTAGs is assayed using the techniques described in theExamples. In other embodiments of the present invention, the genelibrary is cloned into the gene for a surface membrane protein of abacterial cell, and the resulting fusion protein detected by panning (WO88/06630; Fuchs et al. (1991) BioTechnol., 9:1370-1371; and Goward etal. (1992) TIBS 18:136-140). In other embodiments of the presentinvention, fluorescently labeled molecules that bind AcDAGAT can be usedto score for potentially functional AcDAGAT homologs. Cells are visuallyinspected and separated under a fluorescence microscope, or, where themorphology of the cell permits, separated by a fluorescence-activatedcell sorter.

In an alternate embodiment of the present invention, the gene library isexpressed as a fusion protein on the surface of a viral particle. Forexample, foreign peptide sequences are expressed on the surface ofinfectious phage in the filamentous phage system, thereby conferring twosignificant benefits. First, since these phage can be applied toaffinity matrices at very high concentrations, a large number of phagecan be screened at one time. Second, since each infectious phagedisplays the combinatorial gene product on its surface, if a particularphage is recovered from an affinity matrix in low yield, the phage canbe amplified by another round of infection. The group of almostidentical E. coli filamentous phages M13, fd, and fl are most often usedin phage display libraries, as either of the phage gIII or gVIII coatproteins can be used to generate fusion proteins without disrupting theultimate packaging of the viral particle (See for example, WO 90/02909;WO 92/09690; Marks et al. (1992) J. Biol. Chem., 267:16007-16010;Griffths et al. (1993) EMBO J., 12:725-734; Clackson et al. (1991)Nature, 352:624-628; and Barbas et al. (1992) Proc. Natl. Acad. Sci.,89:4457-4461).

In another embodiment of the present invention, the recombinant phageantibody system (for example, RPAS, Pharmacia Catalog number 27-9400-01)is modified for use in expressing and screening of AcDAGAT combinatoriallibraries. The pCANTAB 5 phagemid of the RPAS kit contains the gene thatencodes the phage gil coat protein. In some embodiments of the presentinvention, the AcDAGAT combinatorial gene library is cloned into thephagemid adjacent to the gIII signal sequence such that it is expressedas a gIII fusion protein. In other embodiments of the present invention,the phagemid is used to transform competent E. coli TG1 cells afterligation. In still other embodiments of the present invention,transformed cells are subsequently infected with M13KO7 helper phage torescue the phagemid and its candidate AcDAGAT gene insert. The resultingrecombinant phage contain phagemid DNA encoding a specific candidateAcDAGAT-protein and display one or more copies of the correspondingfusion coat protein. In some embodiments of the present invention, thephage-displayed candidate proteins that are capable of, for example,metabolizing a hydroperoxide, are selected or enriched by panning. Thebound phage is then isolated, and if the recombinant phage express atleast one copy of the wild type gIII coat protein, they will retaintheir ability to infect E. coli. Thus, successive rounds of reinfectionof E. coli and panning will greatly enrich for AcDAGAT homologs, whichcan then be screened for further biological activities in order todifferentiate agonists and antagonists.

In light of the present disclosure, other forms of mutagenesis generallyapplicable will be apparent to those skilled in the art in addition tothe aforementioned rational mutagenesis based on conserved versusnon-conserved residues. For example, AcDAGAT homologs can be generatedand screened using, for example, alanine scanning mutagenesis and thelike (Ruf et al. (1994) Biochem., 33:1565-1572; Wang et al. (1994) J.Biol. Chem., 269:3095-3099; Balint (1993) Gene 137:109-118; Grodberg etal. (1993) Eur. J. Biochem., 218:597-601; Nagashima et al. (1993) J.Biol. Chem., 268:2888-2892; Lowman et al. (1991) Biochem.,30:10832-10838; and Cunningham et al. (1989) Science, 244:1081-1085), bylinker scanning mutagenesis (Gustin et al. (1993) Virol., 193:653-660;Brown et al. (1992) Mol. Cell. Biol., 12:2644-2652; McKnight et al.Science, 232:316); or by saturation mutagenesis (Meyers et al. (1986)Science, 232:613).

VI. Expression of Cloned Diacylglycerol Acetyltransferase

In other embodiment of the present invention, nucleic acid sequencescorresponding to the AcDAGAT genes, homologs and mutants as describedabove may be used to generate recombinant DNA molecules that direct theexpression of the encoded protein product in appropriate host cells.

As will be understood by those of skill in the art, it may beadvantageous to produce AcDAGAT-encoding nucleotide sequences possessingnon-naturally occurring codons. Therefore, in some preferredembodiments, codons preferred by a particular prokaryotic or eukaryotichost (Murray et al. (1989) Nucl. Acids Res., 17) can be selected, forexample, to increase the rate of AcDAGAT expression or to producerecombinant RNA transcripts having desirable properties, such as alonger half-life, than transcripts produced from naturally occurringsequence.

A. Vectors for Production of Plant Diacylglycerol Acetyltransferase

The nucleic acid sequences of the present invention may be employed forproducing polypeptides by recombinant techniques. Thus, for example, thenucleic acid sequence may be included in any one of a variety ofexpression vectors for expressing a polypeptide. In some embodiments ofthe present invention, vectors include, but are not limited to,chromosomal, nonchromosomal and synthetic DNA sequences (for example,derivatives of SV40, bacterial plasmids, phage DNA; baculovirus, yeastplasmids, vectors derived from combinations of plasmids and phage DNA,and viral DNA such as vaccinia, adenovirus, fowl pox virus, andpseudorabies). It is contemplated that any vector may be used as long asit is replicable and viable in the host.

In particular, some embodiments of the present invention providerecombinant constructs comprising one or more of the nucleic acidsequences as broadly described above (for example, SEQ ID NO: 1). Insome embodiments of the present invention, the constructs comprise avector, such as a plasmid or viral vector, into which a nucleic acidsequence of the invention has been inserted, in a forward or reverseorientation. In preferred embodiments of the present invention, theappropriate nucleic acid sequence is inserted into the vector using anyof a variety of procedures. In general, the nucleic acid sequence isinserted into an appropriate restriction endonuclease site(s) byprocedures known in the art.

Large numbers of suitable vectors are known to those of skill in theart, and are commercially available. Such vectors include, but are notlimited to, the following vectors: 1) Bacterial—pQE70, pQE60, pQE-9(Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pBSKS, pNH8A,pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3,pDR540, pRIT5 (Pharmacia); and 2) Eukaryotic—pWLNEO, pSV2CAT, pOG44,PXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). Anyother plasmid or vector may be used as long as they are replicable andviable in the host. In some preferred embodiments of the presentinvention, plant expression vectors comprise an origin of replication, asuitable promoter and enhancer, and also any necessary ribosome bindingsites, polyadenylation sites, splice donor and acceptor sites,transcriptional termination sequences, and 5′ flanking nontranscribedsequences. In other embodiments, DNA sequences derived from the SV40splice, and polyadenylation sites may be used to provide the requirednontranscribed genetic elements.

In certain embodiments of the present invention, a nucleic acid sequenceof the present invention within an expression vector is operativelylinked to an appropriate expression control sequence(s) (promoter) todirect mRNA synthesis. Promoters useful in the present inventioninclude, but are not limited to, the LTR or SV40 promoter, the E. colilac or trp, the phage lambda P_(L) and P_(R), T3 and T7 promoters, andthe cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV)thymidine kinase, and mouse metallothionein-I promoters and otherpromoters known to control expression of gene in prokaryotic oreukaryotic cells or their viruses. In other embodiments of the presentinvention, recombinant expression vectors include origins of replicationand selectable markers permitting transformation of the host cell (forexample, dihydrofolate reductase or neomycin resistance for eukaryoticcell culture, or tetracycline or ampicillin resistance in E. coli).

In some embodiments of the present invention, transcription of the DNAencoding polypeptides of the present invention by higher eukaryotes isincreased by inserting an enhancer sequence into the vector. Enhancersare cis-acting elements of DNA, usually about from 10 to 300 bp that acton a promoter to increase its transcription. Enhancers useful in thepresent invention include, but are not limited to, the SV40 enhancer onthe late side of the replication origin bp 100 to 270, a cytomegalovirusearly promoter enhancer, the polyoma enhancer on the late side of thereplication origin, and adenovirus enhancers.

In other embodiments, the expression vector also contains a ribosomebinding site for translation initiation and a transcription terminator.In still other embodiments of the present invention, the vector may alsoinclude appropriate sequences for amplifying expression.

B. Host Cells for Production of Plant Diacylglycerol Acetyltransferase

In a further embodiment, the present invention provides host cellscontaining any of the above-described constructs. In some embodiments ofthe present invention, the host cell is a higher eukaryotic cell (forexample, a plant cell). In other embodiments of the present invention,the host cell is a lower eukaryotic cell (for example, a yeast cell). Instill other embodiments of the present invention, the host cell can be aprokaryotic cell (for example, a bacterial cell). Specific examples ofhost cells include, but are not limited to, Escherichia coli, Salmonellatyphimurium, Bacillus subtilis, and various species within the generaPseudomonas, Streptomyces, and Staphylococcus, as well as Saccharomyceescerivisiae, Schizosaccharomycees pombe, Drosophila S2 cells, SpodopteraSf9 cells, Chinese hamster ovary (CHO) cells, COS-7 lines of monkeykidney fibroblasts, (Gluzman (1981) Cell 23:175), 293T, C127, 3T3, HeLaand BHK cell lines, NT-1 (tobacco cell culture line), root cell andcultured roots in rhizosecretion (Gleba et al. (1999) Proc Natl Acad SciUSA 96: 5973-5977). Other examples include microspore-derived culturesof oilseed rape (Weselake R J and Taylor D C (1999) Prog. Lipid Res. 38:401), and transformation of pollen and microspore culture systems.Further examples are described in the Examples.

The constructs in host cells can be used in a conventional manner toproduce the gene product encoded by any of the recombinant sequences ofthe present invention described above. In some embodiments, introductionof the construct into the host cell can be accomplished by calciumphosphate transfection, DEAE-Dextran mediated transfection, orelectroporation (See for example, Davis et al. (1986) Basic Methods inMolecular Biology). Alternatively, in some embodiments of the presentinvention, a polypeptide of the invention can be synthetically producedby conventional peptide synthesizers.

Proteins can be expressed in eukaryotic cells, yeast, bacteria, or othercells under the control of appropriate promoters. Cell-free translationsystems can also be employed to produce such proteins using RNAs derivedfrom a DNA construct of the present invention. Appropriate cloning andexpression vectors for use with prokaryotic and eukaryotic hosts aredescribed by Sambrook, et al. (1989) Molecular Cloning: A LaboratoryManual, Second Edition, Cold Spring Harbor, N.Y.

In some embodiments of the present invention, following transformationof a suitable host strain and growth of the host strain to anappropriate cell density, the selected promoter is induced byappropriate means (for example, temperature shift or chemical induction)and cells are cultured for an additional period. In other embodiments ofthe present invention, cells are typically harvested by centrifugation,disrupted by physical or chemical means, and the resulting crude extractretained for further purification. In still other embodiments of thepresent invention, microbial cells employed in expression of proteinscan be disrupted by any convenient method, including freeze-thawcycling, sonication, mechanical disruption, or use of cell lysingagents.

VII. Production of Acetyl Glycerides

In one aspect of the present invention, methods are provided forproducing acetyl glycerides (AcTAGs). Although the following methods aredescribed in terms of production of AcTAGs, it is understood that thesemethods are also applicable to an AcDAGAT that transfers a relatedgroup, resulting in production of TAGs to which the group related toacetyl is transferred. In some embodiments, AcTAGs are produced in vivo,in organisms transformed with a heterologous gene encoding a polypeptideexhibiting diacylglycerol acetyltransferase activity and grown underconditions sufficient to effect production of AcTAGs. In otherembodiments, AcTAGs are produced in vitro, from either nucleic acidsequences encoding an AcDAGAT of the present invention or frompolypeptides exhibiting diacylglycerol acetyltransferase activity.

A. Novel TAGs

By controlling the type of substrate, it is possible to produce novelTAGs. For example, the results from expression of Euonymus AcDAGAT(EaDAGAT) in yeast cells (as described in Example 4) demonstrate that atriacylglycerol species acetyldipalmitolein was produced; thistriacylglycerol species has not been previously reported, and istherefore novel. It is further contemplated that the use of the EaDAGATcan be used to produce structures such as acetyldiricinolein;acetyldivernolin, or acetyldicaprin; these structures also have not beenpreviously reported, and are therefore novel.

In some embodiments, novel compounds are produced by incubating aEaDAGAT enzyme with acetyl-CoA and the appropriate DAG substrate (forexample, diricinolein or divernolin) under suitable conditions such thatthe AcTAG products are synthesized. In other embodiments, novelcompounds are produced by incubating a EaDAGAT enzyme with a DAGsubstrate and an appropriate related group-CoA (for example, cinnamoyl)under suitable conditions such that the AcTAG products are synthesized.It is contemplated that cinnamoyl-TAG will absorb UV and can be used insunscreens. Exemplary suitable conditions for incubations are describedbelow and in the Examples for DAGAT assays.

Such compounds can be produced in vivo by transforming a plant in whichthe appropriate DAG substrate is present with a gene encoding EaDAGATunder control of a suitable promoter (as for example is described inExample 5), such that EaDAGAT is expressed when and where theappropriate DAG substrate is synthesized, resulting in the synthesis ofAcTAG.

B. In Vivo Production in Transgenic Organism

In some embodiments of the present invention, AcTAGs are produced invivo, by providing an organism transformed with a heterologous geneencoding an AcDAGAT of the present invention and growing the transgenicorganism under conditions sufficient to effect production of AcTAGs. Inother embodiments of the present invention, AcTAGs are produced in vivoby transforming an organism with a heterologous gene encoding an AcDAGATof the present invention and growing the transgenic organism underconditions sufficient to effect production of AcTAGs. Illustrativeexamples of transgenic organisms are described below and provided in theExamples.

Organisms which are transformed with a heterologous gene encoding anAcDAGAT of the present invention include preferably those whichnaturally synthesize and store in some manner triacylglycerols (TAGs),and those which are commercially feasible to grow and suitable forharvesting large amounts of the TAG products. Such organisms include butare not limited to, oleaginous yeast and algae, and plants and animals.Examples of yeasts include oleaginous yeast, which include but are notlimited to the genera Lipomyces, Candida, Rhodotorula, Rhodosporidiumand Cryptococcus, which can be grown in commercial-scale fermenters.Examples of plants include preferably oil-producing plants, such assoybean, rapeseed and canola, sunflower, cotton, corn, cocoa, safflower,oil palm, coconut palm, flax, castor, and peanut. Many commercialcultivars can be transformed with heterologous genes. In cases wherethat is not possible, non-commercial cultivars of plants can betransformed, and the trait for expression of AcDAGAT of the presentinvention moved to commercial cultivars by breeding techniqueswell-known in the art.

A heterologous gene encoding an AcDAGAT of the present invention, whichincludes variants of an AcDAGAT, includes any suitable sequence of theinvention as described above. Preferably, the heterologous gene isprovided within an expression vector such that transformation with thevector results in expression of the polypeptide; suitable vectors aredescribed above and following.

A transgenic organism is grown under conditions sufficient to effectproduction of AcTAGs. In some embodiments of the present invention, atransgenic organism is supplied with exogenous substrates of the AcDAGAT(as, for example, in a fermenter). Such substrates can comprise sugarsas carbon sources for TAG synthesis, fatty acids and glycerol useddirectly for the production of DAG and TAG, DAG itself, and acetic acidwhich will both provide a general carbon source and be used for theproduction of acetyl-CoA and/or diacylglycerols (DAGs). When relatedgroups are transferred to DAG, such substrates may instead or inaddition be provided to the transgenic organism; exemplary related groupinclude but are not limited to butyrate, propionate, and cinnamate.Substrates may be supplied in various forms as are well known in theart; such forms include aqueous suspensions prepared by sonication,aqueous suspensions prepared with detergents and other surfactants,dissolution of the substrate into a solvent, and dried powders ofsubstrates. Such forms may be added to organisms or cultured cells ortissues grown in fermenters.

In yet other embodiments of the present invention, a transgenic organismcomprises a heterologous gene encoding an AcDAGAT of the presentinvention operably linked to an inducible promoter, and is grown eitherin the presence of the an inducing agent, or is grown and then exposedto an inducing agent. In still other embodiments of the presentinvention, a transgenic organism comprises a heterologous gene encodingan AcDAGAT of the present invention operably linked to a promoter whichis either tissue specific or developmentally specific, and is grown tothe point at which the tissue is developed or the developmental stage atwhich the developmentally-specific promoter is activated. Such promotersinclude seed specific promoters.

In alternative embodiments, a transgenic organism as described above isengineered to produce greater amounts of the diacylglycerol substrate.Thus, it is contemplated that a transgenic organism may include furthermodifications such that fatty acid synthesis is increased, and may inaddition or instead include exogenous acyltransferases and/orphosphatidic acid phospatases.

In other embodiments of the present invention, a host organism produceslarge amounts of a desired substrate, such as acetyl-CoA or DAG;non-limiting examples include organisms transformed with genes encodingacetyl-CoA synthetases and/or ATP citrate lyase. In some embodiments, itis contemplated that certain DAGs will result in the synthesis of novelAcTAGs with desirable properties. Thus, a particularly suitable host isone which produces a high proportion of such a DAG.

In other embodiments, a host organism produces low amounts of a desiredsubstrate such as DAG. It is contemplated that in such hosts, novel TAGsproduced from an exogenous AcDAGAT are a higher proportion of the totalTAGs; advantages include less expensive purification of the novel TAGs.Non-limiting exemplary hosts include those with low flux through lipidsynthetic systems or with low endogenous DAGAT activity (either or bothDAGAT1 or DAGAT2). Such hosts may occur naturally or via geneticengineering techniques. Non-limiting exemplary techniques includeknock-out produced by EMS and transposon tagging.

In other embodiments of the present invention, the methods for producingAcTAGs further comprise collecting the AcTAGs produced. Such methods areknown generally in the art, and include harvesting the transgenicorganisms and extracting the AcTAGs (see, for example, Christie, W. W.(1982) Lipid Analysis, 2^(nd) Edition (Pergamon Press, Oxford); andKates, M (1986) Techniques of Lipidology (Elsevier, Amsterdam)).Extraction procedures preferably include solvent extraction, andtypically include disrupting cells, as by chopping, mincing, grinding,and/or sonicating, prior to solvent extraction. In one embodiment,lipids are extracted from the tissue according to the method of Blighand Dyer (1959) (Can J Biochem Physiol 37: 911-917). In yet otherembodiments' of the present invention, the AcTAGs are further purified,as for example by thin layer liquid chromatography, gas-liquidchromatography, counter current chromatography or high performanceliquid chromatography.

1. Transgenic Plants, Seeds, and Plant Parts

Plants are transformed with at least a heterologous gene encoding anAcDAGAT of the present invention according to procedures well known inthe art. It is contemplated that the heterologous gene is utilized toincrease the level of the enzyme activities encoded by the heterologousgene.

a. Plants

The methods of the present invention are not limited to any particularplant. Indeed, a variety of plants are contemplated, including but notlimited to tomato, potato, tobacco, pepper, rice, corn, barley, wheat,Brassica, Arabidopsis, sunflower, soybean, poplar, and pine. Preferredplants include oil-producing species, which are plant species whichproduce and store triacylglycerol in specific organs, primarily inseeds. Such species include but are not limited to soybean (Glycinemax), rapeseed and canola (including Brassica napus and B. campestris),sunflower (Helianthus annus), cotton (Gossypium hirsutum), corn (Zeamays), cocoa (Theobroma cacao), safflower (Carthamus tinctorius), oilpalm (Elaeis guineensis), coconut palm (Cocos nucifera), flax (Linumusitatissimum), castor (Ricinus communis) and peanut (Arachis hypogaea).The group also includes non-agronomic species which are useful indeveloping appropriate expression vectors such as tobacco, rapid cyclingBrassica species, and Arabidopsis thaliana, and wild species undergoingdomestication, such as Vernonia and Cuphea, which may be a source ofunique fatty acids. In addition plant lines where the endogenous DAGATgene(s) has been inactivated by any method, but including mutagenesis(Katavic et al, 1995 and Zou et al. (1999), transposon tagging(Routaboul et al., 1999), hairpin RNA (Stoutjesdijk et al. (2002) PlantPhysiol. 129: 1723; Liu et al. (2002) Plant Physiol. 129: 1732) andchimeraplasty (Beetham et al. (1999) Proc. Natl. Acad. Sci. USA 96:8774; Zhu et al. (2000) Nat. Biotechnol. 18: 555) are considered idealfor optimum expression of the Euonymus DAGAT gene. In addition lineswhere DAGAT genes from other gene families and other routes to TAG suchas PDAT have been down regulated are contemplated.

b. Vectors

The methods of the present invention contemplate the use of at least aheterologous gene encoding an AcDAGAT of the present invention, asdescribed above.

Heterologous genes intended for expression in plants are first assembledin expression cassettes comprising a promoter. Methods which are wellknown to those skilled in the art may be used to construct expressionvectors containing a heterologous gene and appropriate transcriptionaland translational control elements. These methods include in vitrorecombinant DNA techniques, synthetic techniques, and in vivo geneticrecombination. Such techniques are widely described in the art (See forexample, Sambrook. et al. (1989) Molecular Cloning, A Laboratory Manual,Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al.(1989) Current Protocols in Molecular Biology, John Wiley & Sons, NewYork, N.Y.).

In general, these vectors comprise a nucleic acid sequence of theinvention encoding an AcDAGAT of the present invention (as describedabove) operably linked to a promoter and other regulatory sequences (forexample, enhancers, polyadenylation signals, etc.) required forexpression in a plant.

Promoters include but are not limited to constitutive promoters,tissue-, organ-, and developmentally-specific promoters, and induciblepromoters. Examples of promoters include but are not limited to:constitutive promoter ³⁵S of cauliflower mosaic virus; a wound-induciblepromoter from tomato, leucine amino peptidase (“LAP,” Chao et al. (1999)Plant Physiol 120: 979-992); a chemically-inducible promoter fromtobacco, Pathogenesis-Related 1 (PR1) (induced by salicylic acid and BTH(benzothiadiazole-7-carbothioic acid S-methyl ester)); a tomatoproteinase inhibitor II promoter (PIN2) or LAP promoter (both induciblewith methyl jasmonate); a heat shock promoter (U.S. Pat. No. 5,187,267);a tetracycline-inducible promoter (U.S. Pat. No. 5,057,422); andseed-specific promoters, such as those for seed storage proteins (forexample, phaseolin, napin, oleosin, and a promoter for soybean betaconglycin (Beachy et al. (1985) EMBO J. 4: 3047-3053)). All referencescited herein are incorporated in their entirety.

The expression cassettes may further comprise any sequences required forexpression of mRNA. Such sequences include, but are not limited totranscription terminators, enhancers such as introns, viral sequences,and sequences intended for the targeting of the gene product to specificorganelles and cell compartments.

A variety of transcriptional terminators are available for use inexpression of sequences using the promoters of the present invention.Transcriptional terminators are responsible for the termination oftranscription beyond the transcript and its correct polyadenylation.Appropriate transcriptional terminators and those which are known tofunction in plants include, but are not limited to, the CaMV ³⁵Sterminator, the tml terminator, the pea rbcS E9 terminator, and thenopaline and octopine synthase terminator (See for example, Odell et al.(1985) Nature 313:810; Rosenberg et al. (1987) Gene, 56:125; Guerineauet al. (1991) Mol. Gen. Genet., 262:141; Proudfoot (1991) Cell, 64:671;Sanfacon et al. Genes Dev., 5:141; Mogen et al. (1990) Plant Cell,2:1261; Munroe et al. (1990) Gene, 91:151; Ballad et al. (1989) NucleicAcids Res. 17:7891; Joshi et al. (1987) Nucleic Acid Res., 15:9627).

In addition, in some embodiments, constructs for expression of the geneof interest include one or more of sequences found to enhance geneexpression from within the transcriptional unit. These sequences can beused in conjunction with the nucleic acid sequence of interest toincrease expression in plants. Various intron sequences have been shownto enhance expression, particularly in monocotyledonous cells. Forexample, the introns of the maize Adhl gene have been found tosignificantly enhance the expression of the wild-type gene under itscognate promoter when introduced into maize cells (Calais et al. (1987)Genes Develop. 1: 1183). Intron sequences have been routinelyincorporated into plant transformation vectors, typically within thenon-translated leader.

In some embodiments of the present invention, the construct forexpression of the nucleic acid sequence of interest also includes aregulator such as a nuclear localization signal (Calderone et al. (1984)Cell 39:499; Lassoer et al. (1991) Plant Molecular Biology 17:229), aplant translational consensus sequence (Joshi (1987) Nucleic AcidsResearch 15:6643), an intron (Luehrsen and Walbot (1991) Mol. Gen.Genet. 225:81), and the like, operably linked to the nucleic acidsequence encoding AcDAGAT.

In preparing a construct comprising a nucleic acid sequence encodingAcDAGAT of the present invention, various DNA fragments can bemanipulated, so as to provide for the DNA sequences in the desiredorientation (for example, sense or antisense) orientation and, asappropriate, in the desired reading frame. For example, adapters orlinkers can be employed to join the DNA fragments or other manipulationscan be used to provide for convenient restriction sites, removal ofsuperfluous DNA, removal of restriction sites, or the like. For thispurpose, in vitro mutagenesis, primer repair, restriction, annealing,resection, ligation, or the like is preferably employed, whereinsertions, deletions or substitutions (for example, transitions andtransversions) are involved.

Numerous transformation vectors are available for plant transformation.The selection of a vector for use will depend upon the preferredtransformation technique and the target species for transformation. Forcertain target species, different antibiotic or herbicide selectionmarkers are preferred. Selection markers used routinely intransformation include the nptII gene which confers resistance tokanamycin and related antibiotics (Messing and Vierra (1982) Gene 19:259; Bevan et al. (1983) Nature 304:184), the bar gene which confersresistance to the herbicide phosphinothricin (White et al. (1990) NuclAcids Res. 18:1062; Spencer et al. (1990) Theor. Appl. Genet. 79:625),the hph gene which confers resistance to the antibiotic hygromycin(Blochlinger and Diggelmann (1984) Mol. Cell. Biol. 4:2929), and thedhfr gene, which confers resistance to methotrexate (Bourouis et al.(1983) EMBO J., 2:1099).

In some preferred embodiments, the vector is adapted for use in anAgrobacterium mediated transfection process (See for example, U.S. Pat.Nos. 5,981,839; 6,051,757; 5,981,840; 5,824,877; and 4,940,838; all ofwhich are incorporated herein by reference). Construction of recombinantTi and Ri plasmids in general follows methods typically used with themore common bacterial vectors, such as pBR322. Additional use can bemade of accessory genetic elements sometimes found with the nativeplasmids and sometimes constructed from foreign sequences. These mayinclude but are not limited to structural genes for antibioticresistance as selection genes.

There are two systems of recombinant Ti and Ri plasmid vector systemsnow in use. The first system is called the “cointegrate” system. In thissystem, the shuttle vector containing the gene of interest is insertedby genetic recombination into a non-oncogenic Ti plasmid that containsboth the cis-acting and trans-acting elements required for planttransformation as, for example, in the pMLJ1 shuttle vector and thenon-oncogenic Ti plasmid pGV3850. The second system is called the“binary” system in which two plasmids are used; the gene of interest isinserted into a shuttle vector containing the cis-acting elementsrequired for plant transformation. The other necessary functions areprovided in trans by the non-oncogenic Ti plasmid as exemplified by thepBIN19 shuttle vector and the non-oncogenic Ti plasmid PAL4404. Some ofthese vectors are commercially available.

In other embodiments of the invention, the nucleic acid sequence ofinterest is targeted to a particular locus on the plant genome.Site-directed integration of the nucleic acid sequence of interest intothe plant cell genome may be achieved by, for example, homologousrecombination using Agrobacterium-derived sequences. Generally, plantcells are incubated with a strain of Agrobacterium which contains atargeting vector in which sequences that are homologous to a DNAsequence inside the target locus are flanked by Agrobacteriumtransfer-DNA (T-DNA) sequences, as previously described (U.S. Pat. No.5,501,967). One of skill in the art knows that homologous recombinationmay be achieved using targeting vectors which contain sequences that arehomologous to any part of the targeted plant gene, whether belonging tothe regulatory elements of the gene, or the coding regions of the gene.Homologous recombination may be achieved at any region of a plant geneso long as the nucleic acid sequence of regions flanking the site to betargeted is known.

In yet other embodiments, the nucleic acids of the present invention areutilized to construct vectors derived from plant (+) RNA viruses (forexample, brome mosaic virus, tobacco mosaic virus, alfalfa mosaic virus,cucumber mosaic virus, tomato mosaic virus, and combinations and hybridsthereof). Generally, the inserted AcDAGAT polynucleotide of the presentinvention can be expressed from these vectors as a fusion protein (forexample, coat protein fusion protein) or from its own subgenomicpromoter or other promoter. Methods for the construction and use of suchviruses are described in U.S. Pat. Nos. 5,846,795; 5,500,360; 5,173,410;5,965,794; 5,977,438; and 5,866,785, all of which are incorporatedherein by reference.

In some embodiments of the present invention the nucleic acid sequenceof interest is introduced directly into a plant. One vector useful fordirect gene transfer techniques in combination with selection by theherbicide Basta (or phosphinothricin) is a modified version of theplasmid pCIB246, with a CaMV ³⁵S promoter in operational fusion to theE. coli GUS gene and the CaMV ³⁵S transcriptional terminator (WO93/07278).

C. Transformation Techniques

Once a nucleic acid sequence encoding an AcDAGAT of the presentinvention is operatively linked to an appropriate promoter and insertedinto a suitable vector for the particular transformation techniqueutilized (for example, one of the vectors described above), therecombinant DNA described above can be introduced into the plant cell ina number of art-recognized ways. Those skilled in the art willappreciate that the choice of method might depend on the type of planttargeted for transformation. In some embodiments, the vector ismaintained episomally. In other embodiments, the vector is integratedinto the genome.

In some embodiments, direct transformation in the plastid genome is usedto introduce the vector into the plant cell (See for example, U.S. Pat.Nos. 5,451,513; 5,545,817; 5,545,818; PCT application WO 95/16783). Thebasic technique for chloroplast transformation involves introducingregions of cloned plastid DNA flanking a selectable marker together withthe nucleic acid encoding the RNA sequences of interest into a suitabletarget tissue (for example, using biolistics or protoplasttransformation with calcium chloride or PEG). The 1 to 1.5 kb flankingregions, termed targeting sequences, facilitate homologous recombinationwith the plastid genome and thus allow the replacement or modificationof specific regions of the plastome. Initially, point mutations in thechloroplast 16S rRNA and rps12 genes conferring resistance tospectinomycin and/or streptomycin are utilized as selectable markers fortransformation (Svab et al. (1990) PNAS, 87:8526; Staub and Maliga,(1992) Plant Cell, 4:39). The presence of cloning sites between thesemarkers allowed creation of a plastid targeting vector introduction offoreign DNA molecules (Staub and Maliga (1993) EMBO J., 12:601).Substantial increases in transformation frequency are obtained byreplacement of the recessive rRNA or r-protein antibiotic resistancegenes with a dominant selectable marker, the bacterial aadA geneencoding the spectinomycin-detoxifying enzymeaminoglycoside-3′-adenyltransferase (Svab and Maliga (1993) PNAS,90:913). Other selectable markers useful for plastid transformation areknown in the art and encompassed within the scope of the presentinvention. Plants homoplasmic for plastid genomes containing the twonucleic acid sequences separated by a promoter of the present inventionare obtained, and are preferentially capable of high expression of theRNAs encoded by the DNA molecule.

In other embodiments, vectors useful in the practice of the presentinvention are microinjected directly into plant cells by use ofmicropipettes to mechanically transfer the recombinant DNA (Crossway(1985) Mol. Gen. Genet, 202:179). In still other embodiments, the vectoris transferred into the plant cell by using polyethylene glycol (Krenset al. (1982) Nature, 296:72; Crossway et al. (1986) BioTechniques,4:320); fusion of protoplasts with other entities, either minicells,cells, lysosomes or other fusible lipid-surfaced bodies (Fraley et al.(1982) Proc. Natl. Acad. Sci., USA, 79:1859); protoplast transformation(EP 0 292 435); direct gene transfer (Paszkowski et al. (1984) EMBO J.,3:2717; Hayashimoto et al. (1990) Plant Physiol. 93:857).

In still further embodiments, the vector may also be introduced into theplant cells by electroporation (Fromm, et al. (1985) Proc. Natl. Acad.Sci. USA 82:5824; Riggs et al. (1986) Proc. Natl. Acad. Sci. USA83:5602). In this technique, plant protoplasts are electroporated in thepresence of plasmids containing the gene construct. Electrical impulsesof high field strength reversibly permeabilize biomembranes allowing theintroduction of the plasmids. Electroporated plant protoplasts reformthe cell wall, divide, and form plant callus.

In yet other embodiments, the vector is introduced through ballisticparticle acceleration using devices (for example, available fromAgracetus, Inc., Madison, Wis. and Dupont, Inc., Wilmington, Del.). (Seefor example, U.S. Pat. No. 4,945,050; and McCabe et al. (1988)Biotechnology 6:923). See also, Weissinger et al. (1988) Annual Rev.Genet. 22:421; Sanford et al. (1987) Particulate Science and Technology,5:27 (onion); Svab et al. (1990) Proc. Natl. Acad. Sci. USA, 87:8526(tobacco chloroplast); Christou et al. (1988) Plant Physiol., 87:671(soybean); McCabe et al. (1988) Bio/Technology 6:923 (soybean); Klein etal. (1988) Proc. Natl. Acad. Sci. USA, 85:4305 (maize); Klein et al.(1988) Bio/Technology, 6:559 (maize); Klein et al. (1988) PlantPhysiol., 91:4404 (maize); Fromm et al. (1990) Bio/Technology, 8:833;and Gordon-Kamm et al. (1990) Plant Cell, 2:603 (maize); Koziel et al.(1993) Biotechnology, 11:194 (maize); Hill et al. (1995) Euphytica,85:119 and Koziel et al. (1996) Annals of the New York Academy ofSciences 792:164; Shimamoto et al. (1989) Nature 338: 274 (rice);Christou et al. (1991) Biotechnology, 9:957 (rice); Datta et al. (1990)Bio/Technology 8:736 (rice); European Patent Application EP 0 332 581(orchardgrass and other Pooideae); Vasil et al. (1993) Biotechnology,11: 1553 (wheat); Weeks et al. (1993) Plant Physiol., 102: 1077 (wheat);Wan et al. (1994) Plant Physiol. 104: 37 (barley); Jahne et al. (1994)Theor. Appl. Genet. 89:525 (barley); Knudsen and Muller (1991) Planta,185:330 (barley); Umbeck et al. (1987) Bio/Technology 5: 263 (cotton);Casas et al. (1993) Proc. Natl. Acad. Sci. USA 90:11212 (sorghum);Somers et al. (1992) Bio/Technology 10:1589 (oat); Torbert et al. (1995)Plant Cell Reports, 14:635 (oat); Weeks et al. (1993) Plant Physiol.,102:1077 (wheat); Chang et al., WO 94/13822 (wheat) and Nehra et al.(1994) The Plant Journal, 5:285 (wheat).

In addition to direct transformation, in some embodiments, the vectorscomprising a nucleic acid sequence encoding an AcDAGAT of the presentinvention are transferred using Agrobacterium-mediated transformation(Hinchee et al. (1988) Biotechnology, 6:915; Ishida et al. (1996) NatureBiotechnology 14:745). Agrobacterium is a representative genus of thegram-negative family Rhizobiaceae. Its species are responsible for planttumors such as crown gall and hairy root disease. In thededifferentiated tissue characteristic of the tumors, amino acidderivatives known as opines are produced and catabolized. The bacterialgenes responsible for expression of opines are a convenient source ofcontrol elements for chimeric expression cassettes. Heterologous geneticsequences (for example, nucleic acid sequences operatively linked to apromoter of the present invention), can be introduced into appropriateplant cells, by means of the Ti plasmid of Agrobacterium tumefaciens.The Ti plasmid is transmitted to plant cells on infection byAgrobacterium tumefaciens, and is stably integrated into the plantgenome (Schell (1987) Science, 237: 1176). Species that are susceptibleinfection by Agrobacterium may be transformed in vitro. Alternatively,plants may be transformed in vivo, such as by transformation of a wholeplant by Agrobacteria infiltration of adult plants, as in a “floral dip”method (Bechtold N, Ellis J, Pelletier G (1993) Cr. Acad. Sci. III-Vie316: 1194-1199).

d. Regeneration

After selecting for transformed plant material that can express theheterologous gene encoding an AcDAGAT of the present invention, wholeplants are regenerated. Plant regeneration from cultured protoplasts isdescribed in Evans et al. (1983) Handbook of Plant Cell Cultures, Vol.1: (MacMillan Publishing Co. New York); and Vasil I. R. (ed.), CellCulture and Somatic Cell Genetics of Plants, Acad. Press, Orlando, Vol.1 (1984), and Vol. III (1986). It is known that many plants can beregenerated from cultured cells or tissues, including but not limited toall major species of sugarcane, sugar beet, cotton, fruit and othertrees, legumes and vegetables, and monocots (for example, the plantsdescribed above). Means for regeneration vary from species to species ofplants, but generally a suspension of transformed protoplasts containingcopies of the heterologous gene is first provided. Callus tissue isformed and shoots may be induced from callus and subsequently rooted.

Alternatively, embryo formation can be induced from the protoplastsuspension. These embryos germinate and form mature plants. The culturemedia will generally contain various amino acids and hormones, such asauxin and cytokinins. Shoots and roots normally develop simultaneously.Efficient regeneration will depend on the medium, on the genotype, andon the history of the culture. The reproducibility of regenerationdepends on the control of these variables.

e. Generation of Transgenic Lines

Transgenic lines are established from transgenic plants by tissueculture propagation. The presence of nucleic acid sequences encoding aheterologous AcDAGAT of the present invention (including mutants orvariants thereof) may be transferred to related varieties by traditionalplant breeding techniques.

These transgenic lines are then utilized for evaluation of oilproduction and other agronomic traits.

C. In Vitro Systems

In other embodiments of the present invention, AcTAGs are produced invitro, from either nucleic acid sequences encoding an AcDAGAT of thepresent invention or from polypeptides exhibiting a diacylglycerolacetyltransferase activity.

1. Using Nucleic Acid Sequences Encoding DiacylglycerolAcetyltransferase

In some embodiments of the present invention, methods for producingAcTAGs comprise adding an isolated nucleic acid sequence encoding anAcDAGAT of the present invention to in vitro expression systems underconditions sufficient to cause production of AcTAGs. The isolatednucleic acid sequence encoding a plant acetyltransferase is any suitablesequence of the invention as described above, and preferably is providedwithin an expression vector such that addition of the vector to an invitro transcription/translation system results in expression of thepolypeptide. Furthermore, the system contemplated is specific for thetranslation and function of eukaryotic membrane proteins, that is, it isa microsomal system. The system further comprises the substrates forAcDAGAT, as previously described. Alternatively, the system furthercomprises the means for generating the substrates for an AcDAGAT of thepresent invention. Such means include but are not limited to thosepreviously described.

In other embodiments of the present invention, the methods for producinglarge quantities of AcTAGs further comprise collecting the AcTAGsproduced. Such methods are known generally in the art, and describedbriefly above. In yet other embodiments of the present invention, theAcTAGs are further purified, as for example by thin layer liquidchromatography, gas-liquid chromatography, high pressure liquidchromatography, crystallization and/or vacuum distillation.

2. Using Diacylglycerol Acetyltransferase Polypeptides

In some embodiments of the present invention, methods for producinglarge quantities of AcTAGs comprise incubating an AcDAGAT of the presentinvention under conditions sufficient to result in the synthesis ofAcTAGs; generally, such incubation is carried out in a mixture thatcomprises the AcDAGAT.

An AcDAGAT of the present invention, as described above, is obtained bypurification of either naturally occurring AcDAGAT or recombinantAcDAGAT from an organism transformed with heterologous gene encoding anAcDAGAT, as described above. A source of naturally occurring AcDAGAT iscontemplated to include but not limited to plants, as for exampleEuonymus, or other members of the plant family Celastraceae, and inaddition in the families Lardizabalaceae, Ranunculaceae and Rosaceae. Asource of recombinant AcDAGAT is either plant, bacterial or othertransgenic organisms, transformed with heterologous gene encodingAcDAGAT of the present invention, as described above. The recombinantAcDAGAT may include means for improving purification, as for example a6×-His tag added to the C-terminus of the protein as described above.Alternatively, AcDAGAT is chemically synthesized.

The incubation mixture further comprises the substrates for AcDAGAT, asdescribed above. Alternatively, the mixture further comprises the meansfor generating the substrates for AcDAGAT, such as the use ofATP-citrate lyase to generate acetyl-CoA from citrate or acetyl-CoAsynthetase to generate acetyl-CoA from acetate, and phosphatidic acidphosphatase to generate diacylglycerol from phosphatidic acid orphospholipase C to generate diacylglycerol from phospholipids.

In other embodiments of the present invention, the methods for producingAcTAGs further comprise collecting the AcTAGs produced; such methods aredescribed above.

VIII. Manipulation of Diacylglycerol Acetyltransferase Activity inPlants

It is further contemplated that the nucleic acids encoding an AcDAGAT ofthe present invention may be utilized to either increase or decrease thelevel of AcDAGAT mRNA and/or protein in transfected cells as compared tothe levels in wild-type cells. Such transgenic cells have great utility,including but not limited to further research as to the effects of theoverexpression of AcDAGAT, and as to the effects as to theunderexpression or lack of AcDAGAT.

Accordingly, in some embodiments, expression in plants of nucleic acidsequences encoding an AcDAGAT of the present invention by the methodsdescribed above leads to the overexpression of AcDAGAT in transgenicplants, plant tissues, or plant cells.

In other embodiments of the present invention, the ACDAGATpolynucleotides are utilized to decrease the level of AcDAGAT protein ormRNA in transgenic plants, plant tissues, or plant cells as compared towild-type plants, plant tissues, or plant cells. One method of reducingAcDAGAT expression utilizes expression of antisense transcripts.Antisense RNA has been used to inhibit plant target genes in atissue-specific manner (for example, van der Krol et al. (1988)Biotechniques 6:958-976). Antisense inhibition has been shown using theentire cDNA sequence as well as a partial cDNA sequence (for example,Sheehy et al. (1988) Proc. Natl. Acad. Sci. USA 85:8805-8809; Cannon etal. (1990) Plant Mol. Biol. 15:39-47). There is also evidence that 3′non-coding sequence fragment and 5′ coding sequence fragments,containing as few as 41 base-pairs of a 1.87 kb cDNA, can play importantroles in antisense inhibition (Ch'ng et al. (1989) Proc. Natl. Acad.Sci. USA 86:10006-10010).

Accordingly, in some embodiments, an AcDAGAT encoding-nucleic acid ofthe present invention (for example, SEQ ID NO: 1, and fragments andvariants thereof) are oriented in a vector and expressed so as toproduce antisense transcripts. To accomplish this, a nucleic acidsegment from the desired gene is cloned and operably linked to apromoter such that the antisense strand of RNA will be transcribed. Theexpression cassette is then transformed into plants and the antisensestrand of RNA is produced. The nucleic acid segment to be introducedgenerally will be substantially identical to at least a portion of theendogenous gene or genes to be repressed. The sequence, however, neednot be perfectly identical to inhibit expression. The vectors of thepresent invention can be designed such that the inhibitory effectapplies to other proteins within a family of genes exhibiting homologyor substantial homology to the target gene.

Furthermore, for antisense suppression, the introduced sequence alsoneed not be full length relative to either the primary transcriptionproduct or fully processed mRNA. Generally, higher homology can be usedto compensate for the use of a shorter sequence. Furthermore, theintroduced sequence need not have the same intron or exon pattern, andhomology of non-coding segments may be equally effective. Normally, asequence of between about 30 or 40 nucleotides and about full lengthnucleotides should be used, though a sequence of at least about 100nucleotides is preferred, a sequence of at least about 200 nucleotidesis more preferred, and a sequence of at least about 500 nucleotides isespecially preferred.

Catalytic RNA molecules or ribozymes can also be used to inhibitexpression of the target gene or genes. It is possible to designribozymes that specifically pair with virtually any target RNA andcleave the phosphodiester backbone at a specific location, therebyfunctionally inactivating the target RNA. In carrying out this cleavage,the ribozyme is not itself altered, and is thus capable of recycling andcleaving other molecules, making it a true enzyme. The inclusion ofribozyme sequences within antisense RNAs confers RNA-cleaving activityupon them, thereby increasing the activity of the constructs.

A number of classes of ribozymes have been identified. One class ofribozymes is derived from a number of small circular RNAs that arecapable of self-cleavage and replication in plants. The RNAs replicateeither alone (viroid RNAs) or with a helper virus (satellite RNAs).Examples include RNAs from avocado sunblotch viroid and the satelliteRNAs from tobacco ringspot virus, lucerne transient streak virus, velvettobacco mottle virus, Solanum nodiflorum mottle virus and subterraneanclover mottle virus. The design and use of target RNA-specific ribozymesis described in Haseloff, et al. (1988) Nature 334:585-591. Ribozymestargeted to the mRNA of a lipid biosynthetic gene, resulting in aheritable increase of the target enzyme substrate, have also beendescribed (Merlo A O et al. (1998) Plant Cell 10: 1603-1621).

Another method of reducing AcDAGAT expression utilizes the phenomenon ofcosuppression or gene silencing (See for example, U.S. Pat. No.6,063,947, incorporated herein by reference). The phenomenon ofcosuppression has also been used to inhibit plant target genes in atissue-specific manner. Cosuppression of an endogenous gene using afull-length cDNA sequence as well as a partial cDNA sequence (730 bp ofa 1770 bp cDNA) are known (for example, Napoli et al. (1990) Plant Cell2:279-289; van der Krol et al. (1990) Plant Cell 2:291-299; Smith et al.(1990) Mol. Gen. Genetics 224:477-481). Accordingly, in some embodimentsthe nucleic acid sequences encoding an AcDAGAT of the present invention(for example including SEQ ID NOs 1, and fragments and variants thereof)are expressed in another species of plant to effect cosuppression of ahomologous gene.

Generally, where inhibition of expression is desired, some transcriptionof the introduced sequence occurs. The effect may occur where theintroduced sequence contains no coding sequence per se, but only intronor untranslated sequences homologous to sequences present in the primarytranscript of the endogenous sequence. The introduced sequence generallywill be substantially identical to the endogenous sequence intended tobe repressed. This minimal identity will typically be greater than about65%, but a higher identity might exert a more effective repression ofexpression of the endogenous sequences. Substantially greater identityof more than about 80% is preferred, though about 95% to absoluteidentity would be most preferred. As with antisense regulation, theeffect should apply to any other proteins within a similar family ofgenes exhibiting homology or substantial homology.

For cosuppression, the introduced sequence in the expression cassette,needing less than absolute identity, also need not be full length,relative to either the primary transcription product or fully processedmRNA. This may be preferred to avoid concurrent production of someplants that are overexpressers. A higher identity in a shorter than fulllength sequence compensates for a longer, less identical sequence.Furthermore, the introduced sequence need not have the same intron orexon pattern, and identity of non-coding segments will be equallyeffective. Normally, a sequence of the size ranges noted above forantisense regulation is used.

An effective method to down regulate a gene is by hairpin RNAconstructs. Guidance to the design of such constructs for efficient,effective and high throughput gene silencing have been described (WesleyS V et al. (2001) Plant J. 27: 581-590). Another method to decreaseexpression of a gene (either endogenous or exogenous) is via siRNAs.siRNAs can be applied to a plant and taken up by plant cells;alternatively, siRNAs can be expressed in vivo from an expressioncassette. Exemplary techniques for lipid gene antisense using hairpinRNA include Stoutjesdijk et al. (2002) Plant Physiol. 129: 1723; Liu etal. (2002) Plant Physiol. 129: 1732).

An advantage of siRNAs is the short length of the mRNA that is targeted;this allows preferential targeting of a first sequence that is verysimilar to a second sequence, while allowing expression of the second,non-targeted sequence. Thus, it is contemplated that AcDAGAT isspecifically targeted, but not DAGAT, which would allow expression ofDAGAT to be expressed.

EXPERIMENTAL

The following examples are provided in order to demonstrate and furtherillustrate certain preferred embodiments and aspects of the presentinvention and are not to be construed as limiting the scope thereof.

In the experimental disclosure which follows, the followingabbreviations apply: N (normal); M (molar); mM (millimolar); μM(micromolar); mol (moles); mmol (millimoles); μmol (micromoles); nmol(nanomoles); pmol (picomoles); g (grams); mg (milligrams); μg(micrograms); ng (nanograms); 1 or L (liters); ml (milliliters); μl(microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm(nanometers); ° C. (degrees Centigrade); PCR (polymerase chainreaction); RT-PCR (reverse-transcriptase-PCR); TAIL-PCR (thermalasymmetric interlaced-PCR); RACE (Rapid Amplification of cDNA Ends);EST, expressed sequence tag; BLAST (Basic Local Alignment Search Tool);C16, C18, etc (fatty acyl group designation by number of carbon atoms inacyl chain); DAG (diacylglycerol); TAG (triacylglycerol); AcTAG(1,2-diacyl-3-acetins); LcTAG (long chain triacylglycerols); PC(phosphatidylcholine); DAGAT (diacylglycerol acyltransferase);diacylglycerol acetyltransferase (AcDAGAT); FAME (fatty acid methylester); GC/MS (gas chromatography/mass spectrometry); TLC (thin layerchromatography); FID (flame ionization detection/detector); SC medium(Saccharomyces cerevisiae medium); NT medium (Nicotiana tabaccummedium); MES (2-(N-morpholino)ethanesulphonic acid); hepes(N-2-hydroxyethylpiperazine-N′-2-ethanesulphonic acid); 2,4-D(2,4-dichlorophenoxyacetic acid); CFH (cell free homogenate); MSU(Michigan State University).

Example 1 Experimental Plant Biochemistry Procedures

A. Materials

Developing Seeds

Euonymus alata developing seeds were collected from bushes on theMichigan State University campus, courtesy of the WJ Beal Garden andCampus Woody Plants. Seed capsules were harvested from mid-Augustthrough November. Seeds were removed from the capsule and from theiryellowish-orange pericarp. Some fresh seeds were halved and usedimmediately for in vivo labeling experiments. For other seeds, the seedcoats were removed and the cotyledons and embryos were eitherimmediately used for the preparation of enzyme extracts or frozen inliquid nitrogen and stored at −80° C. for subsequent RNA extraction, forthe preparation of cell free extracts for enzymology, or for lipidsanalysis.

RadioChemicals

[1-¹⁴C]Acetate was purchased from American Radiolabeled Chemicals, Inc.,while [1-¹⁴C]acetyl-CoA, [1-¹⁴C]palmitoyl-CoA and [1-¹⁴C]oleoyl-CoA werepurchased from New England Nuclear. Specific activities were 50-60Ci/mol. [1-¹⁴C]Acetyl-CoA was also prepared from [1-¹⁴C]acetate usingacetyl-CoA synthetase.

B. Radiolabeling of Developing Euonymus Seeds

Incubations contained 7-10 halved seeds, but no more than 200 mg freshweight of tissue. Each assays contained 10 μCi of [1-¹⁴C] acetic acid.Assays were run in 25 mM NaMES buffer, pH 6.0, with 25 mM sucrose and0.4 M sorbitol osmoticum, and in a total volume of 1.0 ml. Assays wererun for the time specified, at 28° C., with vigorous agitation to assistoxygenation of the medium. Assays were terminated by rapidly washing thetissue twice with distilled water to remove labeled substrate and thenimmediately heated at 90° C. in isopropanol for 5 minutes to inactivateenzymes (and particularly an endogenous phospholipase D activity) priorto lipid extraction. Lipids were extracted from the inactivated,homogenized seed tissue with hexane-isopropanol, as described by Haraand Radin (1978). An aliquot of the heptane-soluble [¹⁴C]lipids wasassayed for radioactivity by liquid scintillation counting.

C. Plant Enzyme Preparation and DAGAT Assays

All procedures were carried out on ice or at 4° C. Frozen embryo andendosperm tissue was added to two volumes of chilled buffer containing0.3 M sucrose, 10 mM NaF, 5 mM MgCl₂, 2 mM dithiothreitol, 1 mM EDTA and40 mM Hepes-NaOH (pH 7.4), homogenized, and filtered through two layersof Miracloth. The residue was rehomogenized in two more volumes ofbuffer and filtered. The filtrates were combined and constitute the cellfree homogenate (CFH). The CFH was frozen and stored at −70° C. untilused and typically contained 12-17 mg protein/ml. Protein concentrationswere estimated using the Bio-Rad protein assay, which is based on theBradford method (1976), using bovine serum albumin as the standard.

The standard (Ac)DAGAT assay contained [1-¹⁴C]acetyl-CoA (100 μM,200,000 d.p.m.) plus 140 μl of homogenization buffer in a total volumeof 200 μl. 1,2-dioleoyl-sn-glycerol (50 μg, 0.4 mM) was added as 1 μl ofethanol solution. The assay was initiated by adding 20 μl of CFH. Thereaction was run at room temperature (25° C.) for 15 min and terminatedby the addition of hot isopropanol (1 ml). Lipids were extracted withhexane and isopropanol as described by Hara and Radin (1978). The[¹⁴C]lipid residue was dissolved in hexane and an aliquot assayed forradioactivity by liquid scintillation counting. The standard long-chainDAGAT assay contained 20 μM [1-¹⁴C]palmitoyl-CoA and 20-40 μl of CFH andwas run for 30 minutes: all other aspects were as for acetyl DAGATassays.

D. Lipid Analysis

To determine total lipid accumulation during Euonymus seed development,dried seeds were extracted with hexane-isopropanol according to Hara andRadin (1978) and the oil weighed. To determine individual lipid classes,internal standards, namely triheptadecanoin and dipentadecanoylphosphatidylcholine, were added to an aliquot of total lipids. The lipidclasses were isolated by preparative TLC. Transmethylation of the totallipids and of the lipid classes was accomplished by heating in sulphuricacid-methanol-toluene (5:95:25 v/v/v) for one hour at 80° C. The lipidclasses recovered after preparative TLC were transmethylated directly onthe silica, with methyl nonadecanoate added to each fraction forrelative quantifications. GLC analysis of fatty acid methyl esters wasaccomplished using a 50 m×0.25 mm CP-Sil88 column temperature programmedfrom 150° C. to 220° C., with FID.

For analysis of triacylglycerols in different tissues of Euonymus,internal standards of triheptadecanoin and acetyldipentadecanoin wereadded to tissue lipid extracts. Long-chain triacylglycerols andacetylglycerides were then isolated by preparative TLC and analyzed byhigh temperature GC using a 30 m×0.25 mm DB-5ht column, temperatureprogrammed from 250 to 360° C., with FID. Aliquots of the sample werealso transmethylated for quantification of total fatty acids.

TLC analysis of unlabeled and labeled lipid classes was conducted usingK6 silica plates (Whatman). 80/20/1 (v/v/v) Hexane/diethyl ether/aceticacid was used for analysis of triacylglycerols; 80/10/10/0.4 (v/v/v/v)toluene/ethyl ether/ethyl acetate/acetic acid was used for analysis ofdiacylglycerols; and 65/25/4 chloroform/methanol/water (v/v/v), 65/25/4(v/v/v) chloroform/methanol/28% aqueous ammonium hydroxide and/or85/15/5/2 (v/v/v/v) chloroform/methanol/acetic acid/water were used foranalysis of polar lipids. Reverse phase analysis of triacylglycerols wascarrier out using KC18F TLC plates developed with 3:1 (v/v)acetone:acetonitrile or 100% methanol. Silver nitrate TLC used silicaTLC plates impregnated with 15% (w/v) silver nitrate in acetonitrile anddeveloped three times with toluene at −15° C. After development of theTLC plates in the above solvent systems, radioactivity in bands wasquantitated with a Packard Instant Imager.

For analysis of lipid classes recovered from TLC plates after in vivolabeling experiments, the transmethylation method of Ichihara et al.(1996) was employed. This derivatization, run at room temperature withsodium hydroxide/methanol/heptane, can be performed with quantitativerecovery of [¹⁴C] long-chain fatty acid methyl esters and complete lossof [¹⁴C] acetyl groups (primarily as methyl acetate). When the [¹⁴C]heptane-soluble material recovered from the transmethylation is analyzedby TLC, the contribution from [¹⁴C] long-chain fatty acid methyl esterscan be measured, and hence the amount of [¹⁴C] long-chain fatty acids inthe original [¹⁴C] lipid determined. The use of transmethylation withcomplete loss of labeled methyl acetate and recovery of long-chain fattyacid methyl esters was also used to quantify the distribution of labelbetween acetyl and long-chain acyl groups in isolated[¹⁴C]3-acetyl-1,2-long-chain diacyl-sn-glycerols.

Example 2 Euonymus Biochemistry

A. Endogenous Lipids and Seed Development

Flowering of Euonymus alata occurs in late May, but the onset of theseed maturation phase is delayed until August. During maturation theseed coat bracts become colored intensely orange. Seed fresh weight, dryweight and lipid accumulation over time is shown in FIG. 1. Theseaccumulations follow a pattern typical for developing oilseeds. The oilcontent of the seed at maturity was 43%. Most of the lipid depositionoccurred in September and during this period approximately 0.24 mglipid/day/seed was deposited. Since this lipid is mainly3-acetyl-1,2-diacyl-sn-glycerol (MW of 1,2-dioleoyl-3-acetyl-sn-glycerolis 662), and since at mid-maturation the average seed fresh weight isabout 30 mg, this gives an average rate of3-acetyl-1,2-diacyl-sn-glycerol deposition of approximately 500nmoles/hr/gfw. This rate of deposition is a useful specific activityagainst which to judge the degree of contribution of exogenous acetateto the biosynthesis of 3-acetyl-1,2-diacyl-sn-glycerols in vivo, formaking pool size estimates, and as a yardstick for in vitro enzymeactivity measurements.

The accumulation of lipid classes, as measured by mass of fatty acidsper seed over time, is shown in FIG. 2. The dominant lipid is3-acetyl-1,2-diacyl-sn-glycerol, which constitutes 95% of the totallipids at maturity. This number is in close agreement with the 98% ofacetoglycerides in Euonymus alata oil reported by Kleiman et al. (1967).A small amount of triacylglycerols, amounting to 1.9% of total lipids,co-accumulates with 3-acetyl-1,2-diacyl-sn-glycerol. 1,2-Diacylglycerolsrepresent an even smaller neutral lipid pool, amounting to 0.9% of thetotal at maturity. Total polar lipids and phosphatidylcholine, the majorpolar lipid, reach maximum levels by mid-maturation. TLC data show noendogenous acetyl-DAG or acetyl-PC. Their presence would have lead to aconsideration of 3-acetyl-1,2-diacyl-sn-glycerol assembly viaacetyl-specific transacylases from these novel lipids to1,2-diacylglycerols.

A range of Euonymus alata tissues were harvested and analyzed for totalfatty acid content, and for long-chain and acetyl triacylglycerolcontent by high temperature GC with the appropriate internal standards.The data are shown in FIG. 3. The lipids in embryos and endosperm,separated by dissection from seeds, were dominated by AcTAG, with only asmall amount of TAG in the embryo and a very small amount of TAG in theendosperm. In all the other tissues, TAG was only a small or very smallpercentage of total lipids, and in all other tissues no AcTAG wasdetected. Thus the acetyl glyceride phenotype is seed-specific.

B. Characterization of Lipid Products from In Vivo Labeling of HalvedSeeds with [¹⁴C]Acetate and Other Substrates

Labeled acetate is readily incorporated into heptane-soluble products bydeveloping seeds of Euonymus alata. The three major labeled lipids from[¹⁴C] acetate were 3-acetyl-1,2-diacyl-sn-glycerols (up to 36%),phosphatidylcholine (up to 23%) and 1,2-diacylglycerols (up to 19%).Triacylglycerols (1-4%), phosphatidylethanolamine (ca. 2%),phosphatidylinositol (ca. 2%) and phosphatidic acid (1-2%) were alsolabeled. No [¹⁴C] acetyl-polar lipids were detected. When the[¹⁴C]3-acetyl-1,2-diacyl-sn-glycerol fraction was purified bypreparative normal phase TLC, and the distribution of label between theacetyl and long-chain acyl groups analyzed, the molecule was found to behighly labeled in the acetyl group relative to the fatty acyl groups.The distribution of this label depends on the age of the tissue and theconcentration of acetate used, such that the label in long-chain acylgroups relative to acetyl groups can vary from 1:10 to 2:1. Digestion oflabeled 3-acetyl-1,2-diacyl-sn-glycerol with pancreatic lipase andanalysis of the resulting products showed that the fatty acids at thesn-1 and sn-2 position had approximately the same specificradioactivity.

Variation of [¹⁴C]Acetate Labeling of Lipids During Seed Development

The incorporation of acetate into total lipids and fatty acids, and intothe various lipid classes over seed maturation, is shown in FIG. 4.There is the expected sharp increase over early maturation phase andsubsequent decline in late maturation, when the activities are expressedon a per seed basis. This rise and fall is also seen when the activitiesare expressed on a gram fresh wt. basis, although the induction anddecay phases are not as pronounced. The maximum rate of incorporationinto [¹⁴Cacetyl] 3-acetyl-1,2-diacyl-sn-glycerol and into [¹⁴Clong-chain acyl] 3-acetyl-1,2-diacyl-sn-glycerol occurs atmid-maturation. The accumulation of labeled DAG, which is largely fromthe endosperm, also peaks at mid-maturation, and, for the six hour assayperiod, gives a similar level of labeling as [¹⁴C long-chain acyl]3-acetyl-1,2-diacyl-sn-glycerol. Over the mid-maturation period (10-60days), the distribution of label in individual fatty acids remainsfairly constant (13-19% 16:0; 7-10% 18:0; 62-70% 18:1; and 5-11% 18:2).During late maturation (day 80-100), labeling of PC and to a lesserextent DAG continues (FIG. 4), whereas the net accumulation ofendogenous polar lipids, phosphatidylcholine and DAG peaks at day 50-60(FIG. 2). The time course defines the period of harvest for mRNApreparation and for enzyme studies.

Time Course for [¹⁴C]Acetate Labeling of Lipids

The time courses for [¹⁴C] acetate incorporation into total lipids andinto total long-chain fatty acids was linear over a six hour period withno lag phase. The distribution of label in [¹⁴Cacetyl] and in[¹⁴Clong-chain acyl] moieties of 3-acetyl-1,2-diacyl-sn-glycerol wasmeasured, and label in both portions also increased in a linear fashionover time. By contrast, labeling of [¹⁴C long-chain acyl] DAG plateausby 6 hours, with [¹⁴C long-chain acyl] TAG labeling increasing overtime, and the rate of PC labeling slowly declining. These resultsdemonstrate that the linear labeling of [¹⁴C long-chainacyl]3-acetyl-1,2-diacyl-sn-glycerol cannot be derived from the[¹⁴Clong-chain acyl] DAG and PC pools, as they do not demonstrate thekinetic precursor-product relationship expected if the relationship didexist. If these were precursor pools, then the rate of synthesis of theacetyl glycerides product would increase exponentially. Finally, theappearance of labeled fatty acids equally in both the sn-1 and sn-2positions of [¹⁴C fatty acyl] 3-acetyl-1,2-diacyl-sn-glycerol isconsistent with a model that involves small pools of intermediates.

In summary, the in vivo labeling kinetics observed are consistent withthe synthesis of acetyl glycerides via a DAGAT utilizing acetyl-CoA as asubstrate. This enzyme activity is referred to below as a diacylglycerolacetyltransferase (AcDAGAT).

[¹⁴C]Propionate Labeling of Lipids during Seed Development: An Exampleof a Related Substrate.

Labeled products from incubation of [¹⁴C] propionate were analyzed byTLC. A band amounting to 4.5% of the total labeled lipids was observedrunning just ahead of the major mass of 3-acetyl-1,2-diacyl-sn-glycerol.A slight reduction in polarity of the 3-propionyl glyceride relative tothe 3-acetyl-glyceride is expected. Reverse-phase TLC shows about 3.5%labeling in the expected region, with the bands one methylene groupoffset, in the more lipophilic direction, compared to3-acetyl-1,2-diacyl-sn-glycerol molecular species bands. This isconsistent with the structure of the product aspropionyl-1,2-diacyl-sn-glycerol. When the [¹⁴C]3-propionyl-1,2-diacyl-sn-glycerol fraction was purified by preparativenormal phase TLC and the distribution of label between the propionyl andlong-chain acyl groups was analyzed by saponification and phenacyl esterderivatization only a labeled band corresponding to the phenacylpropionate standard was observed. Exogenous acetate at optimumconcentration (5 mM) gave a maximum rate of incorporation into[¹⁴Cacetyl]3-acetyl-1,2-diacyl-sn-glycerol of 40 nmoles/hr/g. fresh wt.At the optimum propionate concentration (10 mM) incorporation into [¹⁴Cpropionyl]3-propionyl-1,2-diacyl-sn-glycerol reached a maximum rate ofabout 10 nmoles/hr/g. fresh wt. Thus the maximal rate of propionateincorporation into the sn-3 position of the glycerides is about 25% ofthat for acetate. It is unclear whether this difference is a result ofdifferent rates of uptake and activation of acetate and propionate, ordifferent rates of utilization by the sn-3 acyltransferase. However, theexperiment shows that short-chain acyl groups other than acetate isaccommodated by the EaDAGAT; that is, propionate is a “related”substrate group.

C. Diacylglycerol Acetyltransferase Activity.

Characterization of Triacylglycerol Products

Incubation of cell free homogenates (CFH) from developing Euonymus alataendosperm plus embryo tissues with [¹⁴C]acetyl-CoA produced labeledlipids. Analysis by normal phase TLC showed a major labeled band thatco-eluted with endogenous Ac-TAG. Long-chain TAG elutes ahead of Ac-TAGin this solvent system. When this labeled band was recovered andanalyzed by C18 reversed-phase TLC, the radioactivity migrated with themass bands corresponding to the major Ac-TAG molecular species, namelyC16/C18 and C18/C18. When a unique exogenous diacylglycerol,1,2-dihexanoyl-sn-glycerol, was added to the assays, a novel bandappeared that co-chromatographed with the synthetic3-acetyl-1,2-dihexanoin standard in both normal and reverse phase TLCsystems. The migration of the standard was confirmed by GC analysis ofrecovered fractions from the TLC plates. Acetyldihexanoin is expected torun as a slightly more polar compound than acetyldioleoin on silica TLC,and as a much less hydrophobic compound on C18 reversed-phase TLC. Theseproduct analyses demonstrate that acetyl-CoA and 1,2-diacylglycerol aresubstrates for the synthesis of 3-acetyl-1,2-diacylglycerols by a DAGATreaction.

Optimization of Activity

DAGAT assays with acetyl-CoA were set up to give linear initial rates.There was no apparent lag phase before label appears in the AcTAGproduct, indicating that no detectable [¹⁴C]acetyl-lipid intermediatewas formed. The assay is also dependent on the amount of enzyme added.CFH heated in boiling water for 5 minutes is devoid of activity.

The effects of acetyl-CoA and exogenous diacylglycerol concentrations onactivity were also examined. Acetyl-CoA showed typical saturationkinetics, with the reaction rate reaching a plateau above 300 μM. ALineweaver-Burke reciprocal plot gave estimates of K_(m)=100 μM foracetyl-CoA, and V_(max)=2.5 nmoles/min/gfw. This value comparesfavorably to the average rate of 3-acetyl-1,2-diacyl-sn-glyceroldeposition of approximately 500 nmoles/hr/gfw noted above, whichconverts to 8 nmoles/min/gfw. The standard assay acetyl-CoAconcentration of 20 μM gives about a 10-fold lower activity than themaximum AcDAGAT activity. AcDAGAT activity is enhanced only moderatelyby the addition of exogenous sn-1,2-diolein. Over a concentration rangeof 0.1-1.2 mM, the average enhancement was 30%. Ethanol, which is usedas a carrier for exogenous diacylglycerols, has no effect on activity upto 3% v/v in the assay.

Since short- and medium-chain diacylglycerols were reported as good acylacceptors in (Lc)DAGAT assays with safflower extracts (Ichihara and Noda(1982) Phytochemistry 21:1895-1901), the effect of short chaindiacylglycerol 1,2-dihexanoin, in the AcDAGAT assay was examined. Thissubstrate when acetylated gives a product that is readily separated fromthe endogenous AcTAG by TLC on silica, as described above. At higherconcentrations (4-8 mM), 1,2-dihexanoin effectively out-competes theendogenous DAG as the acetyl acceptor. The maximal rates for synthesiswith C16/C18 and C18/C18 diacylglycerol substrate are similar to thosefor C6/C6. This fact indicates that the AcDAGAT can accommodate a fairlywide range of acyl chain lengths in the diacylglycerol acceptor.

Long-chain DAGAT activity was assayed with 16:0-CoA as substrate.Standardization of this assay showed that it had a linear dependence onCFH to 100 μl (1.5 mg protein) and with a linear incorporation rate forat least 30 minutes. DAGAT activities using either palmitoyl-CoA oracetyl-CoA in the same extract at similar concentrations were compared.The activity with acetyl-CoA was consistently higher than the activitywith palmitoyl-CoA, by almost two-fold.

Example 3

DAGAT Cloning

A Euonymus cDNA for DAGAT was obtained via RT-PCR using degeneratedprimers and subsequently 3′ and 5′ RACE to define the 3′ and 5′ cDNAends. A full length cDNA clone was obtained via RT-PCR using primersbased on the sequence of the 3′ and 5′ RACE products.

A. General Methods

Total RNA from developing Euonymus seeds was extracted according to theprocedures of Schultz et al. (1994) (Plant Mol. Biol. Rep. 12: 310-316)or Chung et al. (1996) (Mol. Cells 6: 108-111). For all PCR reactionsdescribed below, appropriate controls were included, consisting of thePCR reaction with each primer only. Escherichia coli strain HB101 wasgrown at 37° C. in Luria Broth media (Silhavy et al, 1984), supplementedwith the appropriate antibiotics for selection of the constructs:ampicillin 100 mg/ml (pYES2CT), kanamycin 50 mg/ml (pE1776), rifampicine50 mg/ml (pBBPhas). Database searches were done using the BLASTalgorithm. DNA sequences and the deduced amino acid sequence wereanalyzed with the Vector NTI Suite of InforMax.

B. RT-PCR Using Degenerate Primers

An Arabidopsis genomic DAGAT sequence (AC003058, putative DAGAT or ACAT)was used to search the GenBank non-redundant database and the top sixmatches were aligned. Several conserved regions were identified and usedas a basis to design degenerated primers. The degeneracy of all primercombinations is less than 500 in each case. Two sets of primers weredesigned and used first in a pilot PCR experiment with a partial lengthArabidopsis EST for DAGAT. One pair of primers yielded the expectedfragment of 250 bp. Total RNA isolated from Euonymus developing seedswas prepared and cDNA made with the oligodT primer. ³²P-labeled primerssets were used for PCR with the cDNA as template. One set of primers(MP1 and MP6) gave a band of the requisite size. This product waspurified from a polyacrylamide gel, reamplified with unlabeled primers(MP1 and MP3), gel-purified and cloned into the PCR TopoTA cloningvector (Invitrogen). From 24 colonies, selected for plasmid preparationand analyzed for the size of the insert, 9 had an insert of the correctlength. These 7 clones were sequenced (sequencing facility of MSU) fromboth ends and 2 (JO752C-1 and -2) were found to be identical and toshare high sequence similarity with the Arabidopsis DAGAT.

C. 3′ and 5′ RACE

On the basis of the sequence of the positive clone JO752C-1, primerswere designed for 3′ and 5′ RACE (Gibco RACE kit). Following theprotocol of the kit for 3′ RACE, cDNA was prepared from total RNA ofEuonymus seeds using a modified oligodT primer AP (from the kit). Afirst PCR with primer AUAP (from the kit) and gene specific primer(MP10, 11) was carried out, using the cDNA as template, followed by asecond PCR with AUAP and nested gene specific primer MP16. For 5′ RACE,a fresh preparation of Euonymus seeds total RNA was prepared, DNAasetreated and column purified (Qiagen). cDNA was prepared from total RNAof Euonymus seeds using a gene specific primer (MP30). The cDNA wasC-tailed at the 5′ end and nested gene specific primers (MP15 and MP31)in combination with the AAP and AUAP primers were subsequently used toamplify the fragment. Several 3′ and 5′ RT-PCR fragments were obtainedand via southern blot analysis, using the insert of the clone JO752C-1as a probe, positive hybridizing bands were identified for both 3′ and5′ products. These fragments were purified from the gel and cloned intothe PCR TopoTA cloning vector. Colonies carrying the vector with thecorrect insert were selected via colony PCR, using the gene specificprimers MP10 and MP31. Sequence analysis of these positive clonesrevealed that DAGAT sequences had been isolated.

D. Full Length Euonymus DAGAT cDNA

On the basis of the sequence of the 3′ and 5′ RACE products, primerswere designed for the 3′ and 5′ cDNA ends (DAGF and DAGR). Primer namePrimer sequence Mp1  TAY TTY ATG KT5 GCN CCN AC Mp2  TTY TAY ARR GAY TGGTGG Mp3  CCA CCA RTC YYT RTA RAA Mp4  ATG CCN GTI CAY AAR TGG Mp5  CCAYTT RTC IAC NGG CAT Mp6  TYC RTG RAA 5AC NGC NGA Mp10 TAC CCC ATA TGTTCG CAA GG Mp11 ATG CCA TTG AGA GAG TTT TG Mp16 TGG TTC YGC ATG TTC TACTG Mp30 CAG TCC TTG TAG AAC TCA CGA Mp31 CTC TCT CAA TGG CAT ACA AAA AGMp15 GCA GTA GAA CAT GCA GAA CC DAGF ATA TGG ATC CAA TAA TGT CTA TGG CTGCTA ACT TGA ACG AAG DAGR ATA TCT CGA GCA CAA AAC TTG CCT CTA CTC CA

cDNA was first prepared from total RNA of Euonymus seeds, using theoligodT primer (Gibco Superscript Kit). With this cDNA as template, the3′ and 5′ primers, and a high fidelity polymerase (pwo from Roche), afull length cDNA PCR product of correct size was obtained, clonedimmediately into the BamH1/XhoI site of the yeast vector pYES2CT(Invitrogen), and the sequence of the insert analyzed from bothdirections. The cDNA nucleotide sequence and encoded amino acid sequenceare shown in FIGS. 5 and 6.

A comparison of the amino acid sequence of DAGAT identified in Euonymusseed tissue with amino acid sequences of DAGATs from other plants isshown in FIG. 7.

The deduced amino acid sequence is highly similar to all DAGAT proteinsdescribed so far for plants (50.7% identity; 91% similarity). The regionof the Euonymus AcDAGAT protein which is most different from the otherDAGAT proteins is the N-terminal end (93 amino acids). Other regionswith differences include amino acids 158-200 and 243-268. Predictedtransmembrane regions (of which there are about 9 or 10), a putativeacyl-binding site, and a putative active site are described by Jako etal. (2001) Plant Phys 126, 861-874); the putative acyl-binding site andputative active site are shown by underlining in FIG. 7.

Example 4 Analysis of Yeast Transformed with the Full Length EuonymusDAGAT cDNA

The Euonymus DAGAT cDNA was cloned into the yeast vector pYES2CT andexpressed in the yeast strain Saccharomyces cerevisiae strain INVSc1.Two controls were used in subsequent expression analysis. One was theyeast transformed with the empty vector pYES2CT. The second was yeasttransformed with the Arabidopsis DAGAT cDNA cloned into pYES2CT. All 3strains were grown in minimal SC-medium lacking uracil supplemented withraffinose and galactose (for induction of the promoter driving the DAGATexpression) as well as acetate at 5 mM final concentration. Cell growthwas carefully monitored and cells were harvested at beginning stationaryphase, washed and used as described below or the pellets stored at −80°C.

A. Yeast Expression: Lipid Analysis

Methods

Three yeast colonies for each construct were grown in liquid medium andanalyzed for lipid content. For growth-phase dependent analysis, a small3 ml culture of each colony was started in SC-medium with 2% glucose andgrown overnight. This culture was diluted 1 to 100 in a volume of 5 mland grown overnight in SC-medium with 2% glucose until OD of 1 wasobtained. This culture was subsequently centrifuged and washed withsterile water, and recovered cells resuspended in 400 ml SC-mediumsupplemented with galactose and raffinose, with a starting OD of 0.4.Growth was followed over time and 40 ml samples were taken at early andmid exponential phase, and at beginning, mid, and late stationary phase.These samples were washed, pelleted and stored at −4° C. and analyzed asdescribed in the lipid analysis methods. For higher production oflipids, as well as quantitative analysis of the lipid classes, 800 mlyeast cultures of S. cerevisiae transformed with either pYES2CT,pYES2CTEaDagat or pYES2CTAtDagat were grown until start of stationaryphase and treated as described above.

Lipids were extracted from the yeast pellets by resuspending the pelletsin hot isopropanol and then breaking the cells with glass beads. Thelipids were extracted with hexane-isopropanol as described by Hara andRadin (1978). The lipid extract included triheptadecanoin andacetyldipentadecanoin as internal standards. The lipids werehydrogenated using Adams catalyst (platinum(IV) oxide) and hydrogen withhexane as solvent. The saturated long-chain triacylglycerols (LcTAG) andsn-3-acetyltriacylgycerols (AcTAG) were separated by preparative TLC,then analyzed by high temperature GC and GC-MS (DB-5ht column).

Results

The total lipids of the transformed yeast strain carrying the pYES2CTvector (negative control) showed the expected pattern of phospholipids,diacylglycerols, sterols, free fatty acids, triacylglycerols and sterolesters. Yeast cells produce a significant amount of LCTAG, which aremost evident during the stationary phase (Dahlqvist et al, 2000). Theoccurrence of acetyl-TAG has not been reported in yeast. Since TAGsynthesis is reported to be a function of growth phase, the lipidfraction of transformed yeast cells grown over time was tested, fromearly logarithmic to late stationary phase. Indeed, endogenous TAGdeposition starts at beginning stationary phase. Total lipids wereisolated from cultures carrying either the empty vector, thepYES2EaDagat clone (DAGAT of Euonymus), or the pYES2AtDagat clone (DAGATof Arabidopsis thaliana), and analyzed by TLC (with iodine staining tovisualize unsaturated lipids) and after hydrogenated and preparative TLCby high temperature GC.

The pYES2EaDagat clone (DAGAT of Euonymus), when expressed in yeast,increased production of LcTAG 5-fold compared to the vector control.This result shows that the isolated EADAGAT gene can function as along-chain DAGAT. AcTAG was present at 0.26% of the amount of LcTAG. Themaximal deposition of LcTAG and AcTAG were observed at the onset ofstationary phase. The AtDAGAT clone, when expressed in yeast, increasedproduction of TAG 20-fold and, in addition, a small amount of AcTAG wasfound: AcTAG was present at 0.09% of the amount of LcTAG. Thus, theproduction of AcTAG by the Arabidopsis DAGAT in yeast in vivo shows thatAcTAG production is not unique for Euonymus. The EaDAGAT, however, showsan increased propensity to synthesize AcTAG (about 3-fold) when comparedto AtDAGAT; this increased propensity to synthesize AcTAG is referred toas increased specificity for acetyl-CoA as a substrate. The addition ofacetate into the yeast culture had only a small effect on the synthesisof the TAG or AcTAG.

The data in the table below summarizes the analytical data above. YeastLine pYES2CT pYES2EaDagat pYES2AtDagat Total Lipid (mg) 13.8 29.0 46.3Total Fatty Acid 5.4 14.8 34.5 (mg) Total TAG (mg) 1.495 7.75 30.1 TotalAcTAG (mg) nd 0.0204 0.0281The lipid mass is measured for each sample, which is the cells harvestedfrom 800 ml of culture at 45 hours after inoculation. Cell densitieswere approximately equal.

The hydrogenated AcTAG enriched fraction isolated by TLC was analyzed byGC. Three molecular species of AcTAG were identified, namely C2C16C16(22.56 min), C2C16C18 (24.41 min), and C2C18C18 (26.17 min). Theretention times corresponded to synthetic standards. Yeast lipidscontain predominantly 16:0, 16:1, 18:0 and 18:1 fatty acids, so thesehydrogenated species are expected. The C16C18 peak from the GC analysiswas analyzed by mass spectroscopy. From interpretation of the diagnosticions at 239, 267, 355 and 383 in the mass spectrum, the structure isunambiguously acetyl-palmitoylstearoylglycerol.

B. Yeast Expression: In Vitro

Methods

Microsomal fractions were prepared from yeast expressing the emptyvector, the Euonymus DAGAT (EaDAGAT) vector, and the Arabidopsis DAGAT(AtDAGAT) vector, using a protocol modified from that of Dahlqvist etal. (2000) (Proc. Natl. Acad. Sci. USA 97, 6487-6492). 100 ml culturesof yeast grown to beginning stationary phase were centrifuged (˜0.5 g ofyeast pellet) and the yeast pellet was resuspended in 4 ml of ice-coldbuffer (Tris pH 7.9 20 mM, MgCl2 10 mM, EDTA 1 mM, glycerol 5%, DTT 1mM, ammonium sulfate 0.3 M) and vortexed with 2 ml glass beads for 5minutes. The suspension was centrifuged at 1,500 g for 15 min at 6° C.The supernatant was subsequently centrifuged at 100,000 g for 1.5 hoursat 6° C., and the resulting pellet was resuspended in cold 100 mMpotassium phosphate (pH 7.2) and aliquots stored at −80° C. (Ac)DAGATassays were carried out with ¹⁴C-labeled acetyl-CoA or oleoyl-CoA.Assays contained 100-250 nCi of labeled substrate plus 2-5 μl ofmicrosomes (equivalent to about 5-15 μg of protein), in 50 mM potassiumphosphate buffer pH 7.2 and a total volume of 100 μl. The reaction wascarried out at 30° C. for 15 minutes. The reaction mix was immediatelyquenched in hot isopropanol and lipids were extracted and analyzed byTLC as described in Example 1.

Results

The labeled products of DAGAT assays were analyzed by TLC. When[¹⁴C]oleoyl-CoA was used as a substrate, a significant increase oflabeled LcTAG over the amount present in the control (empty vectorpYES2) was observed for both EaDAGAT and AtDAGAT. In addition,incubation with [¹⁴C]acetylCoA resulted in detection of a significantamount of labeled AcTAG in microsomes from yeast expressing the EaDAGATgene. However, only a very small amount of labeled AcTAG was observed inmicrosomes from yeast expressing the AtDAGAT gene, and no labeled AcTAGwas observed in the control yeast. The [¹⁴C]AcTAG produced by themicrosomes from yeast expressing EaDAGAT was first identified bynormal-phase TLC, where it co-eluted with the unlabeled AcTAG. Thisputative [¹⁴C]AcTAG band was recovered and re-analyzed by C18reverse-phase TLC, which showed three bands which could be identified asthe molecular species of AcTAG as follows: 16:1/16:1, 16:0/16:1, and16:1/18:1 in the top band, 16:0/16:1, and 16:1/18:1 in the middle band,and 16:0/18:1, 16:1/18:0, and 18:1/18:1 in the bottom band. Therecovered putative [¹⁴C]AcTAG band was also analyzed by silver nitrateTLC, which showed the label to elute with monoenoic and dienoic AcTAGstandards, as expected. These TLC analyses confirm the product as[¹⁴Cacetyl]AcTAG.

Subsequent assays with yeast microsomes gave the following enzymeactivities, using either 50 μM oleoyl-CoA or 45 μM acetyl-CoA as thesubstrate: Yeast Line pYES2CT pYES2EaDagat pYES2AtDagat Oleoyl-CoA 0.180.22 0.11 Substrate Acetyl-CoA <0.01 0.275 <0.01 SubstrateActivities are expressed as nmoles/min/mg microsomal protein.

In summary, expression of the Euonymus DAGAT gene in yeast cells andanalysis of the lipids produced shows that the gene can function as along-chain DAGAT producing long-chain TAG. AcTAG is also produced, andrelatively more so than with the corresponding Arabidopsis DAGAT gene.Analysis of enzyme activity found in microsomal membrane fractionsclearly shows that the Euonymus DAGAT has substantial acetyltransferaseactivity, at least equivalent to the long-chain DAGAT activity, whilethis acetyltransferase activity is barely detectable (at least a 30-foldreduction) compared with either the endogenous DAGAT activity found inyeast or the activity seen after expressing the Arabidopsis gene.

Example 5 Analysis of Arabidopsis Transformed with the Full LengthEuonymus DAGAT cDNA Under Control of the Phaseolin Seed-SpecificPromoter

The Euonymus DAGAT cDNA was cloned into the plant expression vectorpBBVPhas, at the site of the phaseolin seed-specific promoter. TheEuonymus DAGAT gene under control of this promoter was expressed inArabidopsis thaliana (var. Columbia) to gauge its efficacy to alter oilcontent and increase the AcTAG content of the oil.

A. Vector Construction and Arabidopsis Transformation

The clone pYES2CTPCR5.1 was used as template for PCR using the primersDAGFEapBB (carrying a PstI site) and DAGREaYes (carrying a XhoI site).The 1.5 kbp fragment was cloned (after A-extension) into TopoPCR2.1 toverify the exact sequence and subsequently cloned in the PstI/.XhoIsites of the vector pBBVPhas (Dow Agro Sciences). This vector carries aseed specific phaseolin promoter which is used to express the clonedgene. Agrobacterium tumefaciens strain C58C1 was grown at 28° C. in YEPmedium, supplemented with the appropriate antibiotics: rifampicine 50mg/ml, streptomycin 25 mg/ml or gentamycin at a few mg/ml. Theconstructs (pBBVPhas and pBBVPhas-EaDAGAT) were transferred in A.tumefasciens strain C58C1 via electroporation and the presence/absenceof the DAGAT sequence verified with whole cell PCR, using DAGAT specificprimers.

Six weeks old Arabidopsis plants (ecotype Colombia-2) were transformedvia vacuum-infiltration method with the A. tumefasciens strains,carrying either pBBVPhas or pBBVPhas-EaDAGAT, and the plants grown tomaturity. Seeds (T1) were collected and transgenic plants (T1) wereselected by germination in soil soaked with BASTA 50 mg/ml final(AgrEvo). The surviving herbicide resistant plants were allowed to growto maturity, set seed and desiccate. Seed (T2) from a number of singleplant lines were harvested. A control for T2 seed analysis wasArabidopsis transformed with the empty vector pBBVPhas.

B. T2 Seed Analysis

Arabidopsis thaliana (ecotype Colombia-2) mature T2 seeds were collectedfrom the siliques of 6-8 weeks old plants, grown in the growth chambers(16 h light period, 22° C., 80 to 100 μE light intensity). Seed from 23T2 individual plant lines transformed with pBBVPhas-EaDAGAT wereharvested, along with seed for 11 control lines (transformed withpBBVPhas). Oil was quantitatively extracted, and TAG and AcTAG analyzedafter hydrogenation by high temperature GC using odd-chain internalstandards. GC analysis of the AcTAG fraction required priorconcentration by TLC to remove overlapping peaks. As a control foranalytical variability 8 replicates of a pBBVPhas-EaDAGAT-transformedbulked T2 seed sample were analyzed. Gravimetric oil contentdeterminations were:—

-   -   Wild type (Columbia): 35.3%    -   T2 bulk: 36.9%+0.3%    -   Vector alone: range=32.35-39.1%, average=35.55%    -   DAGAT-transformed lines: range 31.45-38.15%, average=35.45%        AcTAG Content Determinations (% in oil) were:—    -   T2 bulk: 0.036%±0.005%    -   Vector alone: range=0.007-0.014%, average=0.01±0.002%    -   DAGAT-transformed lines: range 0.017-0.072%, average=0.036%        The oil content was not enhanced by expressed of the DAGAT,        indicating that under these conditions and with this particular        line the expression of DAGAT genes is not limiting to oil        content. The AcTAG analysis by GC showed a statistically valid        increase in AcTAG, which is 2- to 7-fold over wild type.        C. Subsequent Generations of Transformed Plants.

To enhance the AcTAG seed phenotype the pBBVPhas-EaDAGAT-transformedlines are screened at the T2 seedling stage for BASTA herbicideresistance. Lines identified with a 3:1 resistant:susceptible ratiocontain a single locus and are used for subsequent generations. Selectedsingle locus lines with the best AcTAG content in their seeds are grownto maturity and T3 mature seed harvested. The lines are identified ashomozygous or heterozygous for the transgene by herbicide screening. Anapproximately 1:2:1 ratio of homozygous:heterozygous:wild type lines areobtained. These are analyzed for total oil content and for AcTAG asdescribed above. The homozygous lines will have higher acetyl glyceridecontents.

The homozygous, single locus T3 lines with the highest AcTAG contents intheir seeds are crossed with Arabidopsis lines containing nulls for theendogenous DAGAT gene, generated by transposon tagging, mutagenesis,siRNA or chimeraplasty. The F1 seed is grown to produce F1 plants, whichin turn produce selfed F2 seed. F2 lines contain double homozygotes forthe null endogenous DAGAT gene and for the heterologous EaDAGAT. Linesfrom these F2 plants are identified by screening F3 seed for oil contentand AcTAG content as described above. The plants that have highest AcTAGcontent are homozygous for the EaDAGAT gene but do not have a functionalendogenous DAGAT gene. The lack of a functional endogenous gene orpolypeptide removes the competition from this gene and allows greaterexpression of the acetyl glyceride phenotype introduced by theacetyltransferase encoding DAGAT gene. The Arabidopsis lines containingnulls for the endogenous DAGAT gene, generated by transposon tagging,mutagenesis, siRNA or chimeraplasty are also transformed with thepBBVPhas-EaDAGAT construct as described in Example V, section A above,to generate T1 plants that are heterozygous for the EaDAGAT gene but donot have a functional endogenous DAGAT gene. On selfing T2 plants thatare homozygous for the EaDAGAT gene but do not have a functionalendogenous DAGAT gene are produced.

Example 6 Synthesis of Novel Triglycerides

A. 1,2-diacyl-3-acetins

Yeast cells transformed with Euonymus diacylglycerol acetyltransferase(EuDAGAT) as described in Example 4 resulted in the production oftriacylglycerol species with 34 and 36 carbon atoms (counting all acylcarbons but not glycerol carbon atoms) containing an acetyl groups.Enzyme assay for DAGAT in microsomes from the transformed yeast showedactivity with both long-chain acyl-CoA and acetyl-CoA. Therefore,expression of this gene results in production of unique triacylglycerolsin transformed cells. Furthermore the DAGAT was shown to have a widespecificity in respect of its DAG substrate, with high rates ofsynthesis with long-chain DAG (C34 or C36) and dihexanoin (C12) (asdescribed above), and therefore is contemplated to accommodate a widerange of novel DAG substrates. In fact, in Example 2, section C, theincubation of acetyl-CoA with 1,2-dihexanoin and a cell free extractfrom Euonymus seeds produced acetyldihexanoin, which is a novel1,2-diacyl-3-acetins.

B. Other Novel Triglycerides

The EaDAGAT gene allows the production of novel triacylglcyerolstructures. For example, in the yeast expression experiment, atriacylglycerol species acetyldipalmitolein was produced; thistriacylglycerol species has not been previously reported, and istherefore novel. It is contemplated that the use of the EaDAGAT can beused to produce structures such as acetyldiricinolein, acetyldivemolin,or acetyldicaprin; these structures also have not been previouslyreported, and are therefore novel.

Such compounds can be produced in vitro by incubating a EaDAGAT enzymewith acetyl-CoA and the appropriate DAG substrate (for example,diricinolein or divemolin) under suitable conditions such that the AcTAGproducts are synthesized. Exemplary suitable conditions are describedabove for DAGAT assays.

Such compounds can be produced in vivo by transforming a plant in whichthe appropriate DAG substrate is present with a gene encoding EaDAGATunder control of a suitable promoter (as for example is described inExample 5), such that EaDAGAT is expressed when and where theappropriate DAG substrate is synthesized, resulting in the synthesis ofAcTAG.

In addition, transformed or native organisms are contemplated to produceother novel glycerides when the organism contains an acetyltransferasegene and a substrate related to acetyl-CoA is present endogenously orcan be generated from a exogenous substrate. An example is the synthesisof propionyl glycerides by seeds of Euonymus when provided with a novelrelated substrate, propionate, as described in Example 2, section B.

All publications and patents mentioned in the above specification areherein incorporated by reference. Various modifications and variationsof the described method and system of the invention will be apparent tothose skilled in the art without departing from the scope and spirit ofthe invention. Although the invention has been described in connectionwith specific preferred embodiments, it should be understood that theinvention as claimed should not be unduly limited to such specificembodiments. Indeed, various modifications of the described modes forcarrying out the invention which are obvious to those skilled inmaterial science, chemistry, and molecular biology or related fields areintended to be within the scope of the following claims.

1. An isolated nucleic acid sequence encoding a diacylglycerolacetyltransferase, wherein said nucleic acid sequence encodes SEQ IDNO:2 or a protein that is at least 90% identical thereto and which hasdiacylglycerol acetyltransferase activity.
 2. The nucleic acid sequenceof claim 1, wherein the diacylglycerol acetyltransferase is from a plantof the genus Euonymus.
 3. The nucleic acid sequence of claim 2, whereinthe plant is a Euonymus alata plant.
 4. The nucleic acid sequence ofclaim 4, wherein the nucleic acid sequence comprises SEQ ID NO:
 1. 5.The nucleic acid sequence of claim 1 operably linked to a heterologouspromoter.
 6. A vector comprising the nucleic acid sequence of claim 1.7. A host cell comprising the vector of claim
 6. 8. The host cell ofclaim 8, wherein said host cell is a plant cell or a microorganism.
 9. Aplant or plant seed comprising the host cell of claim
 7. 10. A purifiedpolypeptide encoded by the nucleic acid sequence of claim
 1. 11. Oilfrom the plant or plant seed of claim
 9. 12. An isolated antisensesequence corresponding to a nucleic acid sequence of claim
 1. 13. Aninterfering RNA targeted to a sequence in an mRNA transcribed from thenucleic acid sequence of claim
 1. 14. A method of producing acetylglycerides comprising one acetyl group and two long-chain acyl groups,comprising: a) providing a host cell transformed with a heterologousgene encoding a diacylglycerol acetyltransferase, wherein saiddiacylglycerol acetyltransferase is selected from the group consistingof SEQ ID NO:2 or a protein that is at least 90% identical thereto andwhich has diacylglycerol acetyltransferase activity; and b) growing thehost cell under conditions sufficient to effect production of acetylglycerides.
 15. A method for producing triglycerides, comprising:providing a substrate to a diacylglycerol acetyltransferase, whereinsaid diacylglycerol acetyltransferase is selected from the groupconsisting of SEQ ID NO:2 or a protein that is at least 90% identicalthereto and which has diacylglycerol acetyltransferase activity, underconditions sufficient to produce a triglyceride produced from saidsubstrate.
 16. The method of claim 15, wherein at least one of the fattyacyl chains of said substrate is selected from the group consistingpalmitoleic acid, a ricinoleic acid, divemolic acid, and capric acid.17. The method of claim 15, wherein said substrate is selected from thegroup consisting of acetyl-CoA, propionyl-CoA, butyryl-CoA, benzoyl-CoA,and cinnamoyl-CoA.
 18. The method of claim 17, wherein said triglyceridecomprises a functional group selected from the group consisting of anacetyl group, a propionyl group, a butyryl group, a benzoyl group, and acinnamoyl group.
 19. A composition comprising a triglyceride selectedfrom the group consisting of acetyldipalmitolein,propionyldipalmitolein, butyryldipalmitolein, benzoyldipalmitolein,cinnamoyldipalmitolein, acetyldiricinolein, acetyldivemolin, andacetyldicaprin.
 20. A method to identify diacylglycerolacetyltransferase coding sequences, comprising: a) obtaining a non-cDNAlibrary for diacylglycerol acyltransferase by using RT-PCR withdegenerated primers to give a partial length clone; b) using 3′ and 5′RACE to define the 3′ and 5′ cDNA ends of said partial length clone togenerate 3′ and 5′ RACE products; c) obtaining a full length cDNA clonevia RT-PCR using primers based on the sequence of said 3′ and 5′ RACEproducts; and d) using said full length cDNA clone to confirm theidentity of the encoded polypeptide as a diacylglycerolacetyltransferase.
 21. The method of claim 20, where confirmation of theidentity of said encoded polypeptide as an AcDAGAT comprises: e)expressing said encoded polypeptide of said full length cDNA, and f)characterizing the expressed polypeptide.
 22. The method of claim 21,where said characterizing the expressed polypeptide comprises detectingthe presence of the expressed polypeptide by antibody-binding.
 23. Themethod of claim 22, where said antibody is specific for AcDAGAT.
 24. Themethod of claim 21, where said characterizing said expressed polypeptideis by detecting reaction products of the expressed polypeptide in anAcDAGAT activity assay.
 25. The method of claim 21, wherein acetylglycerides are present in the tissue from which said non-cDNA library isprepared.